[{"id": 77001, "ingredient1": "Cyclosporine", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs), especially ritonavir, may significantly increase the blood concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves PI inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to PI inhibition of intestinal P-glycoprotein efflux transporter may also contribute.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used in combination with protease inhibitors. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of PI therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients treated with saquinavir should also be monitored for potential PI toxicity and the dosage adjusted accordingly.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Caution is advised if cyclosporine is used in combination with protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77102/", "reference_text": "[1] Brinkman K, Huysmans F, Burger DM \"Pharmacokinetic interaction between saquinavir and cyclosporine.\" Ann Intern Med 129 (1998): 914-5[2] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[4] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[5] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[6] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[10] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[11] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[12] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[15] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[16] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[17] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[18] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[19] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[20] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[21] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[22] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[23] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[24] Cerner Multum, Inc. \"Australian Product Information.\" O 0[25] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[26] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[27] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S \"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.\" Br J Clin Pharmacol 45 (1998): 355-9[28] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[29] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77002, "ingredient1": "Cyclosporine", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "The nephrotoxic effects of cyclosporine and aminoglycosides are additive. The combination generally should be avoided.", "source": "DDInter", "management_text": "If these agents must be used concomitantly, renal function should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "If these agents must be used concomitantly, renal function should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77103/", "reference_text": "[1] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Whiting PH, Simpson JG \"The enhancement of cyclosporin A-induced nephrotoxicity by gentamicin.\" Biochem Pharmacol 32 (1983): 2025-8[4] Termeer A, Hoitsma AJ, Koene RA \"Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients.\" Transplantation 42 (1986): 220-1[5] Chandrasekar PH, Cronin SM \"Nephrotoxicity in bone marrow transplant recipients receiving aminoglycoside plus cyclosporine or aminoglycoside alone.\" J Antimicrob Chemother 27 (1991): 845-9[6] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Paromomycin, Chlorhexidine, Povidone-iodine, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Chlorhexidine, Chlorhexidine, Rifamycin, More", "updated_at": 1767369485}, {"id": 77003, "ingredient1": "Cyclosporine", "ingredient2": "Neratinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77104/", "reference_text": "[1] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[6] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[7] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77004, "ingredient1": "Cyclosporine", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "The nephrotoxic effects of cyclosporine and aminoglycosides are additive. The combination generally should be avoided.", "source": "DDInter", "management_text": "If these agents must be used concomitantly, renal function should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "If these agents must be used concomitantly, renal function should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77105/", "reference_text": "[1] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Whiting PH, Simpson JG \"The enhancement of cyclosporin A-induced nephrotoxicity by gentamicin.\" Biochem Pharmacol 32 (1983): 2025-8[4] Termeer A, Hoitsma AJ, Koene RA \"Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients.\" Transplantation 42 (1986): 220-1[5] Chandrasekar PH, Cronin SM \"Nephrotoxicity in bone marrow transplant recipients receiving aminoglycoside plus cyclosporine or aminoglycoside alone.\" J Antimicrob Chemother 27 (1991): 845-9[6] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Chlorhexidine, Levofloxacin, Povidone-iodine", "updated_at": 1767369485}, {"id": 77005, "ingredient1": "Cyclosporine", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed mechanism is increased clearance due to nevirapine-mediated induction of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates. Dosage adjustments as well as clinical and laboratory monitoring of coadministered drugs should be considered whenever nevirapine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77106/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viramune (nevirapine).\" Boehringer-Ingelheim, Ridgefield, CT.[3] \"Product Information. Viramune XR (nevirapine).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77006, "ingredient1": "Cyclosporine", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Nicardipine may increase blood cyclosporine levels. The mechanism is not known, but may be decreased hepatic metabolism of cyclosporine. The risk of cyclosporine-induced nephrotoxicity and neurotoxicity may be increased.", "source": "DDInter", "management_text": "Cyclosporine levels and renal function, including serum creatinine, should be carefully monitored. The dosage should be adjusted as needed. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache. Amlodipine, isradipine and nitrendipine are not expected to affect cyclosporine to the same extent and may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Cyclosporine levels and renal function, including serum creatinine, should be carefully monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77107/", "reference_text": "[1] Martinez F, Pirson Y, Wallemacq P, et al \"No clinically significant interaction between ciclosporin and isradipine.\" Nephron 59 (1991): 658-9[2] Tjia JF, Back DJ, Breckenridge AM \"Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.\" Br J Clin Pharmacol 28 (1989): 362-5[3] Guan D, Wang R, Lu J, Wang M, Xu C \"Effects of nicardipine on blood cyclosporine levels in renal transplant patients.\" Transplant Proc 28 (1996): 1311-2[4] Jacobs U, Klein B, Klehr HU \"Cumulative side effects of cyclosporine and ca antagonists: hypergalactinemia, mastadenoma, and gynecomastia.\" Transplant Proc 26 (1994): 3122[5] Deray G, Aupetit B, Martinez F, et al \"Ciclosporin-nicardipine interaction.\" Am J Nephrol 9 (1989): 349[6] Sketris IS, Methot ME, Nicol D, Belitsky P, Knox MG \"Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients.\" Ann Pharmacother 28 (1994): 1227-31[7] Cantarovich M, Hiesse C, Lockiec F, Charpentier B, Fries D \"Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients.\" Clin Nephrol 28 (1987): 190-3[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[14] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[15] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.[18] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[19] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[20] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[21] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[25] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[28] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[29] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[30] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[31] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[32] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[33] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[34] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[35] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[36] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[37] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[38] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[39] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Clevidipine, Nimodipine", "updated_at": 1767369485}, {"id": 77007, "ingredient1": "Cyclosporine", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the plasma concentrations of nilotinib, which is a substrate of both the isoenzyme and the efflux transporter. Data are not available for nilotinib in combination with other CYP450 3A4 or P-glycoprotein inhibitors. Theoretically, a reverse interaction may also occur, since many CYP450 3A4 and P-glycoprotein inhibitors are also substrates, and nilotinib is an inhibitor of both.", "source": "DDInter", "management_text": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors. Pharmacologic response to nilotinib should be monitored more closely whenever a CYP450 3A4 or P-glycoprotein inhibitor is added to or withdrawn from therapy, and the nilotinib dosage adjusted as necessary. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 480 msec will require suspension of nilotinib therapy and immediate action to correct any concomitant risk factors before resuming treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Patients should also be monitored for altered efficacy and safety of the concomitant administered drug.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77108/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77008, "ingredient1": "Cyclosporine", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and CYP450 3A4 may increase the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors. Pharmacologic response to nintedanib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the nintedanib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for increased adverse effects such as liver enzyme and bilirubin elevations, diarrhea, nausea, vomiting, gastrointestinal perforation, bleeding, and arterial thromboembolic events (e.g., myocardial infarction).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77109/", "reference_text": "[1] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77009, "ingredient1": "Cyclosporine", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of P-glycoprotein (P-gp) may increase the bioavailability of niraparib, which is a substrate of the efflux transporter. Increased levels of niraparib may lead to increased incidence of hematological toxicity (e.g., thrombocytopenia, anemia, neutropenia) and/or cardiovascular toxicity (e.g., hypertension, hypertensive crisis).", "source": "DDInter", "management_text": "Pharmacologic response to niraparib should be monitored more closely whenever a potent P-gp inhibitor is added to or withdrawn from therapy, and the niraparib dosage adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Pharmacologic response to niraparib should be monitored more closely whenever a potent P-gp inhibitor is added to or withdrawn from therapy, and the niraparib dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77110/", "reference_text": "[1] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77010, "ingredient1": "Cyclosporine", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Cyclosporine may increase serum concentrations of some dihydropyridine calcium channel blockers (CCBs). Serum CCB levels and the risk of side effects may be increased. Data are available for nifedipine. In addition, gingival hyperplasia has been reported with nifedipine and cyclosporine.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety (e.g., increased cyclosporine levels, excessive hypotension, or nephrotoxicity) of the calcium channel blocker is recommended during concomitant therapy and when the dose of cyclosporine is changed or discontinued. CCB dosage adjustments may be required. Patients should be advised to notify their physician if they experience excessive CCB effects such as dizziness, excessive hypotension, syncope, headache, or lower extremity edema.", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77111/", "reference_text": "[1] Sketris IS, Methot ME, Nicol D, Belitsky, Knox MG \"Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients.\" Ann Pharmacother 28 (1994): 1227-31[2] McFadden JP, Pontin JE, Powles AV, Fry L, Idle JR \"Cyclosporin decreases nifedipine metabolism.\" Br Med J 299 (1989): 1244[3] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Jacobs U, Klein B, Klehr HU \"Cumulative side effects of cyclosporine and ca antagonists: hypergalactinemia, mastadenoma, and gynecomastia.\" Transplant Proc 26 (1994): 3122[5] Harper SJ, Moorhouse J, Veitch PS, et al. \"Improved immediate graft function with nifedipine in cyclosporine-treated renal allograft recipients--a randomized prospective study.\" Transplantation 54 (1992): 742-3[6] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[11] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[12] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[13] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[14] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[15] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.[16] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[17] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[18] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[19] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[20] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[21] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[24] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[25] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[26] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[27] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[31] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[32] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[33] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[34] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[35] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[36] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[37] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Clevidipine, Nimodipine", "updated_at": 1767369485}, {"id": 77011, "ingredient1": "Cyclosporine", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77112/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 77012, "ingredient1": "Cyclosporine", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Norfloxacin has been reported to increase serum cyclosporine concentrations by an unknown mechanism, although one study failed to demonstrate such an interaction. The risk of nephrotoxicity may be increased. Pefloxacin may theoretically also interact, although a study reported no alterations in cyclosporine pharmacokinetics after 4 days of concurrent administration.", "source": "DDInter", "management_text": "Cyclosporine levels and renal function should be monitored during concomitant administration. Cyclosporine dosage should be adjusted as needed. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.", "mechanism_text": "Others", "recommendation": "Cyclosporine levels and renal function should be monitored during concomitant administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77113/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Van Burne DH, Koestner J, Adedoyin A, et al \"Effect of ciprofloxacin on cyclosporine pharmacokinetics.\" Transplantation 50 (1990): 888-9[3] Jadoul M, Pirson Y, van Ypersele De Strihou C \"Norfloxacin and cyclosporine--a safe combination.\" Transplantation 47 (1989): 747-8[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (part II).\" Clin Pharmacokinet 19 (1990): 400-15[5] Thomson DJ, Menkis AH, McKenzie FN \"Norfloxacin-cyclosporine interaction.\" Transplantation 46 (1988): 312-3[6] Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Forst RW \"Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.\" Antimicrob Agents Chemother 33 (1989): 1118-20[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[9] Noer BL, Angaran DW \"The effect of enteral feedings on ciprofloxacin pharmacokinetics.\" Pharmacotherapy 10 (1990): 254[10] Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW \"Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction.\" J Clin Pharmacol 42 (2002): 461-6[11] Yuk JH, Nightingale CH, Quintiliani R \"Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition.\" Diagn Microbiol Infect Dis 13 (1990): 99-102[12] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6[13] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[14] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[19] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[20] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[21] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[22] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[23] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[24] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[25] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Cefixime, Levofloxacin, Secnidazole, Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Chlorhexidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 77013, "ingredient1": "Cyclosporine", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "Coadministration with some estrogens or progestins may increase the plasma concentrations of cyclosporine. The risk of cyclosporine-induced nephrotoxicity, hepatotoxicity, and neurotoxicity may be increased. The proposed mechanism is competitive inhibition of cyclosporine metabolism via CYP450 3A4, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with cyclosporine. Cyclosporine blood levels as well as renal and hepatic function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity (e.g., fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, jaundice) or neurotoxicity (e.g., tremor, convulsions).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with cyclosporine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77114/", "reference_text": "[1] Maurer G \"Metabolism of cyclosporine.\" Transplant Proc 17 (1985): 19-26[2] Deray G, Le Hoang P, Cacoub P, et al \"Oral contraceptive interaction with cyclosporin.\" Lancet 1 (1987): 158-9[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[36] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[37] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[38] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[39] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[40] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[41] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[42] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[43] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[44] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[45] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[46] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[47] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 77014, "ingredient1": "Cyclosporine", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77115/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77015, "ingredient1": "Cyclosporine", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Coadministration with somatostatin analogs may decrease the blood concentrations of cyclosporine. The mechanism of interaction is unknown but may involve reduction of intestinal absorption of cyclosporine.", "source": "DDInter", "management_text": "Pharmacologic effects and blood concentrations of cyclosporine should be monitored more closely whenever a somatostatin analog is added to or withdrawn from the patient's anti-rejection regimen, and the cyclosporine dosage adjusted as necessary. \"", "mechanism_text": "Absorption", "recommendation": "Pharmacologic effects and blood concentrations of cyclosporine should be monitored more closely whenever a somatostatin analog is added to or withdrawn from the patient's anti-rejection regimen, and the cyclosporine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77116/", "reference_text": "[1] \"Product Information. Neoral Oral Solution (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5[3] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[4] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ganirelix, Cetrorelix, Nafarelin, Gonadorelin", "updated_at": 1767369485}, {"id": 77016, "ingredient1": "Cyclosporine", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77117/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[7] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77017, "ingredient1": "Cyclosporine", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77118/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990): 66-9[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[6] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, More", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 77018, "ingredient1": "Cyclosporine", "ingredient2": "Olsalazine", "severity": "Moderate", "effect": "Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure.", "source": "DDInter", "management_text": "Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77119/", "reference_text": "[1] \"Product Information. Canasa (mesalamine (5-aminosalicylic acid)).\" Axcan Scandipharm Inc, Birmingham, AL.[2] Schreiber S. Hamling J, Zehnter E, et al \"Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.\" Gut 40 (1997): 761-6[3] \"Product Information. Lialda (mesalamine (5-aminosalicylic acid)).\" Shire US Inc, Florence, KY.[4] Novis BH, Korzets Z, Chen P, Bernheim J \"Nephrotic syndrome after treatment with 5-aminosalicylic acid.\" Br Med J (Clin Res Ed) 296 (1988): 1442", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 77019, "ingredient1": "Cyclosporine", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77120/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Ascorbic acid, Vitamin A, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77020, "ingredient1": "Cyclosporine", "ingredient2": "Omeprazole", "severity": "Moderate", "effect": "Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of other agents that can cause magnesium loss such as cyclosporine. The mechanism via which hypomagnesemia may occur during long-term PPI use is unknown, although changes in intestinal absorption of magnesium may be involved. Coadministration with omeprazole may alter the blood concentrations of cyclosporine in some patients. The mechanism of interaction is unknown. Both increased and decreased cyclosporine levels have been described in isolated case reports of patients treated concomitantly with omeprazole 40 mg/day.", "source": "DDInter", "management_text": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as cyclosporine. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients. A potential interaction with omeprazole should also be considered when cyclosporine levels are altered and no other causes can be identified. Occasionally, a dosage adjustment of cyclosporine may be necessary.", "mechanism_text": "Absorption", "recommendation": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as cyclosporine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77121/", "reference_text": "[1] Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM \"More about omeparazole-cyclosporine interaction.\" Am J Gastroenterol 88 (1993): 154[2] Castellote E, Bonet J, Lauzurica R, Pastor C, Cofan F, Caralps A \"Does interaction between omeprazole and cyclosporin exist?\" Nephron 65 (1993): 478[3] Schouler L, Dumas F, Couzigou P, et al \"Omeprazole-cyclosporin interaction.\" Am J Gastroenterol 86 (1991): 1097[4] Blohme I, Idstrom JP, Andersson T \"A study of the interaction between omeprazole and cyclosporine in renal transplant patients.\" Br J Clin Pharmacol 35 (1993): 156-60[5] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.\" ([2011 Mar 2]):[6] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[7] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[12] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[13] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[14] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[15] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[16] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[17] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[18] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 77021, "ingredient1": "Cyclosporine", "ingredient2": "Orlistat", "severity": "Major", "effect": "Limited clinical data suggest that orlistat may significantly reduce the oral bioavailability of cyclosporine. By partially inhibiting the absorption of dietary fat, orlistat may indirectly reduce the gastrointestinal absorption of cyclosporine, which is a highly lipid-soluble drug. There have been case reports of patients whose cyclosporine blood levels became subtherapeutic shortly following the initiation of orlistat therapy.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate drug levels, orlistat should preferably not be used in transplant patients treated with cyclosporine. If concomitant therapy is necessary, separating the doses by at least 2 hours may help minimize the potential for an interaction. Cyclosporine blood levels should be closely monitored and patients should be monitored for signs of rejection.", "mechanism_text": "Absorption", "recommendation": "Given the risk of organ rejection associated with inadequate drug levels, orlistat should preferably not be used in transplant patients treated with cyclosporine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77122/", "reference_text": "[1] Colman E, Fossler M \"Reduction in blood cyclosporine concentrations by orlistat.\" N Engl J Med 342 (2000): 1141[2] Nagele H, Petersen B, Bonacker U, Rodiger W \"Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient.\" Eur J Clin Pharmacol 55 (1999): 667-9[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Dexfenfluramine, Ephedrine, Fenfluramine, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 77022, "ingredient1": "Cyclosporine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osilodrostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations for signs and symptoms of hypocortisolism such as nausea, vomiting, abdominal pain, loss of appetite, fatigue, dizziness, hypotension, abnormal electrolyte levels, and hypoglycemia. Decrease dosing or temporarily discontinue osilodrostat if patients experience symptoms of hypocortisolism or if urine free cortisol levels fall below the target range or there is a rapid decrease in cortisol levels. Stop osilodrostat and administer exogenous glucocorticoid replacement therapy if patients have symptoms of adrenal insufficiency and serum or plasma cortisol levels are below target range. Osilodrostat therapy may be restarted at a lower dosage when symptoms have resolved and cortisol values are within target range.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77123/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77023, "ingredient1": "Cyclosporine", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77124/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77024, "ingredient1": "Cyclosporine", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of oxaliplatin, which is primarily eliminated unchanged by the kidney.", "source": "DDInter", "management_text": "Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of oxaliplatin such as peripheral sensory neuropathies and neutropenia should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77125/", "reference_text": "[1] \"Product Information. Eloxatin (oxaliplatin).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77025, "ingredient1": "Cyclosporine", "ingredient2": "Oxandrolone", "severity": "Moderate", "effect": "Coadministration with androgens or anabolic steroids may increase the blood concentrations of cyclosporine. The exact mechanism of interaction is unknown but may involve competitive inhibition of the CYP450 3A4 metabolism of cyclosporine.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids. Cyclosporine blood levels, renal function, and liver function tests should be monitored frequently and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of androgen dosage in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77126/", "reference_text": "[1] Ross WB, Roberts D, Griffin PJA, Salaman JR \"Cyclosporin interaction with danazol and norethisterone.\" Lancet 1 (1986): 330[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, Navarro-Ruiz J, Gonzalez-Delgado M, Conesa-Garcia V \"Possible cyclosporin-danazol interaction in a patient with aplastic anaemia.\" Am J Hematol 62 (1999): 63-4[4] Goffin E, Pirson Y, Geubel A, de Strihou C \"Cyclosporine-methyltestosterone interaction.\" Nephron 59 (1991): 174-5[5] Wood P, Liu Yin JA \"Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient.\" Clin Lab Haematol 16 (1994): 201-4[6] Moller BB, Ekelund B \"Toxicity of cyclosporine during treatment with androgens.\" N Engl J Med 313 (1985): 1416[7] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (part II).\" Clin Pharmacokinet 19 (1990): 400-15[8] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[9] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[14] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[15] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[16] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[17] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[18] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[19] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[20] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Prasterone", "updated_at": 1767369485}, {"id": 77026, "ingredient1": "Cyclosporine", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77127/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 77027, "ingredient1": "Cyclosporine", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.", "source": "DDInter", "management_text": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77128/", "reference_text": "[1] Rosche J, Froscher W, Abendroth D, Liebel J \"Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study.\" Clin Neuropharmacol 24 (2001): 113-6[2] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC \"Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.\" Ther Drug Monit 15 (1993): 39-42[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 77028, "ingredient1": "Cyclosporine", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of oxycodone, which is primarily metabolized by the isoenzyme. Increased oxycodone concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Itraconazole, telithromycin and voriconazole are considered potent inhibitors of CYP450 3A4.", "source": "DDInter", "management_text": "Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors. The risk of overdose may be increased following the initiation of a CYP450 3A4 inhibitor in patients already receiving oxycodone. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of oxycodone or development of withdrawal symptoms due to reduced plasma oxycodone levels.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77129/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] Nieminen TH, Hagelberg NM, Saari TI, et al \"Grapefruit juice enhances the exposure to oral oxycodone.\" Basic Clin Pharmacol Toxicol 107 (2010): 782-8", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, Belimumab, More", "alternatives_b": "Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 77029, "ingredient1": "Cyclosporine", "ingredient2": "Oxymetholone", "severity": "Moderate", "effect": "Coadministration with androgens or anabolic steroids may increase the blood concentrations of cyclosporine. The exact mechanism of interaction is unknown but may involve competitive inhibition of the CYP450 3A4 metabolism of cyclosporine.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids. Cyclosporine blood levels, renal function, and liver function tests should be monitored frequently and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of androgen dosage in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77130/", "reference_text": "[1] Ross WB, Roberts D, Griffin PJA, Salaman JR \"Cyclosporin interaction with danazol and norethisterone.\" Lancet 1 (1986): 330[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, Navarro-Ruiz J, Gonzalez-Delgado M, Conesa-Garcia V \"Possible cyclosporin-danazol interaction in a patient with aplastic anaemia.\" Am J Hematol 62 (1999): 63-4[4] Goffin E, Pirson Y, Geubel A, de Strihou C \"Cyclosporine-methyltestosterone interaction.\" Nephron 59 (1991): 174-5[5] Wood P, Liu Yin JA \"Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient.\" Clin Lab Haematol 16 (1994): 201-4[6] Moller BB, Ekelund B \"Toxicity of cyclosporine during treatment with androgens.\" N Engl J Med 313 (1985): 1416[7] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (part II).\" Clin Pharmacokinet 19 (1990): 400-15[8] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[9] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[14] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[15] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[16] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[17] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[18] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[19] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[20] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Prasterone", "updated_at": 1767369485}, {"id": 77030, "ingredient1": "Cyclosporine", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration with breast cancer resistance protein (BCRP) inhibitors may increase the exposure of the active metabolites of ozanimod and the risk of adverse effects. Coadministration with cyclosporine, a BCRP inhibitor, did not alter the AUC of ozanimod, but it did double the exposure of the minor active metabolites of ozanimod, RP101988 and RP101075 which are direct precursors of the major active metabolite CC112273.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "mechanism_text": "Others", "recommendation": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77131/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77031, "ingredient1": "Cyclosporine", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "mechanism_text": "Metabolism", "recommendation": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77132/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K \"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma.\" Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J \"Drug interactions of paclitaxel metabolism in human liver microsomes.\" J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D \"Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.\" Drugs 48 (1994): 794-847[5] \"Product Information. Abraxane (paclitaxel protein-bound).\" American Pharmaceutical Partners, Schaumberg, IL.[6] \"Product Information. Taxol (paclitaxel).\" Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM \"Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract).\" Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[9] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77032, "ingredient1": "Cyclosporine", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with palbociclib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, macrolide immunosuppressants, oral midazolam, pimozide, quinidine, sufentanil, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever palbociclib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when palbociclib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77133/", "reference_text": "[1] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77033, "ingredient1": "Cyclosporine", "ingredient2": "Pamidronic acid", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77134/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 77034, "ingredient1": "Cyclosporine", "ingredient2": "Pancuronium", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77135/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 77035, "ingredient1": "Cyclosporine", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, anorexia, peripheral edema, cardiotoxicity, ECG abnormalities, electrolyte disturbances, bleeding complications, hepatotoxicity and myelosuppression, and the dosage of panobinostat adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77136/", "reference_text": "[1] Hamberg P, Woo MM, Chen LC, et al. \"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\" Cancer Chemother Pharmacol 68 (2011): 805-13[2] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77036, "ingredient1": "Cyclosporine", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.", "source": "DDInter", "management_text": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77137/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.\" ([2011 Mar 2]):[2] \"Product Information. Nexium (esomeprazole)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 77037, "ingredient1": "Cyclosporine", "ingredient2": "Pasireotide", "severity": "Moderate", "effect": "Coadministration with somatostatin analogs may decrease the blood concentrations of cyclosporine. The mechanism of interaction is unknown but may involve reduction of intestinal absorption of cyclosporine.", "source": "DDInter", "management_text": "Pharmacologic effects and blood concentrations of cyclosporine should be monitored more closely whenever a somatostatin analog is added to or withdrawn from the patient's anti-rejection regimen, and the cyclosporine dosage adjusted as necessary. \"", "mechanism_text": "Absorption", "recommendation": "Pharmacologic effects and blood concentrations of cyclosporine should be monitored more closely whenever a somatostatin analog is added to or withdrawn from the patient's anti-rejection regimen, and the cyclosporine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77138/", "reference_text": "[1] \"Product Information. Neoral Oral Solution (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5[3] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[4] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ganirelix, Cetrorelix, Nafarelin, Gonadorelin", "updated_at": 1767369485}, {"id": 77038, "ingredient1": "Cyclosporine", "ingredient2": "Pazopanib", "severity": "Major", "effect": "Coadministration with potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations and risk of toxicity of pazopanib. The proposed mechanism involves inhibition of P-gp- or BCRP-mediated transporters of pazopanib metabolism. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.", "source": "DDInter", "management_text": "Concomitant use of pazopanib with potent inhibitors of P-gp or BCRP should generally be avoided. Selection of an alternate concomitant medication with no or minimal potential to inhibit P-gp or BCRP should be considered. Patients should have liver function tests (ALT, AST, bilirubin), electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. In addition, they should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of pazopanib with potent inhibitors of P-gp or BCRP should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77139/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Tan AR, Gibbon DG, Stein MN, et al. \"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.\" Cancer Chemother Pharmacol 71 (2013): 1635-43[3] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77039, "ingredient1": "Cyclosporine", "ingredient2": "Pegaspargase", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77140/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 77040, "ingredient1": "Cyclosporine", "ingredient2": "Peginesatide", "severity": "Moderate", "effect": "Concomitant use of cyclosporine with erythropoiesis-stimulating agents (ESAs) may produce additive increases on blood pressure. Either treatment alone may commonly cause hypertension, which can be severe or difficult to control in some cases. Additionally, use of ESAs may alter cyclosporine blood levels, since cyclosporine is bound by red blood cells.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is prescribed in combination with ESAs. Blood pressure should be adequately controlled before initiating treatment and monitored periodically during treatment. Patients who develop hypertension that is difficult to control by medications or dietary measures should have their ESA treatment reduced or withheld. In addition, cyclosporine blood levels should be checked regularly, as changes may occur following the addition, withdrawal, or change of dosage of ESA therapy. Dosage adjustments for cyclosporine may be required with increases in hematocrit levels.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if cyclosporine is prescribed in combination with ESAs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77141/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Luspatercept, Daprodustat", "updated_at": 1767369485}, {"id": 77041, "ingredient1": "Cyclosporine", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77142/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, Anakinra, More", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Interferon alfa-2b, More", "updated_at": 1767369485}, {"id": 77042, "ingredient1": "Cyclosporine", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.", "source": "DDInter", "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77143/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 77043, "ingredient1": "Cyclosporine", "ingredient2": "Pemigatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro. Increased exposure to pemigatinib may increase the incidence and severity of serious adverse reactions such as abdominal pain, acute kidney injury, cholangitis, cholangitis infective, diarrhea, failure to thrive, hypercalcemia, hyponatremia, pleural effusion, pyrexia, small intestinal obstruction, and urinary tract infection.", "source": "DDInter", "management_text": "Caution is advised if pemigatinib is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pemigatinib is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77144/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77044, "ingredient1": "Cyclosporine", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Barbiturates may decrease serum cyclosporine concentrations and efficacy. The mechanism is enhanced hepatic microsomal metabolism of cyclosporine.", "source": "DDInter", "management_text": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations.", "mechanism_text": "Metabolism", "recommendation": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77145/", "reference_text": "[1] Burckart GJ, Venkataramanan R, Ptachcinski RJ \"Usefulness of cyclosporin monitoring questioned.\" Clin Pharm 3 (1984): 243[2] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Noguchi M, Kiuchi C, Akiyama H, et al \"Interaction between cyclosporin A and anticonvulsants.\" Bone Marrow Transplant 9 (1992): 391[6] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[7] Kerr LE \"Drug interactions with cyclosporine.\" Clin Pharm 3 (1984): 346,348[8] Carstensen H, Jacobsen N, Dieperink H \"Interaction between cyclosporin A and phenobarbitone.\" Br J Clin Pharmacol 21 (1986): 550-1[9] Wideman CA \"Pharmacokinetic monitoring of cyclosporine.\" Transplant Proc 15(1/2) (1983): 3168-75[10] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[12] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[13] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[17] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[18] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[19] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[20] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[21] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[22] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[23] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[24] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 77045, "ingredient1": "Cyclosporine", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77146/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990): 66-9[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[6] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More", "alternatives_b": "Bempedoic acid", "updated_at": 1767369485}, {"id": 77046, "ingredient1": "Cyclosporine", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.", "source": "DDInter", "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77147/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Anakinra, Inebilizumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77047, "ingredient1": "Cyclosporine", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77148/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More", "alternatives_b": "Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77048, "ingredient1": "Cyclosporine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Phenytoin may significantly reduce cyclosporine serum concentrations. The mechanism may be inhibition of cyclosporine absorption or induction of hepatic CYP450 metabolism or both. This interaction may occur with ethotoin, fosphenytoin, and mephenytoin as well.", "source": "DDInter", "management_text": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when phenytoin is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations. Some experts suggest that this interaction could persist for a week or more following discontinuation of phenytoin.", "mechanism_text": "Metabolism", "recommendation": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when phenytoin is started or stopped.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77149/", "reference_text": "[1] Keown PA, Laupacis A, Carruthers G, et al. \"Interaction between phenytoin and cyclosporine following organ transplantation.\" Transplantation 38 (1984): 304-6[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Freeman DJ, Laupacis A, Keown PA, et al \"Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites.\" Br J Clin Pharmacol 18 (1984): 887-93[4] Keown PA, Stiller CR, Laupacis AL, et al \"The effects and side effects of cyclosporine: relationship to drug pharmacokinetics.\" Transplant Proc 14 (1982): 659-61[5] Rowland M, Gupta SK \"Cyclosporin-phenytoin interaction: re-evaluation using metabolite data.\" Br J Clin Pharmacol 24 (1987): 329-34[6] Formea CM, Evans CG, Karlix JL \"Altered cytochrome p450 metabolism of calcineurin inhibitors: case report and review of the literature.\" Pharmacotherapy 25 (2005): 1021-9[7] Schweitzer EJ, Canafax DM, Gillingham KJ, Najarian JS, Matas AJ \"Phenytoin administration in kidney recipients on csa immunosuppression.\" J Am Soc Nephrol 2 (1991): 816[8] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[9] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Schmidt H, Naumann R, Jaschonek K, Einsele H, Dopfer R, Ehninger G \"Drug interaction between cyclosporin and phenytoin in allogeneic bone marrow transplantation.\" Bone Marrow Transplant 4 (1989): 212-3[12] Cerner Multum, Inc. \"Australian Product Information.\" O 0[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[16] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[17] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[20] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[21] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[22] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[23] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[24] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[25] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[26] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[27] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[28] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[29] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[32] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[33] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[34] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[35] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[36] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[37] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[38] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[39] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[40] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Inebilizumab, Ozanimod, Belimumab, Sutimlimab, Risankizumab, Antilymphocyte immunoglobulin (horse), More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 77049, "ingredient1": "Cyclosporine", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as peripheral edema and QT prolongation, and the pimavanserin dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77150/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 77050, "ingredient1": "Cyclosporine", "ingredient2": "Pimecrolimus (topical)", "severity": "Minor", "effect": "Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77151/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77051, "ingredient1": "Cyclosporine", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme. The use of pimozide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated. Some authorities consider concomitant administration of lurasidone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. With respect to less potent CYP450 3A4 inhibitors, the manufacturers recommend that they also not be used with pimozide.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77152/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[3] Flockhart DA, Drici MD, Kerbusch T, et al \"Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome.\" J Clin Psychopharmacol 20 (2000): 317-24[4] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[5] Desta Z, Kerbusch T, Flockhart DA \"Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).\" Clin Pharmacol Ther 65 (1999): 10-20[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[8] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[9] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ \"Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.\" Am J Med Sci 309 (1995): 315-6[10] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[11] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 77052, "ingredient1": "Cyclosporine", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77153/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 77053, "ingredient1": "Cyclosporine", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77154/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Bromfenac", "updated_at": 1767369485}, {"id": 77054, "ingredient1": "Cyclosporine", "ingredient2": "Pitavastatin", "severity": "Major", "effect": "Coadministration with cyclosporine may significantly increase the plasma concentrations of pitavastatin. The mechanism is cyclosporine inhibition of pitavastatin hepatic uptake via organic anion transporting polypeptide (OATP) 1B1. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.", "source": "DDInter", "management_text": "The use of pitavastatin in combination with cyclosporine is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "The use of pitavastatin in combination with cyclosporine is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77155/", "reference_text": "[1] Neuvonen PJ, Niemi M, Backman JT \"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance.\" Clin Pharmacol Ther 80 (2006): 565-81[2] Hirano M, Maeda K, Shitara Y, Sugiyama Y \"Drug-drug interaction between pitavastatin and various drugs via OATP1B1.\" Drug Metab Dispos 34 (2006): 1229-36[3] \"Product Information. Livalo (pitavastatin).\" Kowa Pharmaceuticals America (formerly ProEthic), Montgomery, AL.[4] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[5] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[10] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[11] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[12] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[13] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[14] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[15] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[16] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Alirocumab", "updated_at": 1767369485}, {"id": 77055, "ingredient1": "Cyclosporine", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "The nephrotoxic effects of cyclosporine and aminoglycosides are additive. The combination generally should be avoided.", "source": "DDInter", "management_text": "If these agents must be used concomitantly, renal function should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "If these agents must be used concomitantly, renal function should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77156/", "reference_text": "[1] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Whiting PH, Simpson JG \"The enhancement of cyclosporin A-induced nephrotoxicity by gentamicin.\" Biochem Pharmacol 32 (1983): 2025-8[4] Termeer A, Hoitsma AJ, Koene RA \"Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients.\" Transplantation 42 (1986): 220-1[5] Chandrasekar PH, Cronin SM \"Nephrotoxicity in bone marrow transplant recipients receiving aminoglycoside plus cyclosporine or aminoglycoside alone.\" J Antimicrob Chemother 27 (1991): 845-9[6] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77056, "ingredient1": "Cyclosporine", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77157/", "reference_text": "[1] \"Product Information. Polivy (polatuzumab vedotin).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 77057, "ingredient1": "Cyclosporine", "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77158/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77058, "ingredient1": "Cyclosporine", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Coadministration of thiazide or thiazide-like diuretics with cyclosporine may potentially result in hypermagnesemia, hyperuricemia, and increase the risk of nephrotoxicity.", "source": "DDInter", "management_text": "Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use. Some authorities advise against concomitant use of these medicines.", "mechanism_text": "Others", "recommendation": "Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77159/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[5] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[10] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[11] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[12] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[13] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[14] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[15] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[16] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Trichlormethiazide, Methyclothiazide, Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, More", "updated_at": 1767369485}, {"id": 77059, "ingredient1": "Cyclosporine", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 1A2, CYP450 3A4, and P-glycoprotein may increase the plasma concentrations of pomalidomide, which has been shown to be primarily metabolized by these isoenzymes and also a substrate of the efflux transporter. Pomalidomide exposure is increased when given with a strong CYP450 1A2 inhibitor (e.g., fluvoxamine) in the presence of a strong CYP450 3A4 and P-gp inhibitor (e.g., ketoconazole). Coadministration with ketoconazole alone did not have a clinically significant effect on exposure to pomalidomide.", "source": "DDInter", "management_text": "The use of pomalidomide with potent inhibitors of CYP450 1A2 (e.g., ciprofloxacin, fluvoxamine, tiabendazole) in the presence of strong CYP450 3A4 and P-gp inhibitors should generally be avoided. If coadministration is considered clinically necessary, the pomalidomide dose should be reduced by 50%. Dose reduction may also be required if pomalidomide is given with a strong inhibitor of CYP450 1A2 in the absence of a coadministered CYP450 3A4 and P-gp inhibitor. Patients should be monitored for occurrence of pomalidomide-related side effects, including nausea, diarrhea, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "The use of pomalidomide with potent inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77160/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77060, "ingredient1": "Cyclosporine", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with ponatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ponatinib.", "source": "DDInter", "management_text": "Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ponatinib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77161/", "reference_text": "[1] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77061, "ingredient1": "Cyclosporine", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Posaconazole may significantly increase cyclosporine concentrations by inhibiting CYP450 3A4 metabolism. The risk of cyclosporine-related adverse effects may be increased. Serious adverse events including nephrotoxicity, leukoencephalopathy, and death were reported during clinical studies. Conversely, cyclosporine may increase plasma levels of posaconazole by inhibiting its clearance via P-glycoprotein-mediated efflux.", "source": "DDInter", "management_text": "Cycloporine dosage should be reduced to approximately 75% of the original dosage upon initiation of posaconazole treatment. Cyclosporine blood levels and renal function, including serum creatinine, should be carefully monitored during concomitant use and upon withdrawal of posaconazole. Patients should be advised to notify their physician if they experience symptoms that could indicate cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Cycloporine dosage should be reduced to approximately 75% of the original dosage upon initiation of posaconazole treatment.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77162/", "reference_text": "[1] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[2] Sansone-Parsons A, Krishna G, Calzetta A, et al. \"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.\" Antimicrob Agents Chemother 50 (2006): 1881-3[3] Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P \"Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations.\" Clin Pharmacokinet 50 (2011): 725-34[4] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[5] Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J \"Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole.\" 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20[6] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[7] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[12] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[13] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[14] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[15] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[16] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[17] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[18] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Micafungin, Oteseconazole", "updated_at": 1767369485}, {"id": 77062, "ingredient1": "Cyclosporine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors. Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77163/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77063, "ingredient1": "Cyclosporine", "ingredient2": "Pravastatin", "severity": "Major", "effect": "Coadministration with cyclosporine may increase the oral bioavailability of pravastatin. The proposed mechanism is cyclosporine inhibition of the intestinal efflux of pravastatin via MRP2 transporter.", "source": "DDInter", "management_text": "The benefits of the use of pravastatin in combination with cyclosporine should be carefully weighed against the potential risks. Pravastatin dosage should start at 10 mg/day and generally not exceed 20 mg/day when used in combination with cyclosporine. Higher dosages should be used with caution. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Absorption", "recommendation": "The benefits of the use of pravastatin in combination with cyclosporine should be carefully weighed against the potential risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77164/", "reference_text": "[1] Holtzman CW, Wiggins BS, Spinler SA \"Role of P-glycoprotein in statin drug interactions.\" Pharmacotherapy 26 (2006): 1601-7[2] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[3] Park JW, Siekmeier R, Merz M, et al. \"Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.\" Int J Clin Pharmacol Ther 40 (2002): 439-50[4] Castelao AM, Grinyo JM, Castineiras MJ, Fiol C, Gilvernet S, Seron D, Torras J, Cruzado JM, Alsina J \"Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone.\" Transplant Proc 27 (1995): 2217-20[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Norman DJ, Illingworth DR, Munson J, Hosenpud J \"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.\" N Engl J Med 318 (1988): 46-7[7] Bancalari E \"Caffeine for apnea of prematurity.\" N Engl J Med 354 (2006): 2179-81[8] Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V \"Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.\" Am J Nephrol 19 (1999): 411-5[9] Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, Monzon A, Rodriguez-Tudela JL \"Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.\" J Antimicrob Chemother 46 (2000): 475-7[10] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[11] Lill J, Bauer LA, Horn JR, Hansten PD \"Cyclosporine-drug interactions and the influence of patient age.\" Am J Health Syst Pharm 57 (2000): 1579-84[12] Yoshimura N, Oka T, Okamoto M, Ohmori Y \"The effects of pravastatin on hyperlipidemia in renal transplant recipients.\" Transplantation 53 (1992): 94-9[13] Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M \"Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.\" Clin Pharmacol Ther 75 (2004): 101-9[14] Kobashigwa JA, Katznelson S, Laks H, et al. \"Effect of pravastatin on outcomes after cardiac transplantation.\" N Engl J Med 333 (1995): 621-7[15] \"Product Information. Pravachol (pravastatin).\" Bristol-Myers Squibb, Princeton, NJ.[16] Launay-Vacher V, Izzedine H, Deray G \"Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.\" Int J Cardiol 101 (2005): 9-17[17] Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A, Vigano M \"Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.\" Transplant Proc 25 (1993): 2732-4[18] Southworth MR, Mauro VF \"The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.\" Ann Pharmacother 31 (1997): 489-91[19] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[20] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[21] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[22] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[25] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[26] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[27] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[28] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[29] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[30] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[31] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "alternatives_b": "Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Alirocumab, Bempedoic acid", "updated_at": 1767369485}, {"id": 77064, "ingredient1": "Cyclosporine", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration of cyclosporine with a corticosteroid may result in altered (usually elevated) plasma concentrations of one or both drugs. Cyclosporine and corticosteroids undergo metabolism primarily by CYP450 3A4, thus competitive inhibition of metabolic clearance may occur during concomitant use.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with cyclosporine and corticosteroids. Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever one or the other agent is added to or withdrawn from therapy in patients stabilized on their existing therapeutic regimen, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with cyclosporine and corticosteroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77165/", "reference_text": "[1] Klintmalm G, Sawe J \"High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients.\" Lancet 1 (1984): 731[2] Durrant S, Chipping PM, Palmer S, Gordon-Smith EC \"Cyclosporin A, methylprednisolone, and convulsions.\" Lancet 2 (1982): 829-30[3] Ost L \"Effects of cyclosporin on prednisolone metabolism.\" Lancet 1 (1984): 451[4] Langhoff E, Madsen S, Flachs H, et al \"Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients.\" Transplantation 39 (1985): 107-9[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Fluocinolone acetonide, Mometasone furoate, Beclomethasone dipropionate, Amcinonide, Fluocinolone acetonide, Mometasone furoate, Chlorhexidine, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, More", "updated_at": 1767369485}, {"id": 77065, "ingredient1": "Cyclosporine", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration of cyclosporine with a corticosteroid may result in altered (usually elevated) plasma concentrations of one or both drugs. Cyclosporine and corticosteroids undergo metabolism primarily by CYP450 3A4, thus competitive inhibition of metabolic clearance may occur during concomitant use.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with cyclosporine and corticosteroids. Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever one or the other agent is added to or withdrawn from therapy in patients stabilized on their existing therapeutic regimen, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with cyclosporine and corticosteroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77166/", "reference_text": "[1] Klintmalm G, Sawe J \"High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients.\" Lancet 1 (1984): 731[2] Durrant S, Chipping PM, Palmer S, Gordon-Smith EC \"Cyclosporin A, methylprednisolone, and convulsions.\" Lancet 2 (1982): 829-30[3] Ost L \"Effects of cyclosporin on prednisolone metabolism.\" Lancet 1 (1984): 451[4] Langhoff E, Madsen S, Flachs H, et al \"Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients.\" Transplantation 39 (1985): 107-9[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 77066, "ingredient1": "Cyclosporine", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Barbiturates may decrease serum cyclosporine concentrations and efficacy. The mechanism is enhanced hepatic microsomal metabolism of cyclosporine.", "source": "DDInter", "management_text": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations.", "mechanism_text": "Metabolism", "recommendation": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77167/", "reference_text": "[1] Burckart GJ, Venkataramanan R, Ptachcinski RJ \"Usefulness of cyclosporin monitoring questioned.\" Clin Pharm 3 (1984): 243[2] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Noguchi M, Kiuchi C, Akiyama H, et al \"Interaction between cyclosporin A and anticonvulsants.\" Bone Marrow Transplant 9 (1992): 391[6] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[7] Kerr LE \"Drug interactions with cyclosporine.\" Clin Pharm 3 (1984): 346,348[8] Carstensen H, Jacobsen N, Dieperink H \"Interaction between cyclosporin A and phenobarbitone.\" Br J Clin Pharmacol 21 (1986): 550-1[9] Wideman CA \"Pharmacokinetic monitoring of cyclosporine.\" Transplant Proc 15(1/2) (1983): 3168-75[10] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[12] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[13] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[17] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[18] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[19] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[20] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[21] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[22] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[23] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[24] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Inebilizumab, Cladribine, Belimumab, Sutimlimab, Risankizumab, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 77067, "ingredient1": "Cyclosporine", "ingredient2": "Probucol", "severity": "Moderate", "effect": "The concomitant administration of probucol may modestly decrease oral cyclosporine concentrations. The mechanism is unknown. Subtherapeutic cyclosporine levels may increase the risk of rejection in transplant patients.", "source": "DDInter", "management_text": "Monitoring for altered efficacy and cyclosporine blood concentrations is recommended during concurrent therapy. Dose adjustments may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "Monitoring for altered efficacy and cyclosporine blood concentrations is recommended during concurrent therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77168/", "reference_text": "[1] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Sundararajan V, Cooper DK, Muchmore J, et al \"Interaction of cyclosporine and probucol in heart transplant patients.\" Transplant Proc 23 (1991): 2028-32[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Alirocumab", "updated_at": 1767369485}, {"id": 77068, "ingredient1": "Cyclosporine", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "Coadministration with some estrogens or progestins may increase the plasma concentrations of cyclosporine. The risk of cyclosporine-induced nephrotoxicity, hepatotoxicity, and neurotoxicity may be increased. The proposed mechanism is competitive inhibition of cyclosporine metabolism via CYP450 3A4, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with cyclosporine. Cyclosporine blood levels as well as renal and hepatic function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity (e.g., fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, jaundice) or neurotoxicity (e.g., tremor, convulsions).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with cyclosporine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77169/", "reference_text": "[1] Maurer G \"Metabolism of cyclosporine.\" Transplant Proc 17 (1985): 19-26[2] Deray G, Le Hoang P, Cacoub P, et al \"Oral contraceptive interaction with cyclosporin.\" Lancet 1 (1987): 158-9[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[36] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[37] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[38] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[39] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[40] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[41] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[42] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[43] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[44] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[45] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[46] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[47] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77069, "ingredient1": "Cyclosporine", "ingredient2": "Propafenone", "severity": "Minor", "effect": "case report suggests that propafenone may increase cyclosporine serum concentrations by an unknown mechanism. Until more data are available, caution should be exercised with concomitant use of these agents and cyclosporine levels should be monitored.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77170/", "reference_text": "[1] Spes CH, Angermann CE, Horn K, et al \"Ciclosporin-propafenone interaction.\" Klin Wochenschr 68 (1990): 872[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 77070, "ingredient1": "Cyclosporine", "ingredient2": "Prucalopride", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77171/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 77071, "ingredient1": "Cyclosporine", "ingredient2": "Pyrazinamide", "severity": "Moderate", "effect": "One case report demonstrated a decrease in cyclosporine blood level of nearly 50% two days after pyrazinamide was added to the patient's drug regimen. The mechanism of this interaction is unknown.", "source": "DDInter", "management_text": "Cyclosporine serum concentrations should be monitored if pyrazinamide is added to or discontinued from the patient's regimen. Patients should be carefully monitored for lack of therapeutic effect. The dosage of cyclosporine may need to be increased.", "mechanism_text": "Others", "recommendation": "Cyclosporine serum concentrations should be monitored if pyrazinamide is added to or discontinued from the patient's regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77172/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] del Cerro LA, Hernandez FR \"Effect of pyrazinamide on ciclosporin levels.\" Nephron 62 (1992): 113[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 77072, "ingredient1": "Cyclosporine", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be monitored for potentially increased adverse effects such as dizziness, drowsiness, dry mouth, constipation, increased appetite, weight gain, extrapyramidal symptoms, tardive dyskinesia, hyperglycemia, dyslipidemia, hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), orthostatic hypotension, blood pressure increases (in children and adolescents), QT prolongation, cognitive and motor impairment, dysphagia, and heat-related illnesses due to disruption of body temperature regulation.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77173/", "reference_text": "[1] Spina E, de Leon J \"Metabolic drug interactions with newer antipsychotics: a comparative review.\" Basic Clin Pharmacol Toxicol 100 (2007): 4-22[2] \"Quetiapine for schizophrenia.\" Med Lett Drugs Ther 39 (1997): 117-8[3] DeVane CL, Nemeroff CB \"Clinical pharmacokinetics of quetiapine - An atypical antipsychotic.\" Clin Pharmacokinet 40 (2001): 509-22[4] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB \"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\" Br J Clin Pharmacol 61 (2006): 58-69[5] Hantson P, Di Fazio V, Wallemacq P \"Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose.\" Drug Metab Lett 4 (2010): 7-8[6] Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. \"Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.\" Pharmacopsychiatry 41 (2008): 258-9[7] Spina E, Scordo MG, D'Arrigo C \"Metabolic drug interactions with new psychotropic agents.\" Fundam Clin Pharmacol 17 (2003): 517-38[8] Urichuk L, Prior TI, Dursun S, Baker G \"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.\" Curr Drug Metab 9 (2008): 410-8[9] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[10] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[17] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[19] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[20] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[21] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[22] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[23] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[24] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[25] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[28] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[29] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[32] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[35] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[36] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[39] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[40] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[41] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 77073, "ingredient1": "Cyclosporine", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77174/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990): 66-9[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[6] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77074, "ingredient1": "Cyclosporine", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Limited clinical data suggest that the concomitant use of quinine and cyclosporine may reduce blood levels of cyclosporine. The mechanism is unknown.", "source": "DDInter", "management_text": "Prescribers should be aware of the potential for an interaction.", "mechanism_text": "Others", "recommendation": "Prescribers should be aware of the potential for an interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77175/", "reference_text": "[1] Tan HW, Ch'ng SL \"Drug interaction between cyclosporine A and quinine in a renal transplant patient with malaria.\" Singapore Med J 32 (1991): 189-90[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[16] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[17] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[18] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[19] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71[20] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Primaquine, Proguanil", "updated_at": 1767369485}, {"id": 77075, "ingredient1": "Cyclosporine", "ingredient2": "Ramipril", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77176/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990): 66-9[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[6] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Bempedoic acid", "updated_at": 1767369485}, {"id": 77076, "ingredient1": "Cyclosporine", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "Coadministration of cyclosporine and ranolazine may increase the plasma concentrations of both drugs. Although the interaction has not been studied, competitive or noncompetitive inhibition of P-glycoprotein and CYP450 3A4 is possible, since these drugs are substrates as well as inhibitors of both the drug efflux transporter and isoenzyme. Drug toxicities may occur. Because ranolazine prolongs the QT interval in a dose-dependent manner, high plasma levels may increase the risk of ventricular arrhythmias including ventricular fibrillation and torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine and ranolazine are used in combination. Cyclosporine blood levels and renal function should be monitored more closely whenever ranolazine is added to or withdrawn from therapy, and the cyclosporine dosage adjusted as necessary. Similarly, pharmacologic response to ranolazine should be monitored more closely in patients who are stabilized on ranolazine and are starting or discontinuing cyclosporine. During concomitant treatment, patients should be advised to notify their physician if they experience signs and symptoms of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine and ranolazine are used in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77177/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Regadenoson, Ubidecarenone", "updated_at": 1767369485}, {"id": 77077, "ingredient1": "Cyclosporine", "ingredient2": "Rapacuronium", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77178/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77078, "ingredient1": "Cyclosporine", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally. Relugolix is a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours. Patients should be monitored more frequently for adverse effects. Alternatively, treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77179/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Ganirelix, Cetrorelix, Nafarelin, Gonadorelin, Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, More", "updated_at": 1767369485}, {"id": 77079, "ingredient1": "Cyclosporine", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77180/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[3] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, Anakinra, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77080, "ingredient1": "Cyclosporine", "ingredient2": "Repaglinide", "severity": "Major", "effect": "Coadministration with cyclosporine may significantly increase the plasma concentrations of repaglinide. The proposed mechanism is cyclosporine inhibition of the hepatic uptake of repaglinide via organic anion transporting polypeptide (OATP) 1B1 and also its metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended if repaglinide is coadministered with cyclosporine. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The manufacturers recommend limiting the total daily dose of repaglinide to 6 mg when coadministered with cyclosporine.", "mechanism_text": "Metabolism", "recommendation": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended if repaglinide is coadministered with cyclosporine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77181/", "reference_text": "[1] Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT \"Cyclosporine markedly raises the plasma concentrations of repaglinide.\" Clin Pharmacol Ther 78 (2005): 388-99[2] Hatorp V \"Clinical pharmacokinetics and pharmacodynamics of repaglinide.\" Clin Pharmacokinet 41 (2002): 471-83[3] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[4] Niemi M, Backman JT, Kajosaari LI, et al. \"Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.\" Clin Pharmacol Ther 77 (2005): 468-78[5] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT \"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.\" Br J Clin Pharmacol 56 (2003): 305-14[6] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[7] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[17] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[23] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[24] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[26] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[30] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[31] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[34] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[35] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[36] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[37] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[38] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[39] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[40] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[41] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[42] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[43] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[44] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[45] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[46] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[47] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[48] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[49] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[50] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 77081, "ingredient1": "Cyclosporine", "ingredient2": "Retapamulin (topical)", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of retapamulin, which is primarily metabolized by the isoenzyme. However, dosage adjustments are not necessary due to the low systemic exposure to retapamulin following topical application.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77182/", "reference_text": "[1] \"Product Information. Altabax (retapamulin topical).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77082, "ingredient1": "Cyclosporine", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters.", "source": "DDInter", "management_text": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77183/", "reference_text": "[1] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[2] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[3] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[4] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[5] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Nedocromil, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 77083, "ingredient1": "Human Rho(D) immune globulin", "ingredient2": "Cyclosporine", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77184/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77084, "ingredient1": "Cyclosporine", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77185/", "reference_text": "[1] Rawden HC, Kokwaro GO, Ward SA, Edwards G \"Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.\" Br J Clin Pharmacol 49 (2000): 313-22[2] Trivier JM, Libersa C, Belloc C, Lhermitte M \"Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report).\" Life Sci 52 (1993): pl91-6[3] Kane GC, Lipsky JJ \"Drug-grapefruit juice interactions.\" Mayo Clin Proc 75 (2000): 933-42[4] Katoh M, Nakajima M, Yamazaki H, Yokoi T \"Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.\" Eur J Pharm Sci 12 (2001): 505-13[5] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM \"Effect of alosetron on the pharmacokinetics of alprazolam.\" J Clin Pharmacol 41 (2001): 452-4[6] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Yu DK \"The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.\" J Clin Pharmacol 39 (1999): 1203-11[8] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[9] Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA \"Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability.\" Am J Trop Med Hyg 66 (2002): 260-3[10] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77085, "ingredient1": "Cyclosporine", "ingredient2": "Rifabutin", "severity": "Major", "effect": "The coadministration with rifamycins, particularly rifampin, may decrease the blood concentrations and pharmacologic effects of cyclosporine. The mechanism probably involves reduced absorption as well as accelerated clearance of cyclosporine due to induction of both intestinal P-glycoprotein drug efflux pumps and hepatic/intestinal CYP450 3A4 isoenzymes by rifamycins.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with rifamycins, particularly rifampin. Cyclosporine blood levels should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of rifamycin therapy in patients who are stabilized on their anti-rejection regimen.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with rifamycins, particularly rifampin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77186/", "reference_text": "[1] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Al-Sulaiman MH, Dhar JM, Al-Khader AA \"Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine.\" Transplantation 50 (1990): 597-8[3] Koselj M, Bren A, Kandus A, Kovac D \"Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections.\" Transplant Proc 26 (1994): 2823-4[4] Van Buren D, Wideman CA, Ried M, et al. \"The antagonistic effect of rifampin upon cyclosporin bioavailability.\" Transplant Proc 16 (1984): 1642-5[5] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[6] Langhoff E, Madsen S \"Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment.\" Lancet 2 (1983): 1031[7] Allen RD, Hunnisett AG, Morris PJ \"Cyclosporin and rifampicin in renal transplantation.\" Lancet 1 (1985): 980[8] Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE \"Acute rejection and massive cyclosporin requirements in heart transplant recipients treated with rifampin.\" Transplantation 39 (1985): 313-4[9] Calne RY, White DJG, Thiru S, Rolles K, Drakopoulos S, Jamieson NV \"Cyclosporin and antituberculous therapy.\" Lancet 1 (1985): 1342-3[10] Daniels NJ, Dover JS, Schachter RK \"Interaction between cyclosporin and rifampicin.\" Lancet 1 (1984): 639[11] Zylber-Katz E \"Multiple drug interactions with cyclosporine in a heart transplant patient.\" Ann Pharmacother 29 (1995): 127-31[12] Howard P, Bixler TJ, Gill B \"Cyclosporine-rifampin drug interaction.\" Drug Intell Clin Pharm 19 (1985): 763-4[13] Cassidy MJ, Zyl-Smit RV, Pascoe MD, et al \"Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient.\" Nephron 41 (1985): 207-8[14] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[15] Watkins PB \"Drug metabolism by cytochromes P450 in the liver and small bowel.\" Gastroenterol Clin North Am 21 (1992): 511-26[16] Vandevelde C, Chang A, Andrews D, et al \"Rifampin and ansamycin interaction with cyclosporine after renal transplantation.\" Pharmacotherapy 11 (1991): 88-9[17] Offermann G, Keller F, Molzahn M \"Low cyclosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment.\" Am J Nephrol 5 (1985): 385-7[18] Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ \"Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.\" Clin Pharmacol Ther 52 (1992): 453-7[19] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[20] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[21] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[22] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[25] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[26] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[27] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[28] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[29] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[30] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[31] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Vonoprazan, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 77086, "ingredient1": "Cyclosporine", "ingredient2": "Rifampicin", "severity": "Major", "effect": "The coadministration with rifamycins, particularly rifampin, may decrease the blood concentrations and pharmacologic effects of cyclosporine. The mechanism probably involves reduced absorption as well as accelerated clearance of cyclosporine due to induction of both intestinal P-glycoprotein drug efflux pumps and hepatic/intestinal CYP450 3A4 isoenzymes by rifamycins.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with rifamycins, particularly rifampin. Cyclosporine blood levels should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of rifamycin therapy in patients who are stabilized on their anti-rejection regimen.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with rifamycins, particularly rifampin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77187/", "reference_text": "[1] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Al-Sulaiman MH, Dhar JM, Al-Khader AA \"Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine.\" Transplantation 50 (1990): 597-8[3] Koselj M, Bren A, Kandus A, Kovac D \"Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections.\" Transplant Proc 26 (1994): 2823-4[4] Van Buren D, Wideman CA, Ried M, et al. \"The antagonistic effect of rifampin upon cyclosporin bioavailability.\" Transplant Proc 16 (1984): 1642-5[5] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[6] Langhoff E, Madsen S \"Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment.\" Lancet 2 (1983): 1031[7] Allen RD, Hunnisett AG, Morris PJ \"Cyclosporin and rifampicin in renal transplantation.\" Lancet 1 (1985): 980[8] Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE \"Acute rejection and massive cyclosporin requirements in heart transplant recipients treated with rifampin.\" Transplantation 39 (1985): 313-4[9] Calne RY, White DJG, Thiru S, Rolles K, Drakopoulos S, Jamieson NV \"Cyclosporin and antituberculous therapy.\" Lancet 1 (1985): 1342-3[10] Daniels NJ, Dover JS, Schachter RK \"Interaction between cyclosporin and rifampicin.\" Lancet 1 (1984): 639[11] Zylber-Katz E \"Multiple drug interactions with cyclosporine in a heart transplant patient.\" Ann Pharmacother 29 (1995): 127-31[12] Howard P, Bixler TJ, Gill B \"Cyclosporine-rifampin drug interaction.\" Drug Intell Clin Pharm 19 (1985): 763-4[13] Cassidy MJ, Zyl-Smit RV, Pascoe MD, et al \"Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient.\" Nephron 41 (1985): 207-8[14] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[15] Watkins PB \"Drug metabolism by cytochromes P450 in the liver and small bowel.\" Gastroenterol Clin North Am 21 (1992): 511-26[16] Vandevelde C, Chang A, Andrews D, et al \"Rifampin and ansamycin interaction with cyclosporine after renal transplantation.\" Pharmacotherapy 11 (1991): 88-9[17] Offermann G, Keller F, Molzahn M \"Low cyclosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment.\" Am J Nephrol 5 (1985): 385-7[18] Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ \"Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.\" Clin Pharmacol Ther 52 (1992): 453-7[19] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[20] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[21] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[22] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[25] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[26] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[27] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[28] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[29] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[30] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[31] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Anakinra, Inebilizumab, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 77087, "ingredient1": "Cyclosporine", "ingredient2": "Rifapentine", "severity": "Major", "effect": "The coadministration with rifamycins, particularly rifampin, may decrease the blood concentrations and pharmacologic effects of cyclosporine. The mechanism probably involves reduced absorption as well as accelerated clearance of cyclosporine due to induction of both intestinal P-glycoprotein drug efflux pumps and hepatic/intestinal CYP450 3A4 isoenzymes by rifamycins.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with rifamycins, particularly rifampin. Cyclosporine blood levels should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of rifamycin therapy in patients who are stabilized on their anti-rejection regimen.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with rifamycins, particularly rifampin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77188/", "reference_text": "[1] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Al-Sulaiman MH, Dhar JM, Al-Khader AA \"Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine.\" Transplantation 50 (1990): 597-8[3] Koselj M, Bren A, Kandus A, Kovac D \"Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections.\" Transplant Proc 26 (1994): 2823-4[4] Van Buren D, Wideman CA, Ried M, et al. \"The antagonistic effect of rifampin upon cyclosporin bioavailability.\" Transplant Proc 16 (1984): 1642-5[5] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[6] Langhoff E, Madsen S \"Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment.\" Lancet 2 (1983): 1031[7] Allen RD, Hunnisett AG, Morris PJ \"Cyclosporin and rifampicin in renal transplantation.\" Lancet 1 (1985): 980[8] Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE \"Acute rejection and massive cyclosporin requirements in heart transplant recipients treated with rifampin.\" Transplantation 39 (1985): 313-4[9] Calne RY, White DJG, Thiru S, Rolles K, Drakopoulos S, Jamieson NV \"Cyclosporin and antituberculous therapy.\" Lancet 1 (1985): 1342-3[10] Daniels NJ, Dover JS, Schachter RK \"Interaction between cyclosporin and rifampicin.\" Lancet 1 (1984): 639[11] Zylber-Katz E \"Multiple drug interactions with cyclosporine in a heart transplant patient.\" Ann Pharmacother 29 (1995): 127-31[12] Howard P, Bixler TJ, Gill B \"Cyclosporine-rifampin drug interaction.\" Drug Intell Clin Pharm 19 (1985): 763-4[13] Cassidy MJ, Zyl-Smit RV, Pascoe MD, et al \"Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient.\" Nephron 41 (1985): 207-8[14] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[15] Watkins PB \"Drug metabolism by cytochromes P450 in the liver and small bowel.\" Gastroenterol Clin North Am 21 (1992): 511-26[16] Vandevelde C, Chang A, Andrews D, et al \"Rifampin and ansamycin interaction with cyclosporine after renal transplantation.\" Pharmacotherapy 11 (1991): 88-9[17] Offermann G, Keller F, Molzahn M \"Low cyclosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment.\" Am J Nephrol 5 (1985): 385-7[18] Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ \"Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.\" Clin Pharmacol Ther 52 (1992): 453-7[19] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[20] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[21] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[22] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[25] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[26] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[27] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[28] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[29] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[30] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[31] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 77088, "ingredient1": "Cyclosporine", "ingredient2": "Rifaximin", "severity": "Moderate", "effect": "Coadministration with cyclosporine may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter such as rifaximin. The proposed mechanism is increased absorption of rifaximin in the intestine due to inhibition of P-gp mediated drug efflux by cyclosporine. Cyclosporine is also an inhibitor of organic anion transporting polypeptide (OATP), breast cancer resistance protein (BCRP) and a weak inhibitor of CYP450 3A4. The inhibition of each of these transporters may also have a part in the increase in rifaximin exposure by cyclosporine.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine must be used concurrently with rifaximin. Monitoring for increased rifaximin adverse effects such as headache, nausea and peripheral edema is recommended.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if cyclosporine must be used concurrently with rifaximin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77189/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Xifaxan (rifaximin).\" Salix Pharmaceuticals, Raleigh, NC.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Rifamycin, Paromomycin, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline", "updated_at": 1767369485}, {"id": 77089, "ingredient1": "Cyclosporine", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77190/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rilonacept, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77090, "ingredient1": "Cyclosporine", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77191/", "reference_text": "[1] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[2] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77091, "ingredient1": "Cyclosporine", "ingredient2": "Rimegepant", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant. The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.", "source": "DDInter", "management_text": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77192/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Frovatriptan, Eptinezumab, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab", "updated_at": 1767369485}, {"id": 77092, "ingredient1": "Cyclosporine", "ingredient2": "Riociguat", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 or moderate to potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) may increase the plasma concentrations of riociguat, which is partially metabolized by CYP450 3A and also a substrate of the P-gp and BCRP efflux transporters. Increased levels of riociguat may increase the risk for hypotension.", "source": "DDInter", "management_text": "Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors. Patients should be monitored for signs and symptoms of hypotension, and the dosage of riociguat adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77193/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Metyrosine", "updated_at": 1767369485}, {"id": 77093, "ingredient1": "Cyclosporine", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration of CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77194/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[19] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77094, "ingredient1": "Cyclosporine", "ingredient2": "Risankizumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77195/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77095, "ingredient1": "Cyclosporine", "ingredient2": "Ritonavir", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs), especially ritonavir, may significantly increase the blood concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves PI inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to PI inhibition of intestinal P-glycoprotein efflux transporter may also contribute.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used in combination with protease inhibitors. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of PI therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients treated with saquinavir should also be monitored for potential PI toxicity and the dosage adjusted accordingly.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Caution is advised if cyclosporine is used in combination with protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77196/", "reference_text": "[1] Brinkman K, Huysmans F, Burger DM \"Pharmacokinetic interaction between saquinavir and cyclosporine.\" Ann Intern Med 129 (1998): 914-5[2] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[4] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[5] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[6] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[10] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[11] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[12] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[15] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[16] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[17] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[18] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[19] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[20] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[21] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[22] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[23] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[24] Cerner Multum, Inc. \"Australian Product Information.\" O 0[25] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[26] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[27] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S \"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.\" Br J Clin Pharmacol 45 (1998): 355-9[28] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[29] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77096, "ingredient1": "Cyclosporine", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with weak or moderate dual inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of rivaroxaban, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops. Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.", "mechanism_text": "Metabolism", "recommendation": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77197/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 77097, "ingredient1": "Cyclosporine", "ingredient2": "Rocuronium", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77198/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 77098, "ingredient1": "Cyclosporine", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77199/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 77099, "ingredient1": "Cyclosporine", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77200/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Voclosporin, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 77100, "ingredient1": "Cyclosporine", "ingredient2": "Rolapitant", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when rolapitant is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when rolapitant is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77201/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Nabilone, Dronabinol, Palonosetron", "updated_at": 1767369485}, {"id": 77101, "ingredient1": "Cyclosporine", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of romidepsin, which is a substrate of the efflux transporter. Although there are no formal drug interaction studies, the interaction may increase the risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.", "source": "DDInter", "management_text": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors. Pharmacologic response to romidepsin should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the romidepsin dosage adjusted as necessary. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77202/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77102, "ingredient1": "Cyclosporine", "ingredient2": "Ropivacaine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine. Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77203/", "reference_text": "[1] Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT \"The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.\" Anesth Analg 91 (2000): 1207-12[2] Ekstrom G, Gunnarsson UB \"Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.\" Drug Metab Dispos 24 (1996): 955-61[3] Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL \"Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.\" Clin Pharmacol Ther 64 (1998): 484-91[4] McClure JH \"Ropivacaine.\" Br J Anaesth 76 (1996): 300-7[5] \"Product Information. Naropin (ropivacaine).\" Astra USA, Westborough, MA.[6] Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M \"Metabolism and excretion of ropivacaine in humans.\" Drug Metab Dispos 24 (1996): 962-8[7] Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y \"Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.\" Anesthesiology 82 (1995): 214-20", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "updated_at": 1767369485}, {"id": 77103, "ingredient1": "Cyclosporine", "ingredient2": "Rosuvastatin", "severity": "Major", "effect": "Coadministration with cyclosporine may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is cyclosporine inhibition of the hepatic uptake of rosuvastatin via organic anion transporting polypeptide C (OATP-C). Rosuvastatin did not affect the plasma concentrations of cyclosporine.", "source": "DDInter", "management_text": "The daily dosage of rosuvastatin should not exceed 5 mg when used in combination with cyclosporine. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Rosuvastatin should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "The daily dosage of rosuvastatin should not exceed 5 mg when used in combination with cyclosporine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77204/", "reference_text": "[1] Simonson SG, Raza A, Martin PD, et al. \"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.\" Clin Pharmacol Ther 76 (2004): 167-77[2] \"Product Information. Crestor (rosuvastatin).\" AstraZeneca Pharma Inc, Mississauga, ON.[3] Holtzman CW, Wiggins BS, Spinler SA \"Role of P-glycoprotein in statin drug interactions.\" Pharmacotherapy 26 (2006): 1601-7[4] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[5] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[10] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[11] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[12] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[13] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[14] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[15] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[16] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Bempedoic acid, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Alirocumab, Lixisenatide, Albiglutide, Guar gum, More", "updated_at": 1767369485}, {"id": 77104, "ingredient1": "Cyclosporine", "ingredient2": "Rotavirus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77205/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, Vitamin A, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77105, "ingredient1": "Cyclosporine", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77206/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, Vitamin A, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77106, "ingredient1": "Cyclosporine", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of P-glycoprotein (P-gp) may increase the plasma concentration and the risk of adverse effects of rucaparib, which has been shown to be a substrate of P-gp. However, the effects on the pharmacokinetics of rucaparib have not been evaluated in vivo.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with potent P-gp inhibitors. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent P-gp inhibitor is added to or withdrawn from therapy with rucaparib.", "mechanism_text": "Others", "recommendation": "Caution is advised if rucaparib is used concomitantly with potent P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77207/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77107, "ingredient1": "Cyclosporine", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Rufinamide may modestly or moderately decrease the plasma concentrations and therapeutic effects of drugs that are CYP450 3A4 substrates. The mechanism is enhanced metabolism by CYP450 3A4 enzyme induction.", "source": "DDInter", "management_text": "During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose. Dose adjustments of the coadministered drug may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77208/", "reference_text": "[1] \"Product Information. Banzel (rufinamide).\" Eisai Inc, Teaneck, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[4] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[5] \"Product Information. Banzel (rufinamide).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 77108, "ingredient1": "Cyclosporine", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "Coadministration with ruxolitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein efflux transporter and/or the breast cancer resistance protein (BRCP) in the intestine. The mechanism is decreased clearance via these routes due to inhibition by ruxolitinib.", "source": "DDInter", "management_text": "Caution is advised if ruxolitinib must be used concurrently with medications that are substrates of the P-glycoprotein efflux transporter and/or the breast cancer resistance protein (BRCP) , particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ruxolitinib is added to or withdrawn from therapy. The interaction may possibly be avoided or minimized if the doses of the affected medications are separated for as long as possible.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if ruxolitinib must be used concurrently with medications that are substrates of the P-glycoprotein efflux transporter and/or the breast cancer resistance protein (BRCP) , particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77209/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77109, "ingredient1": "Cyclosporine", "ingredient2": "Salsalate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77210/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 77110, "ingredient1": "Cyclosporine", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs), especially ritonavir, may significantly increase the blood concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves PI inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to PI inhibition of intestinal P-glycoprotein efflux transporter may also contribute.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used in combination with protease inhibitors. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of PI therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients treated with saquinavir should also be monitored for potential PI toxicity and the dosage adjusted accordingly.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Caution is advised if cyclosporine is used in combination with protease inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77211/", "reference_text": "[1] Brinkman K, Huysmans F, Burger DM \"Pharmacokinetic interaction between saquinavir and cyclosporine.\" Ann Intern Med 129 (1998): 914-5[2] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[4] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[5] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[6] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[10] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[11] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[12] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[15] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[16] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[17] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[18] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[19] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[20] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[21] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[22] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[23] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[24] Cerner Multum, Inc. \"Australian Product Information.\" O 0[25] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[26] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[27] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S \"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.\" Br J Clin Pharmacol 45 (1998): 355-9[28] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[29] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77111, "ingredient1": "Cyclosporine", "ingredient2": "Sarecycline", "severity": "Moderate", "effect": "Coadministration with sarecycline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by sarecycline.", "source": "DDInter", "management_text": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sarecycline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77212/", "reference_text": "[1] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Omadacycline, Oxytetracycline, Eravacycline, Demeclocycline", "updated_at": 1767369485}, {"id": 77112, "ingredient1": "Cyclosporine", "ingredient2": "Sarilumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77213/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77113, "ingredient1": "Cyclosporine", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77214/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Eculizumab, Anifrolumab, Deucravacitinib, Ponesimod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77114, "ingredient1": "Cyclosporine", "ingredient2": "Satralizumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77215/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77115, "ingredient1": "Cyclosporine", "ingredient2": "Saxagliptin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may alter the plasma concentrations of saxagliptin and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to saxagliptin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to saxagliptin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77216/", "reference_text": "[1] \"Product Information. Onglyza (saxagliptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 77116, "ingredient1": "Cyclosporine", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Barbiturates may decrease serum cyclosporine concentrations and efficacy. The mechanism is enhanced hepatic microsomal metabolism of cyclosporine.", "source": "DDInter", "management_text": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations.", "mechanism_text": "Metabolism", "recommendation": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77217/", "reference_text": "[1] Burckart GJ, Venkataramanan R, Ptachcinski RJ \"Usefulness of cyclosporin monitoring questioned.\" Clin Pharm 3 (1984): 243[2] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Noguchi M, Kiuchi C, Akiyama H, et al \"Interaction between cyclosporin A and anticonvulsants.\" Bone Marrow Transplant 9 (1992): 391[6] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[7] Kerr LE \"Drug interactions with cyclosporine.\" Clin Pharm 3 (1984): 346,348[8] Carstensen H, Jacobsen N, Dieperink H \"Interaction between cyclosporin A and phenobarbitone.\" Br J Clin Pharmacol 21 (1986): 550-1[9] Wideman CA \"Pharmacokinetic monitoring of cyclosporine.\" Transplant Proc 15(1/2) (1983): 3168-75[10] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[12] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[13] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[17] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[18] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[19] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[20] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[21] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[22] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[23] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[24] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 77117, "ingredient1": "Cyclosporine", "ingredient2": "Secukinumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77218/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77118, "ingredient1": "Cyclosporine", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when selpercatinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as QT interval prolongation, liver transaminase and bilirubin elevations, hypertension, hemorrhage, edema and hypersensitivity reactions (e.g., fever, rash, arthralgias/myalgias with concurrent decreased platelets or transaminitis), and the dosing of selpercatinib adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selpercatinib is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77219/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77119, "ingredient1": "Cyclosporine", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3. Increased exposures to selumetinib and N-desmethyl selumetinib may increase the risk and/or severity of serious adverse effects such as cardiomyopathy (decrease in left ventricular ejection fraction by 10% or more below baseline), ocular toxicity (blurred vision, photophobia, cataracts, ocular hypertension, retinal pigment epithelial detachment, retinal vein occlusion), gastrointestinal toxicity (diarrhea, colitis), skin toxicity (dermatitis acneiform, maculopapular rash, eczema), and musculoskeletal toxicity (creatine phosphokinase elevations, myalgia, rhabdomyolysis).", "source": "DDInter", "management_text": "Caution is advised when selumetinib is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance. Please refer to the product labeling for specific guidelines on dosing adjustments.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77220/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77120, "ingredient1": "Cyclosporine", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "The concomitant administration of sertraline and cyclosporine been associated with serotonin syndrome. The mechanism is unknown but may involve inhibition of CYP450 3A4 metabolism by cyclosporine. The mechanism may involve competition for CYP450 3A4-mediated metabolism, of which both drugs are substrates.", "source": "DDInter", "management_text": "Until more information is available, monitoring patients for adverse effects, and changes in cyclosporine concentrations and renal function may be advisable. Patients should be advised to notify their physician if they experience symptoms of cyclosporine toxicity (including nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache) or signs of excessive serotonergic activity (CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia).", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, monitoring patients for adverse effects, and changes in cyclosporine concentrations and renal function may be advisable.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77221/", "reference_text": "[1] Wong Eh, Chan NN, Sze KH, Or KH \"Serotonin syndrome in a renal transplant patient.\" J R Soc Med 95 (2002): 304-5[2] Lill J, Bauer LA, Horn JR, Hansten PD \"Cyclosporine-drug interactions and the influence of patient age.\" Am J Health Syst Pharm 57 (2000): 1579-84[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[5] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[6] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 77121, "ingredient1": "Cyclosporine", "ingredient2": "Sevelamer", "severity": "Moderate", "effect": "Coadministration with sevelamer may reduce blood levels of oral cyclosporine, mycophenolate mofetil, and tacrolimus. The mechanism is reduction of absorption by sevelamer.", "source": "DDInter", "management_text": "The immunosuppressant may be given at least 1 to 2 hours before or 2 to 3 hours after sevelamer administration to minimize the impact on absorption. It is recommended to closely monitor blood concentrations of the immunosuppressant during concomitant use and after discontinuation of sevelamer.", "mechanism_text": "Absorption", "recommendation": "The immunosuppressant may be given at least 1 to 2 hours before or 2 to 3 hours after sevelamer administration to minimize the impact on absorption.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77222/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[6] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Renagel (sevelamer).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 77122, "ingredient1": "Cyclosporine", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of sildenafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77223/", "reference_text": "[1] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000): 392-7[4] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001): 239-48[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 77123, "ingredient1": "Cyclosporine", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of the P-glycoprotein (P-gp) efflux transporter may significantly increase the oral bioavailability of silodosin, which has been shown in vitro to be a substrate of P-gp.", "source": "DDInter", "management_text": "Concomitant use of silodosin with potent P-gp inhibitors such as cyclosporine is not recommended.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of silodosin with potent P-gp inhibitors such as cyclosporine is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77224/", "reference_text": "[1] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[4] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77124, "ingredient1": "Cyclosporine", "ingredient2": "Siltuximab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77225/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77125, "ingredient1": "Cyclosporine", "ingredient2": "Simeprevir", "severity": "Major", "effect": "Coadministration of simeprevir with cyclosporine may lead to significantly increased plasma concentrations of simeprevir. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake, P-glycoprotein (P-gp), and CYP450 3A4 by cyclosporine.", "source": "DDInter", "management_text": "Coadministration of cyclosporine and simeprevir should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of cyclosporine and simeprevir should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77226/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 77126, "ingredient1": "Cyclosporine", "ingredient2": "Simvastatin", "severity": "Major", "effect": "Coadministration with cyclosporine may significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their pharmacologically active metabolites. The proposed mechanism is cyclosporine inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme responsible for the metabolic clearance of HMG-CoA reductase inhibitors like atorvastatin, lovastatin, and simvastatin. In addition, atorvastatin, its metabolites, and the active beta-hydroxyacid form of simvastatin, simvastatin acid, are substrates of the hepatic uptake transporter, organic anion transporting polypeptide protein (OATP) 1B1, which is also inhibited by cyclosporine. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Use of cyclosporine with simvastatin or other HMG-CoA reductase inhibitors has resulted in musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.", "source": "DDInter", "management_text": "Concomitant use of simvastatin and cyclosporine is considered contraindicated by the manufacturer of simvastatin. Fluvastatin or pravastatin may be considered as alternatives in patients receiving cyclosporine as they are not extensively metabolized by CYP450 3A4. However, the benefits of the use of these medicines in combination with cyclosporine should be carefully weighed against the potential risks. Statin therapy should be initiated at a lower dosage and titrated with caution.All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise, and/or dark-colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of simvastatin and cyclosporine is considered contraindicated by the manufacturer of simvastatin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77227/", "reference_text": "[1] \"Product Information. Lescol (fluvastatin).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Holtzman CW, Wiggins BS, Spinler SA \"Role of P-glycoprotein in statin drug interactions.\" Pharmacotherapy 26 (2006): 1601-7[3] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002): 35-40[4] Campana C, Iacona I, Regassi MB, et al. \"Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.\" Ann Pharmacother 29 (1995): 235-9[5] Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V \"Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.\" Am J Nephrol 19 (1999): 411-5[6] Arnadottir M, Eriksson LO, Thysell H, Karkas JD \"Plasma concentration profiles of simvastatin 3-hydroxy- 3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.\" Nephron 65 (1993): 410-3[7] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[8] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[9] Southworth MR, Mauro VF \"The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.\" Ann Pharmacother 31 (1997): 489-91[10] Francis L, Bonilla E, Soforo E, et al. \"Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin.\" Clin Rheumatol 27 (2008): 129-31[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Arnadottir M, Eriksson LO, Germershausen JI, Thysell H \"Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.\" Nephron 68 (1994): 57-62[15] Norman DJ, Illingworth DR, Munson J, Hosenpud J \"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.\" N Engl J Med 318 (1988): 46-7[16] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999): 811-5[17] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[18] \"Product Information. Pravachol (pravastatin).\" Bristol-Myers Squibb, Princeton, NJ.[19] Rodriguez JA, CrespoLeiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, CastroBeiras A \"Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.\" Transplant Proc 31 (1999): 2522-3[20] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[21] Maltz HC, Balog DL, Cheigh JS \"Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.\" Ann Pharmacother 33 (1999): 1176-9[22] Jardine A, Holdaas H \"Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.\" J Clin Pharm Ther 24 (1999): 397-408[23] Rifkin SI \"Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report.\" Medscape J Med 10 (2008): 264[24] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[25] Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW \"Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.\" Am J Med Sci 320 (2000): 394-7[26] Najafian B, Franklin DB, Fogo AB \"Acute renal failure and myalgia in a transplant patient.\" J Am Soc Nephrol 18 (2007): 2870-4[27] Vanhaecke J, Vancleemput J, Vanlierde J, Daenen W, Degeest H \"Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine.\" Transplantation 58 (1994): 42-5[28] Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S \"Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.\" Transplant Proc 31 (1999): 2163-5[29] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[30] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[31] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[32] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[33] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[34] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[35] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[36] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[37] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[38] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[39] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[40] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[41] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[42] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[43] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[44] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[45] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[46] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[47] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[48] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[49] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 77127, "ingredient1": "Cyclosporine", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77228/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Siponimod, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77128, "ingredient1": "Cyclosporine", "ingredient2": "Sipuleucel-T", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77229/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Interferon alfa-2b, More", "updated_at": 1767369485}, {"id": 77129, "ingredient1": "Cyclosporine", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "INTERVAL: The simultaneous administration of cyclosporine and sirolimus may significantly increase plasma concentrations of the latter. The proposed mechanism is cyclosporine inhibition of P-glycoprotein, which is responsible for the active efflux of sirolimus and other drugs back into the intestinal lumen.", "source": "DDInter", "management_text": "The manufacturer recommends that sirolimus be administered 4 hours after a cyclosporine dose. Renal function and blood levels of both drugs should be closely monitored, and the dosages adjusted accordingly. During chronic administration, the clearance of cyclosporine may decrease and the dosage may need to be reduced to maintain target concentrations.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends that sirolimus be administered 4 hours after a cyclosporine dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77230/", "reference_text": "[1] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Cyclosporine, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 77130, "ingredient1": "Cyclosporine", "ingredient2": "Sitagliptin", "severity": "Minor", "effect": "Coadministration with cyclosporine, a potent inhibitor of P-glycoprotein efflux transporter, does not appear to significantly alter the pharmacokinetics of sitagliptin, which is a substrate of P-glycoprotein. These changes are not considered clinically significant. The renal clearance of sitagliptin was also not significantly altered in the presence of cyclosporine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77231/", "reference_text": "[1] \"Product Information. Januvia (sitagliptin).\" Merck & Company Inc, West Point, PA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[13] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[17] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[18] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[19] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[20] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[21] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[22] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[23] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[24] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 77131, "ingredient1": "Cyclosporine", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77232/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, Vitamin A, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77132, "ingredient1": "Cyclosporine", "ingredient2": "Salicylic acid (sodium)", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77233/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77133, "ingredient1": "Cyclosporine", "ingredient2": "Sofosbuvir", "severity": "Minor", "effect": "Coadministration with cyclosporine may significantly increase the plasma concentrations of sofosbuvir, but appears to have little effect on the pharmacokinetics of the predominant metabolite, GS-331007. The proposed mechanism is cyclosporine inhibition of the P-glycoprotein-mediated intestinal efflux of sofosbuvir.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77234/", "reference_text": "[1] \"Product Information. Sovaldi (sofosbuvir).\" Gilead Sciences, Foster City, CA.[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77134, "ingredient1": "Cyclosporine", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of solifenacin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of solifenacin such as severe abdominal pain or constipation for 3 or more days. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77235/", "reference_text": "[1] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77135, "ingredient1": "Cyclosporine", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77236/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 77136, "ingredient1": "Cyclosporine", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77237/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 77137, "ingredient1": "Cyclosporine", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77238/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 77138, "ingredient1": "Cyclosporine", "ingredient2": "Sonidegib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sonidegib is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse reactions, particularly musculoskeletal toxicity, and sonidegib treatment interrupted or discontinued accordingly.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sonidegib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77239/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77139, "ingredient1": "Cyclosporine", "ingredient2": "Sorafenib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with sorafenib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by sorafenib.", "source": "DDInter", "management_text": "Caution is advised when sorafenib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sorafenib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when sorafenib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77240/", "reference_text": "[1] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77140, "ingredient1": "Cyclosporine", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with St. John's wort may decrease the blood concentrations and pharmacologic effects of cyclosporine. The mechanism involves reduced absorption as well as accelerated clearance due to induction of intestinal P-glycoprotein drug efflux pumps and hepatic/intestinal CYP450 3A4 isoenzymes by constituents of St. John's wort.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant blood levels, St. John's wort should preferably not be used in transplant patients treated with cyclosporine. Caution is advised if these agents are used together. Immunosuppressant blood levels should be closely monitored and the dosage(s) adjusted accordingly, particularly following initiation, discontinuation or change of dosage of St. John's wort in patients who are stabilized on their anti-rejection regimen. Transplant patients should be advised to consult their caregiver before using any alternative medicines.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant blood levels, St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77241/", "reference_text": "[1] Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G \"Acute heart transplant rejection due to Saint John's wort.\" Lancet 355 (2000): 548-9[2] Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE \"Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation.\" J Hepatol 33 (2000): 853-5[3] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[4] Ernst E \"Second thoughts about safety of St John's wort.\" Lancet 354 (1999): 2014-6[5] Dresser GK, Schwarz UI, Wilkinson GR, Kim RB \"Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.\" Clin Pharmacol Ther 73 (2003): 41-50[6] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[7] Moschella C, Jaber BL \"Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation.\" Am J Kidney Dis 38 (2001): 1105-7[8] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[9] Ahmed SM, Banner NR, Dubrey SW \"Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients.\" J Heart Lung Transplant 20 (2001): 795[10] Bauer S, Stormer E, Johne A, et al. \"Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.\" Br J Clin Pharmacol 55 (2003): 203-11[11] Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR \"Drug interaction between St. John's wort and cyclosporine.\" Ann Pharmacother 34 (2000): 1013-6[12] Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH \"St John's Wort: Effect on CYP3A4 activity.\" Clin Pharmacol Ther 67 (2000): 451-7[13] Mai I, Kr&uuml,ger H, Budde K, Johne A, Brockm&ouml,ller J, Neumayer HH, Roots I \"Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin.\" Int J Clin Pharm Therapeutics 38 (2000): 500-2[14] Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Kiempnauer J \"Drug interaction of St John's wort with ciclosporin.\" Lancet 355 (2000): 1912[15] Barone GW, Gurley BJ, Ketel BL, AbulEzz SR \"Herbal supplements: A potential for drug interactions in transplant recipients.\" Transplantation 71 (2001): 239-41[16] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[17] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[18] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[19] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[20] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[21] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[22] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[23] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[24] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[25] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[26] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[27] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[28] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[29] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[30] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 77141, "ingredient1": "Cyclosporine", "ingredient2": "Stanozolol", "severity": "Moderate", "effect": "Coadministration with androgens or anabolic steroids may increase the blood concentrations of cyclosporine. The exact mechanism of interaction is unknown but may involve competitive inhibition of the CYP450 3A4 metabolism of cyclosporine.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids. Cyclosporine blood levels, renal function, and liver function tests should be monitored frequently and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of androgen dosage in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77242/", "reference_text": "[1] Ross WB, Roberts D, Griffin PJA, Salaman JR \"Cyclosporin interaction with danazol and norethisterone.\" Lancet 1 (1986): 330[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, Navarro-Ruiz J, Gonzalez-Delgado M, Conesa-Garcia V \"Possible cyclosporin-danazol interaction in a patient with aplastic anaemia.\" Am J Hematol 62 (1999): 63-4[4] Goffin E, Pirson Y, Geubel A, de Strihou C \"Cyclosporine-methyltestosterone interaction.\" Nephron 59 (1991): 174-5[5] Wood P, Liu Yin JA \"Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient.\" Clin Lab Haematol 16 (1994): 201-4[6] Moller BB, Ekelund B \"Toxicity of cyclosporine during treatment with androgens.\" N Engl J Med 313 (1985): 1416[7] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (part II).\" Clin Pharmacokinet 19 (1990): 400-15[8] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[9] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[14] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[15] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[16] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[17] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[18] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[19] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[20] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Prasterone", "updated_at": 1767369485}, {"id": 77142, "ingredient1": "Cyclosporine", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may increase plasma concentrations and toxic effects of certain hepatically metabolized drugs including ergot alkaloids, quinidine, immunosuppressants, and statins. The mechanism is inhibition of CYP450 3A4 metabolism by stiripentol.", "source": "DDInter", "management_text": "The manufacturer recommends that concomitant use should be avoided, unless strictly necessary.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that concomitant use should be avoided, unless strictly necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77243/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 77143, "ingredient1": "Cyclosporine", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "The nephrotoxic effects of cyclosporine and aminoglycosides are additive. The combination generally should be avoided.", "source": "DDInter", "management_text": "If these agents must be used concomitantly, renal function should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "If these agents must be used concomitantly, renal function should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77244/", "reference_text": "[1] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Whiting PH, Simpson JG \"The enhancement of cyclosporin A-induced nephrotoxicity by gentamicin.\" Biochem Pharmacol 32 (1983): 2025-8[4] Termeer A, Hoitsma AJ, Koene RA \"Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients.\" Transplantation 42 (1986): 220-1[5] Chandrasekar PH, Cronin SM \"Nephrotoxicity in bone marrow transplant recipients receiving aminoglycoside plus cyclosporine or aminoglycoside alone.\" J Antimicrob Chemother 27 (1991): 845-9[6] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Rifamycin, Paromomycin", "updated_at": 1767369485}, {"id": 77144, "ingredient1": "Cyclosporine", "ingredient2": "Succinylcholine", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77245/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 77145, "ingredient1": "Cyclosporine", "ingredient2": "Sucralfate", "severity": "Moderate", "effect": "INTERVAL: The blood concentrations of orally administered cyclosporine were reported to have decreased rapidly in a pediatric patient who had been administered cyclosporine combined with dried aluminum hydroxide gel. The proposed mechanism of this interaction is adsorption or complex formation by aluminum. Other aluminum salts may interact in a similar manner.", "source": "DDInter", "management_text": "Oral cyclosporine should be administered 2 hours before or 6 hours after the aluminum salt in order to avoid this potential interaction. The patient's therapeutic response should be monitored.", "mechanism_text": "Absorption", "recommendation": "Oral cyclosporine should be administered 2 hours before or 6 hours after the aluminum salt in order to avoid this potential interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77246/", "reference_text": "[1] Ichisawa M, Ohta I, Suzuki R, et al. \"The effect of dried aluminum hydroxide gel on the blood concentration of cyclosporine-A.\" Jpn J Hosp Pharm 23 (1997): 407-13[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 77146, "ingredient1": "Cyclosporine", "ingredient2": "Sulfadiazine", "severity": "Major", "effect": "Sulfonamides may significantly reduce serum cyclosporine concentrations by an unknown mechanism. Allograft rejections have resulted. Hyperkalemia and additive nephrotoxicity has also been reported. The mechanism is unknown. Data are available for intravenous trimethoprim-sulfamethoxazole, intravenous sulfamethazine (no longer marketed), oral sulfadiazine, and sulfasalazine. Oral trimethoprim-sulfamethoxazole reportedly does not affect cyclosporine levels.", "source": "DDInter", "management_text": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "mechanism_text": "Others", "recommendation": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77247/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[3] Berg K, Gjellestad A, Nordby G, et al \"Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.\" Nephron 53 (1989): 218-22[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[5] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[6] Spes CH, Angermann CE, Stempfle HU, et al \"Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.\" Clin Investig 70 (1992): 752-4[7] Wallwork J, McGregor CG, Wells FC, et al \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 02/12/83 (1983): 366-7[8] DuCheyron D, Debruyne D, Lobbedez T, Richer C, Ryckelynck JP, deLigny BH \"Effect of sulfasalazine on cyclosporin blood concentration.\" Eur J Clin Pharmacol 55 (1999): 227-8[9] Jones DK, Hakim M, Wallwork J, Higenbottam TW \"Serious interaction between cyclosporin A and sulphadimidine.\" Br Med J 292 (1986): 728-9[10] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[11] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[16] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[17] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[18] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[19] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[20] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[21] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[22] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 77147, "ingredient1": "Cyclosporine", "ingredient2": "Sulfadoxine", "severity": "Major", "effect": "Sulfonamides may significantly reduce serum cyclosporine concentrations by an unknown mechanism. Allograft rejections have resulted. Hyperkalemia and additive nephrotoxicity has also been reported. The mechanism is unknown. Data are available for intravenous trimethoprim-sulfamethoxazole, intravenous sulfamethazine (no longer marketed), oral sulfadiazine, and sulfasalazine. Oral trimethoprim-sulfamethoxazole reportedly does not affect cyclosporine levels.", "source": "DDInter", "management_text": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "mechanism_text": "Others", "recommendation": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77248/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[3] Berg K, Gjellestad A, Nordby G, et al \"Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.\" Nephron 53 (1989): 218-22[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[5] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[6] Spes CH, Angermann CE, Stempfle HU, et al \"Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.\" Clin Investig 70 (1992): 752-4[7] Wallwork J, McGregor CG, Wells FC, et al \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 02/12/83 (1983): 366-7[8] DuCheyron D, Debruyne D, Lobbedez T, Richer C, Ryckelynck JP, deLigny BH \"Effect of sulfasalazine on cyclosporin blood concentration.\" Eur J Clin Pharmacol 55 (1999): 227-8[9] Jones DK, Hakim M, Wallwork J, Higenbottam TW \"Serious interaction between cyclosporin A and sulphadimidine.\" Br Med J 292 (1986): 728-9[10] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[11] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[16] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[17] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[18] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[19] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[20] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[21] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[22] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Primaquine, Proguanil, Ascorbic acid, Methazolamide, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 77148, "ingredient1": "Cyclosporine", "ingredient2": "Sulfamethizole", "severity": "Major", "effect": "Sulfonamides may significantly reduce serum cyclosporine concentrations by an unknown mechanism. Allograft rejections have resulted. Hyperkalemia and additive nephrotoxicity has also been reported. The mechanism is unknown. Data are available for intravenous trimethoprim-sulfamethoxazole, intravenous sulfamethazine (no longer marketed), oral sulfadiazine, and sulfasalazine. Oral trimethoprim-sulfamethoxazole reportedly does not affect cyclosporine levels.", "source": "DDInter", "management_text": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "mechanism_text": "Others", "recommendation": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77249/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[3] Berg K, Gjellestad A, Nordby G, et al \"Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.\" Nephron 53 (1989): 218-22[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[5] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[6] Spes CH, Angermann CE, Stempfle HU, et al \"Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.\" Clin Investig 70 (1992): 752-4[7] Wallwork J, McGregor CG, Wells FC, et al \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 02/12/83 (1983): 366-7[8] DuCheyron D, Debruyne D, Lobbedez T, Richer C, Ryckelynck JP, deLigny BH \"Effect of sulfasalazine on cyclosporin blood concentration.\" Eur J Clin Pharmacol 55 (1999): 227-8[9] Jones DK, Hakim M, Wallwork J, Higenbottam TW \"Serious interaction between cyclosporin A and sulphadimidine.\" Br Med J 292 (1986): 728-9[10] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[11] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[16] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[17] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[18] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[19] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[20] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[21] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[22] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, More", "alternatives_b": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium chloride, Chlorhexidine, Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, More", "updated_at": 1767369485}, {"id": 77149, "ingredient1": "Cyclosporine", "ingredient2": "Sulfamethoxazole", "severity": "Major", "effect": "Sulfonamides may significantly reduce serum cyclosporine concentrations by an unknown mechanism. Allograft rejections have resulted. Hyperkalemia and additive nephrotoxicity has also been reported. The mechanism is unknown. Data are available for intravenous trimethoprim-sulfamethoxazole, intravenous sulfamethazine (no longer marketed), oral sulfadiazine, and sulfasalazine. Oral trimethoprim-sulfamethoxazole reportedly does not affect cyclosporine levels.", "source": "DDInter", "management_text": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "mechanism_text": "Others", "recommendation": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77250/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[3] Berg K, Gjellestad A, Nordby G, et al \"Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.\" Nephron 53 (1989): 218-22[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[5] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[6] Spes CH, Angermann CE, Stempfle HU, et al \"Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.\" Clin Investig 70 (1992): 752-4[7] Wallwork J, McGregor CG, Wells FC, et al \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 02/12/83 (1983): 366-7[8] DuCheyron D, Debruyne D, Lobbedez T, Richer C, Ryckelynck JP, deLigny BH \"Effect of sulfasalazine on cyclosporin blood concentration.\" Eur J Clin Pharmacol 55 (1999): 227-8[9] Jones DK, Hakim M, Wallwork J, Higenbottam TW \"Serious interaction between cyclosporin A and sulphadimidine.\" Br Med J 292 (1986): 728-9[10] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[11] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[16] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[17] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[18] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[19] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[20] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[21] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[22] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Anakinra, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, More", "updated_at": 1767369485}, {"id": 77150, "ingredient1": "Cyclosporine", "ingredient2": "Sulfasalazine", "severity": "Major", "effect": "Sulfonamides may significantly reduce serum cyclosporine concentrations by an unknown mechanism. Allograft rejections have resulted. Hyperkalemia and additive nephrotoxicity has also been reported. The mechanism is unknown. Data are available for intravenous trimethoprim-sulfamethoxazole, intravenous sulfamethazine (no longer marketed), oral sulfadiazine, and sulfasalazine. Oral trimethoprim-sulfamethoxazole reportedly does not affect cyclosporine levels.", "source": "DDInter", "management_text": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "mechanism_text": "Others", "recommendation": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77251/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[3] Berg K, Gjellestad A, Nordby G, et al \"Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.\" Nephron 53 (1989): 218-22[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[5] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[6] Spes CH, Angermann CE, Stempfle HU, et al \"Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.\" Clin Investig 70 (1992): 752-4[7] Wallwork J, McGregor CG, Wells FC, et al \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 02/12/83 (1983): 366-7[8] DuCheyron D, Debruyne D, Lobbedez T, Richer C, Ryckelynck JP, deLigny BH \"Effect of sulfasalazine on cyclosporin blood concentration.\" Eur J Clin Pharmacol 55 (1999): 227-8[9] Jones DK, Hakim M, Wallwork J, Higenbottam TW \"Serious interaction between cyclosporin A and sulphadimidine.\" Br Med J 292 (1986): 728-9[10] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[11] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[16] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[17] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[18] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[19] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[20] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[21] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[22] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 77151, "ingredient1": "Cyclosporine", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "The coadministration with sulfinpyrazone may decrease the blood concentrations and pharmacologic effects of cyclosporine. The mechanism is unknown.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with sulfinpyrazone. Cyclosporine blood levels should be monitored regularly and the dosage adjusted accordingly, particularly following initiation or discontinuation of sulfinpyrazone therapy in patients who are stabilized on their anti-rejection regimen.", "mechanism_text": "Antagonism", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if cyclosporine must be coadministered with sulfinpyrazone.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77252/", "reference_text": "[1] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Caforio ALP, Gambino A, Tona F, Feltrin G, Marchini F, Pompei E, Testolin L, Angelini A, DallaVolta S, Casarotto D \"Sulfinpyrazone reduces cyclosporine levels. A new drug interaction in heart transplant recipients.\" J Heart Lung Transplant 19 (2000): 1205-8[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Pegloticase, Febuxostat, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 77152, "ingredient1": "Cyclosporine", "ingredient2": "Sulfisoxazole", "severity": "Major", "effect": "Sulfonamides may significantly reduce serum cyclosporine concentrations by an unknown mechanism. Allograft rejections have resulted. Hyperkalemia and additive nephrotoxicity has also been reported. The mechanism is unknown. Data are available for intravenous trimethoprim-sulfamethoxazole, intravenous sulfamethazine (no longer marketed), oral sulfadiazine, and sulfasalazine. Oral trimethoprim-sulfamethoxazole reportedly does not affect cyclosporine levels.", "source": "DDInter", "management_text": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "mechanism_text": "Others", "recommendation": "Renal function and cyclosporine levels should be closely monitored if these drugs must be used concomitantly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77253/", "reference_text": "[1] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[2] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[3] Berg K, Gjellestad A, Nordby G, et al \"Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.\" Nephron 53 (1989): 218-22[4] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[5] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[6] Spes CH, Angermann CE, Stempfle HU, et al \"Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.\" Clin Investig 70 (1992): 752-4[7] Wallwork J, McGregor CG, Wells FC, et al \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 02/12/83 (1983): 366-7[8] DuCheyron D, Debruyne D, Lobbedez T, Richer C, Ryckelynck JP, deLigny BH \"Effect of sulfasalazine on cyclosporin blood concentration.\" Eur J Clin Pharmacol 55 (1999): 227-8[9] Jones DK, Hakim M, Wallwork J, Higenbottam TW \"Serious interaction between cyclosporin A and sulphadimidine.\" Br Med J 292 (1986): 728-9[10] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[11] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[15] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[16] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[17] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[18] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[19] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[20] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[21] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[22] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 77153, "ingredient1": "Cyclosporine", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77254/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 77154, "ingredient1": "Cyclosporine", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if suvorexant is prescribed with inhibitors of CYP450 3A4. Patients should be monitored for excessive sedation and other side effects, and the suvorexant dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if suvorexant is prescribed with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77255/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 77155, "ingredient1": "Cyclosporine", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "Coadministration of tacrolimus and cyclosporine may increase the risk and severity of nephrotoxicity due to additive effects on the kidney. Clinical experience indicates that the combination is associated with increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. In vitro and animal data also suggest that tacrolimus may inhibit the intestinal first-pass metabolism of cyclosporine via CYP450 3A4, resulting in significantly increased bioavailability of the latter.", "source": "DDInter", "management_text": "To avoid undue nephrotoxicity, tacrolimus and cyclosporine should not be used simultaneously. Tacrolimus or cyclosporine should be discontinued for at least 24 hours prior to initiating the other. In the presence of elevated tacrolimus or cyclosporine concentrations, dosing with the other drug usually should be further delayed.", "mechanism_text": "Metabolism, Synergism", "recommendation": "To avoid undue nephrotoxicity, tacrolimus and cyclosporine should not be used simultaneously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77256/", "reference_text": "[1] Pichard L, Fabre I, Domergue J, Joyeux H, Maurel P \"Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA (cyclosporine).\" Transplant Proc 23 (1991): 2791-3[2] McCauley J, Takaya S, Fung J, et al \"The question of FK 506 nephrotoxicity after liver transplantation.\" Transplant Proc 23 (1991): 1444-7[3] Wu YM, Venkataramanan R, Suzuki M, et al \"Interaction between FK 506 and cyclosporine in dogs.\" Transplant Proc 23 (1991): 2797-9[4] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[5] Ali Shah I, Whiting PH, Omar G, Thomson AW, Burke MD \"Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro.\" Transplant Proc 23 (1991): 2783-5[6] Christians U, Braun F, Sattler M, Almeidal VM, Linck A, Sewing KF \"Interactions of FK 506 and cyclosporine metabolism.\" Transplant Proc 23 (1991): 2794-6[7] Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K \"Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.\" Res Commun Chem Pathol Pharmacol 82 (1993): 209-16[8] Burke MD, Omar G, Thomson AW, Whiting PH \"Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506.\" Transplantation 50 (1990): 901-2[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[22] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[23] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Povidone-iodine, Cyclosporine, More", "updated_at": 1767369485}, {"id": 77156, "ingredient1": "Cyclosporine", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tadalafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone. Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77257/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 77157, "ingredient1": "Cyclosporine", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of this efflux membrane transporter. However, the effect of BCRP inhibitors on the pharmacokinetics of talazoparib has not been studied in vivo.", "source": "DDInter", "management_text": "Caution is recommended when talazoparib is coadministered with inhibitors of BCRP. Some authorities advise that concomitant use of talazoparib with potent BCRP inhibitors such as cyclosporine should be avoided (UK). Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Others", "recommendation": "Caution is recommended when talazoparib is coadministered with inhibitors of BCRP.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77258/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77158, "ingredient1": "Cyclosporine", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77259/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, Vitamin A, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77159, "ingredient1": "Cyclosporine", "ingredient2": "Tazemetostat", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in an increased risk of the frequency or severity of adverse reactions due to tazemetostat such as hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. Data are not available for other, less potent inhibitors.", "source": "DDInter", "management_text": "Caution and clinical monitoring is recommended with the concomitant use of tazemetostat with CYP450 3A4 inhibitors. Patients should be advised to notify their health care professional if they experience signs or symptoms of possible tazemetostat-related adverse effects including secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring is recommended with the concomitant use of tazemetostat with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77260/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77160, "ingredient1": "Cyclosporine", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may significantly increase the plasma concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to inhibition of intestinal P-glycoprotein efflux transporter may also contribute.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used in combination with boceprevir or telaprevir. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of the HCV NS3/4A protease inhibitor. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Some authorities recommend against the use of telaprevir in organ transplant candidates or recipients.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used in combination with boceprevir or telaprevir.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77261/", "reference_text": "[1] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[4] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77161, "ingredient1": "Cyclosporine", "ingredient2": "Telbivudine", "severity": "Moderate", "effect": "Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of telbivudine and/or the coadministered drug.", "source": "DDInter", "management_text": "Caution is advised if telbivudine is prescribed in combination with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during therapy with telbivudine.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if telbivudine is prescribed in combination with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77262/", "reference_text": "[1] \"Product Information. Tyzeka (telbivudine).\" IDEC Pharmaceuticals Corporation, San Diego, CA.", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77162, "ingredient1": "Cyclosporine", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative treatment that do not interfere with cyclosporine metabolism should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77263/", "reference_text": "[1] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 77163, "ingredient1": "Cyclosporine", "ingredient2": "Telmisartan", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77264/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990): 66-9[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[6] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 77164, "ingredient1": "Cyclosporine", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77265/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77165, "ingredient1": "Cyclosporine", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of temsirolimus with inhibitors of CYP450 3A4 may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors. Pharmacologic response to temsirolimus should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the temsirolimus dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77266/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77166, "ingredient1": "Cyclosporine", "ingredient2": "Terbinafine", "severity": "Minor", "effect": "Terbinafine may increase the clearance of cyclosporine by up to 15%. The mechanism is unknown. Although this interaction is unlikely to be of clinical importance, it may be appropriate to monitor the patient for decreased cyclosporine efficacy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77267/", "reference_text": "[1] \"Product Information. Lamisil (terbinafine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Lo ACY, Lui SL, Lo WK, Chan DTM, Cheng IKP \"The interaction of terbinafine and cyclosporine A in renal transplant patients.\" Br J Clin Pharmacol 43 (1997): 340-1[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Selenium Sulfide, Thiabendazole, Econazole, Tioconazole, Chlorphenesin", "updated_at": 1767369485}, {"id": 77167, "ingredient1": "Cyclosporine", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "Coadministration of leflunomide with other immuno- or myelosuppressive antirheumatic agents may potentiate the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy.", "source": "DDInter", "management_text": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided. When switching from leflunomide to one of these agents, consideration should be given to administering a washout procedure with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. This will decrease the overlap of systemic exposure to both compounds and reduce the likelihood of additive hematologic toxicities. However, the washout procedure may also induce disease worsening if the patient had been responding to leflunomide treatment. Patients who do not receive the washout procedure prior to switching should be monitored closely for hematologic toxicity. All patients treated with leflunomide or teriflunomide should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped and washout procedure administered.", "mechanism_text": "Others", "recommendation": "Concomitant use of leflunomide with other immuno- or myelosuppressive antirheumatic agents should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77268/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teriflunomide, Apremilast, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77168, "ingredient1": "Cyclosporine", "ingredient2": "Testosterone (topical)", "severity": "Moderate", "effect": "Coadministration with androgens or anabolic steroids may increase the blood concentrations of cyclosporine. The exact mechanism of interaction is unknown but may involve competitive inhibition of the CYP450 3A4 metabolism of cyclosporine.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids. Cyclosporine blood levels, renal function, and liver function tests should be monitored frequently and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of androgen dosage in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77269/", "reference_text": "[1] Ross WB, Roberts D, Griffin PJA, Salaman JR \"Cyclosporin interaction with danazol and norethisterone.\" Lancet 1 (1986): 330[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, Navarro-Ruiz J, Gonzalez-Delgado M, Conesa-Garcia V \"Possible cyclosporin-danazol interaction in a patient with aplastic anaemia.\" Am J Hematol 62 (1999): 63-4[4] Goffin E, Pirson Y, Geubel A, de Strihou C \"Cyclosporine-methyltestosterone interaction.\" Nephron 59 (1991): 174-5[5] Wood P, Liu Yin JA \"Oxymetholone hepatotoxicity enhanced by concomitant use of cyclosporin A in a bone marrow transplant patient.\" Clin Lab Haematol 16 (1994): 201-4[6] Moller BB, Ekelund B \"Toxicity of cyclosporine during treatment with androgens.\" N Engl J Med 313 (1985): 1416[7] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (part II).\" Clin Pharmacokinet 19 (1990): 400-15[8] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[9] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[14] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[15] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[16] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[17] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[18] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[19] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[20] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Prasterone", "updated_at": 1767369485}, {"id": 77169, "ingredient1": "Cyclosporine", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77270/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Tabloid (thioguanine).\" Prasco Laboratories, Cincinnati, OH.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 77170, "ingredient1": "Cyclosporine", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Barbiturates may decrease serum cyclosporine concentrations and efficacy. The mechanism is enhanced hepatic microsomal metabolism of cyclosporine.", "source": "DDInter", "management_text": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations.", "mechanism_text": "Metabolism", "recommendation": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77271/", "reference_text": "[1] Burckart GJ, Venkataramanan R, Ptachcinski RJ \"Usefulness of cyclosporin monitoring questioned.\" Clin Pharm 3 (1984): 243[2] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Noguchi M, Kiuchi C, Akiyama H, et al \"Interaction between cyclosporin A and anticonvulsants.\" Bone Marrow Transplant 9 (1992): 391[6] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[7] Kerr LE \"Drug interactions with cyclosporine.\" Clin Pharm 3 (1984): 346,348[8] Carstensen H, Jacobsen N, Dieperink H \"Interaction between cyclosporin A and phenobarbitone.\" Br J Clin Pharmacol 21 (1986): 550-1[9] Wideman CA \"Pharmacokinetic monitoring of cyclosporine.\" Transplant Proc 15(1/2) (1983): 3168-75[10] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[11] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[12] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[13] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[17] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[18] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[19] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[20] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[21] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[22] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[23] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[24] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Halothane, Etomidate, Remimazolam, More", "updated_at": 1767369485}, {"id": 77171, "ingredient1": "Cyclosporine", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration of cyclosporine and ticagrelor may increase the plasma concentrations of both drugs. Although the interaction has not been studied, competitive or noncompetitive inhibition of P-glycoprotein and CYP450 3A4 is possible, since these drugs are substrates as well as inhibitors of both the drug efflux transporter and isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine and ticagrelor are used in combination. Cyclosporine blood levels and renal function should be monitored more closely whenever ticagrelor is added to or withdrawn from therapy, and the cyclosporine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience bleeding complications or signs and symptoms of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine and ticagrelor are used in combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77272/", "reference_text": "[1] van Sloten T, de Klaver P, van den Wall Bake A \"Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man.\" Br J Clin Pharmacol 0 (2017): epub[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[5] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[10] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[11] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[12] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[13] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[14] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[15] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[16] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 77172, "ingredient1": "Cyclosporine", "ingredient2": "Ticlopidine", "severity": "Moderate", "effect": "During two courses of ticlopidine therapy, one patient experienced significant reductions in cyclosporine serum concentrations and relapse of nephrotic syndrome. The mechanism of this interaction is not known.", "source": "DDInter", "management_text": "Patient response and cyclosporine concentrations should be monitored when ticlopidine is used concomitantly.", "mechanism_text": "Others", "recommendation": "Patient response and cyclosporine concentrations should be monitored when ticlopidine is used concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77273/", "reference_text": "[1] Birmele B, Lebranchu Y, Bagros P, Nivet H, Furet Y, Pengloan J \"Interaction of cyclosporin and ticlopidine .\" Nephrol Dial Transplant 6 (1991): 150-1[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[15] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc, Palo Alto, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 77173, "ingredient1": "Cyclosporine", "ingredient2": "Tigecycline", "severity": "Moderate", "effect": "Coadministration of tigecycline with calcineurin inhibitors (e.g., tacrolimus, cyclosporine) may lead to an increase in serum trough concentrations of the calcineurin inhibitors. The mechanism for this interaction is unknown.", "source": "DDInter", "management_text": "Close monitoring is recommended whenever tigecycline is used concomitantly with a calcineurin inhibitor. Clinical and laboratory monitoring should be considered whenever tigecycline is added to or withdrawn from therapy with a calcineurin inhibitor, and the dosage of the calcineurin inhibitor adjusted as necessary. Patients should be monitored for development of adverse effects associated with the calcineurin inhibitor.", "mechanism_text": "Others", "recommendation": "Close monitoring is recommended whenever tigecycline is used concomitantly with a calcineurin inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77274/", "reference_text": "[1] Stumpf AN, Schmidt C, Hiddemann W, Gerbitz A \"High serum concentrations of ciclosporin related to administration of tigecycline.\" Eur J Clin Pharmacol (2008):[2] Pavan M, Chaudhari AP, Ranganth R \"Altered bioavailability of tacrolimus following intravenous administration of tigecycline.\" Am J Kidney Dis 57 (2011): 354[3] Chow KM, Pang WF, Chan GCK, Leung CB, Szeto CC, Li PKT \"Beware of drug interaction between tigecycline and tacrolimus.\" Nephrology (Carlton) 25 (2020): 99-100[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[7] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "Omadacycline, Oxytetracycline, Eravacycline, Demeclocycline", "updated_at": 1767369485}, {"id": 77174, "ingredient1": "Cyclosporine", "ingredient2": "Tildrakizumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77275/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77175, "ingredient1": "Cyclosporine", "ingredient2": "Tinidazole", "severity": "Moderate", "effect": "Coadministration with a nitroimidazole may increase the blood concentrations of cyclosporine. The interaction has been reported with metronidazole, and the proposed mechanism is inhibition of hepatic cyclosporine metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used with metronidazole. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of metronidazole therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience potential symptoms of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used with metronidazole.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77276/", "reference_text": "[1] Zylber-Katz E, Rubinger D, Berlatzky Y \"Cyclosporine interactions with metronidazole and cimetidine.\" Drug Intell Clin Pharm 22 (1988): 504-5[2] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[3] \"Product Information. Tindamax (tinidazole).\" Presutti Laboratories Inc, Arlington Heights, IL.[4] Herzig K, Johnson DW \"Marked elevation of blood cyclosporine and tacrolimus levels due to concurrent metronidazole therapy.\" Nephrol Dial Transplant 14 (1999): 521-3[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[18] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[19] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[20] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[21] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[22] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[23] \"Product Information. Tindamax (tinidazole).\" Presutti Laboratories Inc, Arlington Heights, IL.[24] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[25] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[26] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Cefixime, Levofloxacin, Secnidazole, Vonoprazan, Bismuth subcitrate potassium, Levofloxacin, Oritavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, More", "updated_at": 1767369485}, {"id": 77176, "ingredient1": "Cyclosporine", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with tipranavir in combination with ritonavir may alter the pharmacokinetics of immunosuppressants that are dual substrates of CYP450 3A4 and P-glycoprotein. The potential changes cannot be predicted due to the conflicting effects of tipranavir and ritonavir on CYP450 3A4 and P-glycoprotein. Specifically, ritonavir is a potent inhibitor of CYP450 3A4 and tend to reduce clearance of substrate drugs, while tipranavir is a potent inducer of P-glycoprotein intestinal efflux transporters and tend to increase clearance of substrate drugs.", "source": "DDInter", "management_text": "Caution is advised if immunosuppressants such as cyclosporine, sirolimus, and tacrolimus are coadministered with tipranavir/ritonavir. More frequent concentration monitoring of these drugs is recommended until blood levels have been stabilized.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if immunosuppressants such as cyclosporine, sirolimus, and tacrolimus are coadministered with tipranavir/ritonavir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77277/", "reference_text": "[1] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77177, "ingredient1": "Cyclosporine", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "The nephrotoxic effects of cyclosporine and aminoglycosides are additive. The combination generally should be avoided.", "source": "DDInter", "management_text": "If these agents must be used concomitantly, renal function should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "If these agents must be used concomitantly, renal function should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77278/", "reference_text": "[1] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Whiting PH, Simpson JG \"The enhancement of cyclosporin A-induced nephrotoxicity by gentamicin.\" Biochem Pharmacol 32 (1983): 2025-8[4] Termeer A, Hoitsma AJ, Koene RA \"Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients.\" Transplantation 42 (1986): 220-1[5] Chandrasekar PH, Cronin SM \"Nephrotoxicity in bone marrow transplant recipients receiving aminoglycoside plus cyclosporine or aminoglycoside alone.\" J Antimicrob Chemother 27 (1991): 845-9[6] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Chlorhexidine, Levofloxacin, Povidone-iodine", "updated_at": 1767369485}, {"id": 77178, "ingredient1": "Cyclosporine", "ingredient2": "Tocilizumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77279/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77179, "ingredient1": "Cyclosporine", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "Coadministration of tofacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids.", "source": "DDInter", "management_text": "Tofacitinib should not be used in combination with other Janus kinase inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine). Patients receiving tofacitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Tofacitinib should not be used in combination with other Janus kinase inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77280/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Baricitinib, Tofacitinib, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77180, "ingredient1": "Cyclosporine", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "Glipizide may decrease the metabolism of cyclosporine. Cyclosporine levels may be increased by as much as 150%. It is not known whether other sulfonylureas will exhibit a similar interaction, although limited data do exist for glyburide. The proposed mechanism is inhibition of CYP450 hepatic metabolism.", "source": "DDInter", "management_text": "If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.", "mechanism_text": "Metabolism", "recommendation": "If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77281/", "reference_text": "[1] Islam SI, Masuda QN, Bolaji OO, Shaheen FM, Sheikh IA \"Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients.\" Ther Drug Monit 18 (1996): 624-6[2] Chidester PD, Connito DJ \"Interaction between glipizide and cyclosporine: report of two cases.\" Transplant Proc 25 (1993): 2136-7[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[13] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[14] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[19] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[20] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[21] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[22] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[23] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[24] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[25] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 77181, "ingredient1": "Cyclosporine", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "Glipizide may decrease the metabolism of cyclosporine. Cyclosporine levels may be increased by as much as 150%. It is not known whether other sulfonylureas will exhibit a similar interaction, although limited data do exist for glyburide. The proposed mechanism is inhibition of CYP450 hepatic metabolism.", "source": "DDInter", "management_text": "If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.", "mechanism_text": "Metabolism", "recommendation": "If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77282/", "reference_text": "[1] Islam SI, Masuda QN, Bolaji OO, Shaheen FM, Sheikh IA \"Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients.\" Ther Drug Monit 18 (1996): 624-6[2] Chidester PD, Connito DJ \"Interaction between glipizide and cyclosporine: report of two cases.\" Transplant Proc 25 (1993): 2136-7[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[13] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[14] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[19] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[20] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[21] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[22] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[23] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[24] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[25] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, More", "updated_at": 1767369485}, {"id": 77182, "ingredient1": "Cyclosporine", "ingredient2": "Tolmetin", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77283/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77183, "ingredient1": "Cyclosporine", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered. Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.", "source": "DDInter", "management_text": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77284/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L \"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.\" Br J Clin Pharmacol 48 (1999): 564-72", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77184, "ingredient1": "Cyclosporine", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the oral bioavailability of tolvaptan, which has been shown in vitro to be a substrate of the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine. Serum sodium concentration and neurologic status should be closely monitored, and the tolvaptan dosage adjusted accordingly. Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Discontinuation or interruption of tolvaptan therapy should be considered in patients who develop too rapid a rise in serum sodium.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77285/", "reference_text": "[1] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77185, "ingredient1": "Cyclosporine", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy. Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should be obtained periodically. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77286/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone, Exemestane", "updated_at": 1767369485}, {"id": 77186, "ingredient1": "Cyclosporine", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.", "source": "DDInter", "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77287/", "reference_text": "[1] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[2] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Topotecan, Teniposide, Vinorelbine", "updated_at": 1767369485}, {"id": 77187, "ingredient1": "Cyclosporine", "ingredient2": "Trandolapril", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77288/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990): 66-9[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[6] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[7] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[8] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[9] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[10] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[14] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[15] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[16] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[17] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[18] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[19] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[20] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[21] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77188, "ingredient1": "Cyclosporine", "ingredient2": "Triamcinolone (ophthalmic)", "severity": "Moderate", "effect": "Coadministration of cyclosporine with a corticosteroid may result in altered (usually elevated) plasma concentrations of one or both drugs. Cyclosporine and corticosteroids undergo metabolism primarily by CYP450 3A4, thus competitive inhibition of metabolic clearance may occur during concomitant use.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with cyclosporine and corticosteroids. Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever one or the other agent is added to or withdrawn from therapy in patients stabilized on their existing therapeutic regimen, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with cyclosporine and corticosteroids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77289/", "reference_text": "[1] Klintmalm G, Sawe J \"High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients.\" Lancet 1 (1984): 731[2] Durrant S, Chipping PM, Palmer S, Gordon-Smith EC \"Cyclosporin A, methylprednisolone, and convulsions.\" Lancet 2 (1982): 829-30[3] Ost L \"Effects of cyclosporin on prednisolone metabolism.\" Lancet 1 (1984): 451[4] Langhoff E, Madsen S, Flachs H, et al \"Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients.\" Transplantation 39 (1985): 107-9[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Anifrolumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Fluocinolone acetonide, Mometasone furoate, Beclomethasone dipropionate, Amcinonide, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, More", "updated_at": 1767369485}, {"id": 77189, "ingredient1": "Cyclosporine", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Cyclosporine may cause hyperkalemia. The concurrent use of potassium-sparing diuretics and cyclosporine may result in or exacerbate hyperkalemia.", "source": "DDInter", "management_text": "The concomitant use of potassium-sparing diuretics and cyclosporine should be avoided. A different class of antihypertensive should be considered.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of potassium-sparing diuretics and cyclosporine should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77290/", "reference_text": "[1] \"Product Information. Neoral Oral Solution (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[3] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[4] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77190, "ingredient1": "Cyclosporine", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77291/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77191, "ingredient1": "Cyclosporine", "ingredient2": "Trimethoprim", "severity": "Moderate", "effect": "Increased serum creatinine levels and decreased efficacy of cyclosporine have been reported when administered concurrently with trimethoprim. The mechanism of this interaction is unknown.", "source": "DDInter", "management_text": "Caution is advised if these medications must be used concomitantly. The patient's renal function and efficacy and safety of both drugs should be monitored during concomitant administration. Use of an alternative antibiotic may be appropriate.", "mechanism_text": "Others", "recommendation": "Caution is advised if these medications must be used concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77292/", "reference_text": "[1] Ringden O, Myrenfors P, Klintmalm G, Tyden G, Ost L \"Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.\" Lancet 1 (1984): 1016-7[2] Berg K, Nordby G, Rootwelt K, et al \"Effects on renal function of combined treatment with trimethoprim and cyclosporine A in kidney transplant patients.\" Transplant Proc 20 (1988): 413-5[3] Thompson JF, Chalmers DH, Hunnisett AG, et al \"Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine.\" Transplantation 36 (1983): 204-6[4] Wallwork J, McGregor CG, Wells FC, Cory-Pearace R, English TA \"Cyclosporin and intravenous sulphadimidine and trimethoprim therapy.\" Lancet 1 (1983): 326-7[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 77192, "ingredient1": "Cyclosporine", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.", "source": "DDInter", "management_text": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77293/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis, Morris Plains, NJ.[2] Fraser CG, Fierro L \"Comment: troglitazone.\" Ann Pharmacother 32 (1998): 1111-2[3] Park MH, Pelegrin D, Haug MT, Young JB \"Troglitazone, a new antidiabetic agent, decreases cyclosporine level.\" J Heart Lung Transplant 17 (1998): 1139-40[4] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP \"Potential interaction of troglitazone and cyclosporine.\" Transplantation 65 (1998): 1399-400[5] Frantz RP, Nguyen TT \"Rezulin (troglitazone) greatly increases cyclosporine metabolism.\" J Heart Lung Transplant 17 (1998): 1037-8[6] Burgess SJ, Singer GG, Brennan DC \"Effect of troglitazone on cyclosporine whole blood levels.\" Transplantation 66 (1998): 272[7] Terra SG, Washam JB, May DB \"Comment: troglitazone drug interactions.\" Ann Pharmacother 32 (1998): 1111[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 77193, "ingredient1": "Cyclosporine", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with macrolide antibiotics that are potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative antibiotics that do not interfere with cyclosporine metabolism should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77294/", "reference_text": "[1] Ptachcinski RJ, Carpenter BJ, Burckart GJ, Venkataramanan R, Rosenthal J \"Effect of erythromycin on cyclosporine levels.\" N Engl J Med 313 (1985): 1416-7[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Gomez E, Sanchez JE, Aguado S, Grande JA \"Interaction between azithromycin and cyclosporin?\" Nephron 73 (1996): 724[4] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 ( Suppl (1996): 133-42[6] Gupta SK, Bakran A, Johnson RW, Rowland M \"Cyclosporin-erythromycin interaction in renal transplant patients.\" Br J Clin Pharmacol 27 (1989): 475-81[7] Grino JM, Sabate I, Castelao AM, et al \"Erythromycin and cyclosporine.\" Ann Intern Med 105 (1986): 467-8[8] Wadhwa NK, Schroeder TJ, O'Flaherty E, et al \"Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient.\" Ther Drug Monit 9 (1987): 123-5[9] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[10] Kohan DE \"Possible interaction between cyclosporine and erythromycin.\" N Engl J Med 314 (1986): 448[11] Ljutic D, Rumboldt Z \"Possible interaction between azithromycin and cyclosporin: a case report.\" Nephron 70 (1995): 130[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, O'Connell PJ \"The mechanism of cyclosporine toxicity induced by clarithromycin.\" Br J Clin Pharmacol 43 (1997): 194-6[14] Kessler M, Louis J, Renoult E, et al \"Interaction between cyclosporin and erythromycin in a kidney transplant patient.\" Eur J Clin Pharmacol 30 (1986): 633-4[15] Freeman DJ, Martell R, Carruthers SG, et al \"Cyclosporin-erythromycin interaction in normal subjects.\" Br J Clin Pharmacol 23 (1987): 776-8[16] Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y \"The interaction between clarithromycin and cyclosporine in kidney transplant recipients.\" Transplantation 58 (1994): 725-7[17] Murray BM, Edwards L, Morse GD, et al \"Clinically important interaction of cyclosporine and erythromycin.\" Transplantation 43 (1987): 602-4[18] Zylber-Katz E \"Multiple drug interactions with cyclosporine in a heart transplant patient.\" Ann Pharmacother 29 (1995): 127-31[19] Sketris IS, Wright MR, West ML \"Possible role of the intestinal p-450 enzyme system in a cyclosporine clarithromycin interaction.\" Pharmacotherapy 16 (1996): 301-5[20] Fabre I, Fabre G, Maurel P, et al \"Metabolism of cyclosporin A. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions.\" Drug Metab Dispos 16 (1988): 296-301[21] Knower MT, LabellaWalker K, McFadden PM, Kantrow SP, Valentine VG \"Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients.\" South Med J 93 (2000): 1087-92[22] Jensen CW, Flechner SM, Van Buren CT, et al. \"Exacerbation of cyclosporin toxicity by concomitant administration of erythromycin.\" Transplantation 43 (1987): 263-70[23] Gersema LM, Porter CB, Russell EH \"Suspected drug interaction between cyclosporine and clarithromycin.\" J Heart Lung Transplant 13 (1994): 343-5[24] Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S \"The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients.\" Int Heart J (2014):[25] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[26] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[27] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[31] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[32] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[33] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[34] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[35] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[36] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[37] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 77194, "ingredient1": "Cyclosporine", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77295/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77195, "ingredient1": "Cyclosporine", "ingredient2": "Tubocurarine", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77296/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 77196, "ingredient1": "Cyclosporine", "ingredient2": "Tucatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative treatment that do not interfere with cyclosporine metabolism should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77297/", "reference_text": "[1] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77197, "ingredient1": "Cyclosporine", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77298/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77198, "ingredient1": "Cyclosporine", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77299/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, Voclosporin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77199, "ingredient1": "Cyclosporine", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors. If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Distribution", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77300/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Frovatriptan, Eptinezumab, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab", "updated_at": 1767369485}, {"id": 77200, "ingredient1": "Cyclosporine", "ingredient2": "Ulipristal", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ulipristal.", "source": "DDInter", "management_text": "Caution is advised when ulipristal is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ulipristal is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when ulipristal is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77301/", "reference_text": "[1] \"Product Information. ella (ulipristal).\" Afaxys Inc., Charleston, SC.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Estetrol, Ospemifene, Prasterone, Bazedoxifene", "updated_at": 1767369485}, {"id": 77201, "ingredient1": "Cyclosporine", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration of upadacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving upadacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. The most common serious infections reported with upadacitinib treatment include pneumonia and cellulitis. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis. Lymphoma and other malignancies, including non-melanoma skin cancers, have also been observed with the use of upadacitinib and other Janus kinase (JAK) inhibitors.", "source": "DDInter", "management_text": "Concomitant use of upadacitinib with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine) is not recommended. Patients receiving upadacitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Concomitant use of upadacitinib with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77302/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Upadacitinib, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77202, "ingredient1": "Cyclosporine", "ingredient2": "Ursodeoxycholic acid", "severity": "Minor", "effect": "Bile acid salts may increase the bioavailability of oral cyclosporine. Data have been conflicting. The mechanism and clinical significance are unknown. No action is necessary; however, clinicians should be aware of the possibility of an interaction.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77303/", "reference_text": "[1] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Odevixibat, Maralixibat, Chenodeoxycholic acid", "updated_at": 1767369485}, {"id": 77203, "ingredient1": "Cyclosporine", "ingredient2": "Ustekinumab", "severity": "Moderate", "effect": "The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.", "source": "DDInter", "management_text": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77304/", "reference_text": "[1] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[2] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[7] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[8] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ustekinumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 77204, "ingredient1": "Cyclosporine", "ingredient2": "Valaciclovir", "severity": "Moderate", "effect": "The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions. Cases of acute renal failure have been reported.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77305/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Valtrex (valacyclovir).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77205, "ingredient1": "Cyclosporine", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77306/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989): 445-6[2] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle, Skokie, IL.[3] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987): 213-4[4] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[5] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988): 598-9[6] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991): 252[7] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[8] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[13] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[14] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[15] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[16] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[17] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[18] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[19] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 77206, "ingredient1": "Cyclosporine", "ingredient2": "Valganciclovir", "severity": "Moderate", "effect": "Concurrent use of cyclosporine and ganciclovir or its prodrug, valganciclovir, may increase the risk of nephrotoxicity. Increased serum creatinine has been reported in transplant patients receiving intravenous ganciclovir and cyclosporine. Cases of eye movement disorders and ptosis have also been reported. The mechanism is unknown. In addition, use of cyclosporine and ganciclovir may increase the risk and severity of hematologic toxicity due to additive myelosuppressive effects.", "source": "DDInter", "management_text": "Close monitoring of renal function and for the development of severe hematologic adverse effects is recommended. In addition, consideration should be given to discontinuing one or both drugs if an eye movement disorder occurs.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of renal function and for the development of severe hematologic adverse effects is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77307/", "reference_text": "[1] Openshaw H, Slatkin NE, Smith E \"Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir.\" Bone Marrow Transplant 19 (1997): 5035[2] \"Product Information. Neoral Soft Gelatin Capsules (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Brown F, Banken L, Saywell K, Arum I \"Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositiv volunteers.\" Clin Pharmacokinet 37 (1999): 167-76[7] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[8] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[9] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[14] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[15] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[16] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[17] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[18] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[19] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[20] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Siponimod, Anakinra, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 77207, "ingredient1": "Cyclosporine", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles. Coadministration with inhibitors of the hepatic uptake transporter OATP 1B1 such as cyclosporine may increase the systemic exposure to valsartan, which is a substrate of the transporter.", "source": "DDInter", "management_text": "Caution is advised if valsartan is used in combination with cyclosporine. Pharmacologic response and blood pressure should be monitored more closely following the addition, discontinuation, or change of dosage of cyclosporine, and the valsartan regimen adjusted as necessary. Serum potassium levels and renal function should also be checked regularly. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Distribution, Excretion", "recommendation": "Caution is advised if valsartan is used in combination with cyclosporine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77308/", "reference_text": "[1] \"Product Information. Exforge (amlodipine-valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Nebivolol, Bempedoic acid", "updated_at": 1767369485}, {"id": 77208, "ingredient1": "Cyclosporine", "ingredient2": "Vancomycin", "severity": "Moderate", "effect": "The potential nephrotoxic effects of cyclosporine and glycopeptide antibiotics may be additive.", "source": "DDInter", "management_text": "Serum drug concentrations and renal function, including serum creatinine, should be carefully monitored during concurrent administration.", "mechanism_text": "Synergism", "recommendation": "Serum drug concentrations and renal function, including serum creatinine, should be carefully monitored during concurrent administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77309/", "reference_text": "[1] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Kureishi A, Jewesson PJ, Rubinger M, et al \"Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A.\" Antimicrob Agents Chemother 35 (1991): 2246-52[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Oritavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin, Rifamycin, Paromomycin, Rifamycin, Oxytetracycline, Lomefloxacin, More", "updated_at": 1767369485}, {"id": 77209, "ingredient1": "Cyclosporine", "ingredient2": "Vardenafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.", "source": "DDInter", "management_text": "Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77310/", "reference_text": "[1] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77210, "ingredient1": "Cyclosporine", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77311/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, Vitamin A, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77211, "ingredient1": "Cyclosporine", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "mechanism_text": "Others", "recommendation": "Patients should be monitored for excessive and/or prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77312/", "reference_text": "[1] Wood GG \"Cyclosporin-vercuronium interaction.\" Can J Anaesth 36 (1989): 358-66[2] Crosby E, Robblee JA \"Cyclosporine-pancuronium interaction in a patient with a renal allograft.\" Can J Anaesth 35 (1988): 300-2[3] Sidi A, Kaplan RF, Davis RF \"Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.\" Can J Anaesth 37 (1990): 543-8[4] Sharpe MD, Gelb AW \"Cyclosporin potentiates vercuronium blockade and prolongs recovery time in humans.\" Can J Anaesth 39 (1992): a126[5] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 77212, "ingredient1": "Cyclosporine", "ingredient2": "Vemurafenib", "severity": "Minor", "effect": "Cyclosporine and vemurafenib may theoretically increase each other's plasma concentrations. Both drugs are inhibitors of the P-glycoprotein efflux transporter. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77313/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 77213, "ingredient1": "Cyclosporine", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of venetoclax with P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77314/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77214, "ingredient1": "Cyclosporine", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV). The possibility of prolonged and/or increased pharmacologic effects of venlafaxine should be considered. Although venlafaxine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of venlafaxine. The interaction may be of greater concern in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77315/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[15] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[16] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[17] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[18] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[23] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[24] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[25] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[26] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[27] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[28] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[35] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[36] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[37] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[38] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[39] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 77215, "ingredient1": "Cyclosporine", "ingredient2": "Vilazodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "mechanism_text": "Metabolism", "recommendation": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77316/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 77216, "ingredient1": "Cyclosporine", "ingredient2": "Vinblastine", "severity": "Minor", "effect": "An in vitro test has shown cyclosporine to have inhibitory effects on the biotransformation of vinblastine. Both drugs are believed to be metabolized by the liver cytochrome P-450. If cyclosporine and vinblastine are used concomitantly, caution and close observation are advised.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77317/", "reference_text": "[1] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Topotecan, Teniposide, Vinorelbine", "updated_at": 1767369485}, {"id": 77217, "ingredient1": "Cyclosporine", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Limited data suggest that cyclosporine given to reverse multidrug resistance can enhance the toxicity of some antineoplastic agents such as dactinomycin and vincristine. The proposed mechanism is cyclosporine inhibition of multidrug resistance protein 1 (MDR1), also known as P-glycoprotein, a plasma membrane efflux transporter that has been demonstrated as a primary cause of multidrug resistance in tumors. Inhibiting P-glycoprotein increases the intracellular concentration of substrate antineoplastic agents, thereby potentiating their cytotoxic effects.", "source": "DDInter", "management_text": "Patients receiving antineoplastic agents that are known substrates of P-glycoprotein should be closely monitored for potentially increased toxicities during coadministration with cyclosporine, and their dosages adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Patients receiving antineoplastic agents that are known substrates of P-glycoprotein should be closely monitored for potentially increased toxicities during coadministration with cyclosporine, and their dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77318/", "reference_text": "[1] Cowie F, Pinkerton CR \"Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance.\" J Clin Oncol 12 (1994): 1998-9[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Topotecan, Teniposide, Vinorelbine", "updated_at": 1767369485}, {"id": 77218, "ingredient1": "Cyclosporine", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Limited data suggest that cyclosporine given to reverse multidrug resistance can enhance the toxicity of some antineoplastic agents such as dactinomycin and vincristine. The proposed mechanism is cyclosporine inhibition of multidrug resistance protein 1 (MDR1), also known as P-glycoprotein, a plasma membrane efflux transporter that has been demonstrated as a primary cause of multidrug resistance in tumors. Inhibiting P-glycoprotein increases the intracellular concentration of substrate antineoplastic agents, thereby potentiating their cytotoxic effects.", "source": "DDInter", "management_text": "Patients receiving antineoplastic agents that are known substrates of P-glycoprotein should be closely monitored for potentially increased toxicities during coadministration with cyclosporine, and their dosages adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Patients receiving antineoplastic agents that are known substrates of P-glycoprotein should be closely monitored for potentially increased toxicities during coadministration with cyclosporine, and their dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77319/", "reference_text": "[1] Cowie F, Pinkerton CR \"Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance.\" J Clin Oncol 12 (1994): 1998-9[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Topotecan, Teniposide, Vinorelbine", "updated_at": 1767369485}, {"id": 77219, "ingredient1": "Cyclosporine", "ingredient2": "Vismodegib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein may increase the plasma concentrations of vismodegib, which has been shown in vitro to be a substrate of the efflux transporter. The potential for increased pharmacologic effects of vismodegib, including adverse effects such as muscle spasm, alopecia, dysgeusia/ageusia, weight loss, fatigue, nausea, vomiting, diarrhea, decreased appetite, constipation and arthralgia, should be considered.", "source": "DDInter", "management_text": "Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.", "mechanism_text": "Others", "recommendation": "Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77320/", "reference_text": "[1] \"Product Information. Erivedge (vismodegib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 77220, "ingredient1": "Cyclosporine", "ingredient2": "Vitamin E", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77321/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Alemtuzumab, Siponimod, Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Pomalidomide, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77221, "ingredient1": "Cyclosporine", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with voriconazole may increase the blood concentrations of cyclosporine. The mechanism is voriconazole inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of cyclosporine.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine must be used concomitantly with voriconazole. Patients who are already receiving cyclosporine should have the dosage reduced to one-half the original dosage upon initiation of voriconazole therapy. Close monitoring of renal function and cyclosporine blood levels is recommended both following initiation and withdrawal of voriconazole therapy, and the cyclosporine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine must be used concomitantly with voriconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77322/", "reference_text": "[1] Romero AJ, Pogamp PL, Nilsson LG, Wood N \"Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.\" Clin Pharmacol Ther 71 (2002): 226-34[2] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[16] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[17] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Micafungin, Oteseconazole", "updated_at": 1767369485}, {"id": 77222, "ingredient1": "Cyclosporine", "ingredient2": "Voxelotor", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the systemic exposure (AUC) to voxelotor, which has been shown to be a substrate of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor. Dose adjustments may be necessary. Patients should be closely monitored for signs of voxelotor-related adverse effects, including headache, diarrhea, abdominal pain, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if voxelotor is to be used with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77323/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc., South San Francisco, CA.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77223, "ingredient1": "Cyclosporine", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "A few case reports have suggested that the concomitant use of cyclosporine and warfarin may result in both increased and reduced effects of both agents, although this interaction is not well established. The mechanism is unknown. A similar reaction may occur with other oral coumarin anticoagulants.", "source": "DDInter", "management_text": "It may be advisable to monitor prothrombin time (PT) and/or International Normalized Ratio(INR), as well as cyclosporine blood concentrations and the patient's response is recommended if these agents are used together.", "mechanism_text": "Others", "recommendation": "It may be advisable to monitor prothrombin time (PT) and/or International Normalized Ratio(INR), as well as cyclosporine blood concentrations and the patient's response is recommended if these agents are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77324/", "reference_text": "[1] Snyder DS \"Interaction between cyclosporine and warfarin.\" Ann Intern Med 108 (1988): 311[2] Cockburn I \"Cyclosporine A: a clinical evaluation of drug interactions.\" Transplant Proc 18 (1986): 50-5[3] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[4] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[9] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[10] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[11] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[12] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[13] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[14] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[15] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9[16] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[17] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[18] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[19] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[20] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[21] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[22] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[23] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[24] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[25] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[26] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[27] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[28] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[29] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[30] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[31] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[32] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[33] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[34] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[35] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[36] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[37] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[38] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[39] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[40] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[41] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[42] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[43] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[44] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[45] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[46] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[47] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[48] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[49] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[50] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[51] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[52] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 77224, "ingredient1": "Cyclosporine", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77325/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, Vitamin A, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77225, "ingredient1": "Cyclosporine", "ingredient2": "Zanubrutinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when zanubrutinib is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as rash, diarrhea, constipation, cough, hemorrhage, infection, cytopenias, and atrial fibrillation or flutter, and the zanubrutinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zanubrutinib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77326/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77226, "ingredient1": "Cyclosporine", "ingredient2": "Zileuton", "severity": "Minor", "effect": "Zileuton is believed to be a weak inhibitor of CYP450 3A4 enzymes, of which cyclosporine is a known substrate. Although no studies have been conducted to verify or quantify the interaction, caution is recommended when using this combination until further data is available.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77327/", "reference_text": "[1] \"Product Information. Zylo Filmtab (zileuton).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[3] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[8] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[9] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[10] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[11] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[12] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[13] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[14] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77227, "ingredient1": "Cyclosporine", "ingredient2": "Zinc acetate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77328/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate, Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, More", "updated_at": 1767369485}, {"id": 77228, "ingredient1": "Cyclosporine", "ingredient2": "Zinc chloride", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77329/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate, Sodium acetate, Magnesium sulfate, Arginine, Sodium glycerophosphate, Tromethamine, Sodium phosphate, monobasic, Sodium chloride, More", "updated_at": 1767369485}, {"id": 77229, "ingredient1": "Cyclosporine", "ingredient2": "Zinc gluconate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77330/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate, Magnesium gluconate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 77230, "ingredient1": "Cyclosporine", "ingredient2": "Zinc sulfate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77331/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate, Magnesium gluconate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 77231, "ingredient1": "Cyclosporine", "ingredient2": "Ziprasidone", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77332/", "reference_text": "[1] Miceli JJ, Smith M, Robarge L, Morse T, Laurent A \"The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.\" Br J Clin Pharmacol 49(suppl 1) (2000): s71-6[2] Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D \"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.\" Br J Clin Pharmacol 49(Suppl 1) (2000): 35S-42S[3] Wilner KD, Hansen RA, Folger CJ, Geoffroy P \"The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.\" Br J Clin Pharmacol 49(Suppl 1) (2000): 57S-60S[4] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 77232, "ingredient1": "Cyclosporine", "ingredient2": "Zoledronic acid", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77333/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 77233, "ingredient1": "Amikacin (liposome)", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77334/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 77234, "ingredient1": "Amphotericin B (cholesteryl sulfate)", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77335/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77235, "ingredient1": "Amphotericin B (liposomal)", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77336/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77236, "ingredient1": "Diatrizoate", "ingredient2": "Arbutamine", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77337/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "alternatives_b": "Droxidopa, Norepinephrine, Midodrine, Angiotensin II, Ephedrine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, Mephentermine, Methoxamine, Isoprenaline", "updated_at": 1767369485}, {"id": 77237, "ingredient1": "Diatrizoate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77338/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77238, "ingredient1": "Diatrizoate", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77339/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77239, "ingredient1": "Diatrizoate", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77340/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77240, "ingredient1": "Diatrizoate", "ingredient2": "Bromfenac", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77341/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "updated_at": 1767369485}, {"id": 77241, "ingredient1": "Diatrizoate", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77342/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, More", "updated_at": 1767369485}, {"id": 77242, "ingredient1": "Diatrizoate", "ingredient2": "Deferasirox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77343/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Promethazine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 77243, "ingredient1": "Diatrizoate", "ingredient2": "Deferoxamine", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77344/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Promethazine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 77244, "ingredient1": "Diclofenamide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77345/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77245, "ingredient1": "Diflunisal", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77346/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 77246, "ingredient1": "Digitoxin", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77347/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77247, "ingredient1": "Digoxin", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77348/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77248, "ingredient1": "Disopyramide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77349/", "reference_text": "[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U \"Iohexol contrast medium induces QT prolongation in amiodarone patients.\" Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Lidocaine, Dronedarone, Tocainide, Propafenone, Flecainide, Mexiletine, Bretylium, Moricizine", "updated_at": 1767369485}, {"id": 77249, "ingredient1": "Dobutamine", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77350/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "alternatives_b": "Droxidopa, Norepinephrine, Midodrine, Angiotensin II, Ephedrine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, Mephentermine, Methoxamine, Isoprenaline", "updated_at": 1767369485}, {"id": 77250, "ingredient1": "Dofetilide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77351/", "reference_text": "[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U \"Iohexol contrast medium induces QT prolongation in amiodarone patients.\" Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Lidocaine, Dronedarone, Tocainide, Propafenone, Flecainide, Mexiletine, Bretylium, Moricizine", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 77251, "ingredient1": "Dopamine", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77352/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "alternatives_b": "Droxidopa, Norepinephrine, Midodrine, Angiotensin II, Ephedrine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, Mephentermine, Methoxamine, Isoprenaline", "updated_at": 1767369485}, {"id": 77252, "ingredient1": "Edetate calcium disodium anhydrous", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77353/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77253, "ingredient1": "Edetate disodium anhydrous", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77354/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77254, "ingredient1": "Esmolol", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77355/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77255, "ingredient1": "Etacrynic acid", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77356/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77256, "ingredient1": "Etidronic acid", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77357/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 77257, "ingredient1": "Etodolac", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77358/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77258, "ingredient1": "Everolimus", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77359/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 77259, "ingredient1": "Felodipine", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77360/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Ioversol, Iohexol, Iodixanol, Ethiodized oil, Iopromide, Iopamidol, Metrizamide", "alternatives_b": "Acetylsalicylic acid, Ivabradine, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "updated_at": 1767369485}, {"id": 77260, "ingredient1": "Fenoprofen", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77361/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77261, "ingredient1": "Flurbiprofen", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77362/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Chlorhexidine, Povidone-iodine, More", "updated_at": 1767369485}, {"id": 77262, "ingredient1": "Foscarnet", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77363/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 77263, "ingredient1": "Furosemide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77364/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77264, "ingredient1": "Gallium nitrate", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77365/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77265, "ingredient1": "Gentamicin", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77366/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 77266, "ingredient1": "Givosiran", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77367/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 77267, "ingredient1": "Hydroflumethiazide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77368/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77268, "ingredient1": "Ibutilide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77369/", "reference_text": "[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U \"Iohexol contrast medium induces QT prolongation in amiodarone patients.\" Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Lidocaine, Dronedarone, Tocainide, Propafenone, Flecainide, Mexiletine, Bretylium, Moricizine", "updated_at": 1767369485}, {"id": 77269, "ingredient1": "Ifosfamide", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77370/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "updated_at": 1767369485}, {"id": 77270, "ingredient1": "Amrinone", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77371/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "alternatives_b": "Droxidopa, Norepinephrine, Midodrine, Angiotensin II, Ephedrine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, Mephentermine, Methoxamine, Isoprenaline", "updated_at": 1767369485}, {"id": 77271, "ingredient1": "Indapamide", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77372/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Tamsulosin, More", "updated_at": 1767369485}, {"id": 77272, "ingredient1": "Indomethacin", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77373/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 77273, "ingredient1": "Inotersen", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77374/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 77274, "ingredient1": "Iobenguane (I-131)", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77375/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77275, "ingredient1": "Iopanoic acid", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Others", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77376/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[3] \"Product Information. Omniscan (gadodiamide).\" Novation, Irving, TX.", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More", "updated_at": 1767369485}, {"id": 77276, "ingredient1": "Iopodic acid", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Others", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77377/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[3] \"Product Information. Omniscan (gadodiamide).\" Novation, Irving, TX.", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More", "updated_at": 1767369485}, {"id": 77277, "ingredient1": "Isradipine", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77378/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Ioversol, Iohexol, Iodixanol, Ethiodized oil, Iopromide, Iopamidol, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77278, "ingredient1": "Diatrizoate", "ingredient2": "Kanamycin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77379/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 77279, "ingredient1": "Diatrizoate", "ingredient2": "Ketoprofen", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77380/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77280, "ingredient1": "Diatrizoate", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77381/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77281, "ingredient1": "Diatrizoate", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77382/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Ioversol, Iohexol, Iodixanol, Ethiodized oil, Iopromide, Iopamidol, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77282, "ingredient1": "Diatrizoate", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77383/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77283, "ingredient1": "Diatrizoate", "ingredient2": "Levobunolol (ophthalmic)", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77384/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77284, "ingredient1": "Diatrizoate", "ingredient2": "Lithium carbonate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77385/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77285, "ingredient1": "Diatrizoate", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77386/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77286, "ingredient1": "Diatrizoate", "ingredient2": "Mannitol", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77387/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More", "updated_at": 1767369485}, {"id": 77287, "ingredient1": "Diatrizoate", "ingredient2": "Meclofenamic acid", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77388/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77288, "ingredient1": "Diatrizoate", "ingredient2": "Mefenamic acid", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77389/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77289, "ingredient1": "Diatrizoate", "ingredient2": "Meloxicam", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77390/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "updated_at": 1767369485}, {"id": 77290, "ingredient1": "Diatrizoate", "ingredient2": "Methazolamide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77391/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77291, "ingredient1": "Diatrizoate", "ingredient2": "Methotrexate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77392/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 77292, "ingredient1": "Diatrizoate", "ingredient2": "Methoxyflurane", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77393/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 77293, "ingredient1": "Diatrizoate", "ingredient2": "Metipranolol (ophthalmic)", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77394/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77294, "ingredient1": "Diatrizoate", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77395/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77295, "ingredient1": "Diatrizoate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77396/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77296, "ingredient1": "Diatrizoate", "ingredient2": "Milrinone", "severity": "Moderate", "effect": "Addition of an inotropic agent to ionic radiocontrast media may produce a paradoxical depressant response that can be deleterious to the ischemic myocardium. The exact mechanism of interaction is unknown, although ionic radiocontrast agents are known to have a direct depressant effect on cardiac muscles.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media. Patients should be monitored closely for adverse cardiac effects.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction when an inotropic agent is used in combination with ionic radiocontrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77397/", "reference_text": "[1] \"Product Information. Hypaque (diatrizoate).\" Amersham Health, Princeton, NJ.", "alternatives_a": "Droxidopa, Norepinephrine, Midodrine, Angiotensin II, Ephedrine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, Mephentermine, Methoxamine, Isoprenaline", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, More", "updated_at": 1767369485}, {"id": 77297, "ingredient1": "Diatrizoate", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77398/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77298, "ingredient1": "Diatrizoate", "ingredient2": "Nabumetone", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77399/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77299, "ingredient1": "Diatrizoate", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77400/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77300, "ingredient1": "Diatrizoate", "ingredient2": "Naproxen", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77401/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "updated_at": 1767369485}, {"id": 77301, "ingredient1": "Diatrizoate", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77402/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Valsartan, Irbesartan, Losartan, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Sacubitril, Aliskiren, Eprosartan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77302, "ingredient1": "Diatrizoate", "ingredient2": "Neomycin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77403/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rifamycin, Miconazole, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Chlorhexidine, Povidone-iodine, Tetracycline, Mupirocin, More", "updated_at": 1767369485}, {"id": 77303, "ingredient1": "Diatrizoate", "ingredient2": "Netilmicin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77404/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 77304, "ingredient1": "Diatrizoate", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77405/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Ioversol, Iohexol, Iodixanol, Ethiodized oil, Iopromide, Iopamidol, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77305, "ingredient1": "Diatrizoate", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77406/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Ioversol, Iohexol, Ethiodized oil, Iopromide, Iopamidol, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77306, "ingredient1": "Diatrizoate", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.", "source": "DDInter", "management_text": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.", "mechanism_text": "Synergism", "recommendation": "Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77407/", "reference_text": "[1] Morris DL, Wisneski JA, Gertz EW, et al \"Potentiation by nifedipine and diltiazem of the hypotensive response after contrast angiography.\" J Am Coll Cardiol 6 (1985): 785-91[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Ioxilan, Iomeprol, Ioversol, Iohexol, Iodixanol, Ethiodized oil, Iopromide, Iopamidol, Metrizamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77307, "ingredient1": "Diatrizoate", "ingredient2": "Olsalazine", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77408/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Budesonide, Hydrocortisone, Cromoglicic acid, Prednisone, Prednisolone, Betamethasone, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 77308, "ingredient1": "Diatrizoate", "ingredient2": "Oxaprozin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77409/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77309, "ingredient1": "Diatrizoate", "ingredient2": "Pamidronic acid", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77410/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 77310, "ingredient1": "Diatrizoate", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77411/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77311, "ingredient1": "Diatrizoate", "ingredient2": "Penicillamine", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77412/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Auranofin, Aurothioglucose, Sodium aurothiomalate", "updated_at": 1767369485}, {"id": 77312, "ingredient1": "Diatrizoate", "ingredient2": "Pentamidine", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77413/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Miltefosine, Fexinidazole, Nifurtimox, Benznidazole", "updated_at": 1767369485}, {"id": 77313, "ingredient1": "Diatrizoate", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77414/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Acetylsalicylic acid, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77314, "ingredient1": "Diatrizoate", "ingredient2": "Pindolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77415/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77315, "ingredient1": "Diatrizoate", "ingredient2": "Piroxicam", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77416/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Salicylic acid, Fluocinolone acetonide, Cortisone, More", "updated_at": 1767369485}, {"id": 77316, "ingredient1": "Diatrizoate", "ingredient2": "Plazomicin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77417/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77317, "ingredient1": "Diatrizoate", "ingredient2": "Polymyxin B", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77418/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tetracycline, Rifamycin, Miconazole, Ciprofloxacin, Chloramphenicol, Chlorhexidine, Ofloxacin, Tetracycline, Ciprofloxacin, Chlorhexidine, Chloramphenicol, More", "updated_at": 1767369485}, {"id": 77318, "ingredient1": "Diatrizoate", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77419/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77319, "ingredient1": "Diatrizoate", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77420/", "reference_text": "[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U \"Iohexol contrast medium induces QT prolongation in amiodarone patients.\" Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Lidocaine, Dronedarone, Tocainide, Propafenone, Flecainide, Mexiletine, Bretylium, Moricizine", "updated_at": 1767369485}, {"id": 77320, "ingredient1": "Diatrizoate", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77421/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77321, "ingredient1": "Diatrizoate", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77422/", "reference_text": "[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U \"Iohexol contrast medium induces QT prolongation in amiodarone patients.\" Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Lidocaine, Dronedarone, Tocainide, Propafenone, Flecainide, Mexiletine, Bretylium, Moricizine", "updated_at": 1767369485}, {"id": 77322, "ingredient1": "Diatrizoate", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient, sulfobutylether-beta-cyclodextrin sodium (SBECD). Both GS-441524 and SBECD are primarily eliminated by the kidneys, thus renal impairment secondary to the use of nephrotoxic agents may reduce their clearance and increase the risk of accumulation.", "source": "DDInter", "management_text": "Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function. Caution is advised if remdesivir is used in patients who have recently received potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function (estimated glomerular filtration rate, or eGFR, for adult and pediatric patients older than 28 days; serum creatinine for full-term neonates at least 7 days up to 28 days old) should be evaluated prior to starting remdesivir and monitored daily during treatment or as clinically appropriate.", "mechanism_text": "Excretion", "recommendation": "Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77423/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 77323, "ingredient1": "Diatrizoate", "ingredient2": "Rofecoxib", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77424/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77324, "ingredient1": "Diatrizoate", "ingredient2": "Salsalate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77425/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 77325, "ingredient1": "Diatrizoate", "ingredient2": "Sirolimus", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77426/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "updated_at": 1767369485}, {"id": 77326, "ingredient1": "Iodide I-123", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "INTERVAL: Iodine-containing products may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides. These effects may last up to 8 weeks.", "source": "DDInter", "management_text": "Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.", "mechanism_text": "Others", "recommendation": "Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77427/", "reference_text": "[1] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Iopanoic acid, Tyropanoic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77327, "ingredient1": "Iodide I-131", "ingredient2": "Diatrizoate", "severity": "Moderate", "effect": "INTERVAL: Iodine-containing products may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides. These effects may last up to 8 weeks.", "source": "DDInter", "management_text": "Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.", "mechanism_text": "Others", "recommendation": "Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77428/", "reference_text": "[1] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Iopanoic acid, Tyropanoic acid", "alternatives_b": "Ibritumomab tiuxetan, Tositumomab", "updated_at": 1767369485}, {"id": 77328, "ingredient1": "Diatrizoate", "ingredient2": "Sotalol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77429/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77329, "ingredient1": "Diatrizoate", "ingredient2": "Streptomycin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77430/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 77330, "ingredient1": "Diatrizoate", "ingredient2": "Streptozocin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77431/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "updated_at": 1767369485}, {"id": 77331, "ingredient1": "Diatrizoate", "ingredient2": "Sulfasalazine", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77432/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77332, "ingredient1": "Diatrizoate", "ingredient2": "Sulindac", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77433/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77333, "ingredient1": "Diatrizoate", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77434/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 77334, "ingredient1": "Diatrizoate", "ingredient2": "Telavancin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77435/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 77335, "ingredient1": "Diatrizoate", "ingredient2": "Temsirolimus", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77436/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 77336, "ingredient1": "Diatrizoate", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77437/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77337, "ingredient1": "Diatrizoate", "ingredient2": "Tobramycin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77438/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, More", "updated_at": 1767369485}, {"id": 77338, "ingredient1": "Diatrizoate", "ingredient2": "Tolmetin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77439/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 77339, "ingredient1": "Diatrizoate", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77440/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 77340, "ingredient1": "Diatrizoate", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77441/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Eplerenone, Finerenone", "updated_at": 1767369485}, {"id": 77341, "ingredient1": "Diatrizoate", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77442/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 77342, "ingredient1": "Diatrizoate", "ingredient2": "Tyropanoic acid", "severity": "Moderate", "effect": "INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "mechanism_text": "Others", "recommendation": "Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77443/", "reference_text": "[1] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.[2] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[3] \"Product Information. Omniscan (gadodiamide).\" Novation, Irving, TX.", "alternatives_a": "Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide", "alternatives_b": "Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More", "updated_at": 1767369485}, {"id": 77343, "ingredient1": "Diatrizoate", "ingredient2": "Urea", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77444/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tromethamine", "updated_at": 1767369485}, {"id": 77344, "ingredient1": "Diatrizoate", "ingredient2": "Valaciclovir", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77445/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 77345, "ingredient1": "Diatrizoate", "ingredient2": "Valdecoxib", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77446/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 77346, "ingredient1": "Diatrizoate", "ingredient2": "Vancomycin", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77447/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More", "updated_at": 1767369485}, {"id": 77347, "ingredient1": "Diatrizoate", "ingredient2": "Zoledronic acid", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77448/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 77348, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Amikacin (liposome)", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77449/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77349, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Amphotericin B (cholesteryl sulfate)", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77450/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77350, "ingredient1": "Amphotericin B (liposomal)", "ingredient2": "Human cytomegalovirus immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77451/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77351, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77452/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77352, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Bromfenac", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77453/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77353, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Deferasirox", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77454/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77354, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Diflunisal", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77455/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77355, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Ethotoin", "severity": "Moderate", "effect": "A possible interaction between phenytoin and intravenous immunoglobulin (IVIG) was suspected in a case of fatal hypersensitivity myocarditis.", "source": "DDInter", "management_text": "Due to the serious nature of the possible interaction, clinicians should consider monitoring hematologic parameters such as eosinophil counts as well as blood pressure and ECG tracings if immunoglobulins are used in patients receiving phenytoin.", "mechanism_text": "Others", "recommendation": "Due to the serious nature of the possible interaction, clinicians should consider monitoring hematologic parameters such as eosinophil counts as well as blood pressure and ECG tracings if immunoglobulins are used in patients receiving phenytoin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77456/", "reference_text": "[1] Koehler PJ, Koudstaal J \"Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillan-Barre syndrome, in combination with phenytoin.\" J Neurol 243 (1996): 366-7[2] Mostella J, Pieroni R, Jones R, Finch CK \"Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin.\" South Med J 97 (2004): 319-21[3] Fenoglio JJ, McAllister HA, Mullick FG \"Drug related myocarditis: I. Hypersensitivity myocarditis.\" Hum Pathol 12 (1981): 900-7[4] Cumbo-Nacheli G, Weinberger J, Alkhalil M, Thati N, Baptist AP \"Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation?\" Epilepsia 49 (2008): 2108-12[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77356, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Etidronic acid", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77457/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77357, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Etodolac", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77458/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77358, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Fenoprofen", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77459/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77359, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Flurbiprofen", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77460/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Chlorhexidine, Povidone-iodine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77360, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Gentamicin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77461/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77361, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Givosiran", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77462/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 77362, "ingredient1": "Indomethacin", "ingredient2": "Human cytomegalovirus immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77463/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77363, "ingredient1": "Inotersen", "ingredient2": "Human cytomegalovirus immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77464/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 77364, "ingredient1": "Iobenguane (I-131)", "ingredient2": "Human cytomegalovirus immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77465/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77365, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Kanamycin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77466/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77366, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Ketoprofen", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77467/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77367, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Lithium carbonate", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77468/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77368, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77469/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77369, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77470/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77370, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Meclofenamic acid", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77471/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77371, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Mefenamic acid", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77472/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77372, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Meloxicam", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77473/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77373, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "A possible interaction between phenytoin and intravenous immunoglobulin (IVIG) was suspected in a case of fatal hypersensitivity myocarditis.", "source": "DDInter", "management_text": "Due to the serious nature of the possible interaction, clinicians should consider monitoring hematologic parameters such as eosinophil counts as well as blood pressure and ECG tracings if immunoglobulins are used in patients receiving phenytoin.", "mechanism_text": "Others", "recommendation": "Due to the serious nature of the possible interaction, clinicians should consider monitoring hematologic parameters such as eosinophil counts as well as blood pressure and ECG tracings if immunoglobulins are used in patients receiving phenytoin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77474/", "reference_text": "[1] Koehler PJ, Koudstaal J \"Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillan-Barre syndrome, in combination with phenytoin.\" J Neurol 243 (1996): 366-7[2] Mostella J, Pieroni R, Jones R, Finch CK \"Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin.\" South Med J 97 (2004): 319-21[3] Fenoglio JJ, McAllister HA, Mullick FG \"Drug related myocarditis: I. Hypersensitivity myocarditis.\" Hum Pathol 12 (1981): 900-7[4] Cumbo-Nacheli G, Weinberger J, Alkhalil M, Thati N, Baptist AP \"Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation?\" Epilepsia 49 (2008): 2108-12[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77374, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Methotrexate", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77475/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77375, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Methoxyflurane", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77476/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77376, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Moxetumomab Pasudotox", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77477/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77377, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77478/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77378, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Nabumetone", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77479/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77379, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Naproxen", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77480/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77380, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Neomycin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77481/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rifamycin, Miconazole, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Chlorhexidine, Povidone-iodine, Tetracycline, Mupirocin, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77381, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Netilmicin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77482/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77382, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Olsalazine", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77483/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Budesonide, Hydrocortisone, Cromoglicic acid, Prednisone, Prednisolone, Betamethasone, Beclomethasone dipropionate", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77383, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Oxaprozin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77484/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77384, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Pamidronic acid", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77485/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77385, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Pentamidine", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77486/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Miltefosine, Fexinidazole, Nifurtimox, Benznidazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77386, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77487/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77387, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "A possible interaction between phenytoin and intravenous immunoglobulin (IVIG) was suspected in a case of fatal hypersensitivity myocarditis.", "source": "DDInter", "management_text": "Due to the serious nature of the possible interaction, clinicians should consider monitoring hematologic parameters such as eosinophil counts as well as blood pressure and ECG tracings if immunoglobulins are used in patients receiving phenytoin.", "mechanism_text": "Others", "recommendation": "Due to the serious nature of the possible interaction, clinicians should consider monitoring hematologic parameters such as eosinophil counts as well as blood pressure and ECG tracings if immunoglobulins are used in patients receiving phenytoin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77488/", "reference_text": "[1] Koehler PJ, Koudstaal J \"Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillan-Barre syndrome, in combination with phenytoin.\" J Neurol 243 (1996): 366-7[2] Mostella J, Pieroni R, Jones R, Finch CK \"Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin.\" South Med J 97 (2004): 319-21[3] Fenoglio JJ, McAllister HA, Mullick FG \"Drug related myocarditis: I. Hypersensitivity myocarditis.\" Hum Pathol 12 (1981): 900-7[4] Cumbo-Nacheli G, Weinberger J, Alkhalil M, Thati N, Baptist AP \"Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation?\" Epilepsia 49 (2008): 2108-12[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77388, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Piroxicam", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77489/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Salicylic acid, Fluocinolone acetonide, Cortisone, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77389, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Plazomicin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77490/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77390, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Polymyxin B", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77491/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tetracycline, Rifamycin, Miconazole, Ciprofloxacin, Chloramphenicol, Chlorhexidine, Ofloxacin, Tetracycline, Ciprofloxacin, Chlorhexidine, Chloramphenicol, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77391, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Rofecoxib", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77492/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77392, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Rotavirus vaccine", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77493/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77393, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Rubella virus vaccine", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77494/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77394, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Salsalate", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77495/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77395, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Sirolimus", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77496/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77396, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77497/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77397, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Streptomycin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77498/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77398, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Sulfasalazine", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77499/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77399, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Sulindac", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77500/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77400, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77501/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77401, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Telavancin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77502/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77402, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Temsirolimus", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77503/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77403, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Tobramycin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77504/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ofloxacin, Acyclovir, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77404, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Tolmetin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77505/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77405, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Typhoid vaccine (live)", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77506/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77406, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Valdecoxib", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77507/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77407, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Vancomycin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77508/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77408, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77509/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77409, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Yellow Fever Vaccine", "severity": "Moderate", "effect": "INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.", "source": "DDInter", "management_text": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin. If such vaccinations are given shortly before or after immune globulin therapy, a revaccination may be necessary.", "mechanism_text": "Others", "recommendation": "Varicella virus vaccine should not be given for at least 5 months, and other live vaccines should not be given for at least 3 months, after administration of immune globulin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77510/", "reference_text": "[1] \"Product Information. Varicella Zoster Immune Globulin (varicella zoster immune globulin).\" American Red Cross Blood Services, Dedham, MA.[2] \"Product Information. Vivaglobin (immune globulin subcutaneous).\" ZLB Bioplasma Inc, Glendale, CA.[3] \"Product Information. Bayrab (rabies immune globulin, human).\" Bayer, West Haven, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Rhophylac (RHo (D) immune globulin).\" ZLB Bioplasma Inc, Glendale, CA.[6] \"Product Information. Nabi-HB (hepatitis B immune globulin).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[7] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[10] \"Product Information. BayRHo-D (RHo (D) immune globulin).\" Bayer, West Haven, CT.[11] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[12] \"Interference of immune globulin with measles and rubella immunization.\" Eur J Pediatr 152 (1993): 536[13] \"Product Information. BayGam (immune globulin intramuscular)\" Bayer, West Haven, CT.[14] \"Product Information. Imogam Rabies-HT (rabies immune globulin, human).\" sanofi pasteur, Swiftwater, PA.[15] \"Product Information. Thymoglobulin (immune globulin intravenous).\" SangStat Medical Corporation, Menlo Park, CA.[16] \"Product Information. WinRho SDF (RHo (D) immune globulin).\" Nabi, Boca Raton, FL.[17] \"Product Information. Baytet (tetanus immune globulin).\" Bayer, West Haven, CT.[18] \"Product Information. Varivax (varicella virus vaccine live).\" Merck & Co, Inc, West Point, PA.[19] \"Product Information. Hyperhep B (hepatitis B immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.[20] \"Product Information. Immune Globulin IV (Human). Sandoglobulin (immune globulin intravenous).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[21] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[22] \"Product Information. H-BIG (hepatitis B immune globulin).\" Allscripts Pharmaceutical Company, Vernon Hills, IL.[23] \"Product Information. Bayhep B (hepatitis B immune globulin).\" Bayer Pharmaceutical Inc, West Haven, CT.[24] \"Product Information. HyperRHO S/D Full Dose (RHo (D) immune globulin).\" Talecris Biotherapeutics, Research Triangle Park, NC.", "alternatives_a": "Bezlotoxumab, Palivizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77410, "ingredient1": "Human cytomegalovirus immune globulin", "ingredient2": "Zoledronic acid", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77511/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 77411, "ingredient1": "Grepafloxacin", "ingredient2": "Citric acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77512/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 77412, "ingredient1": "Citric acid", "ingredient2": "Sparfloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77513/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 77413, "ingredient1": "Anistreplase", "ingredient2": "Human C1-esterase inhibitor", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77514/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77414, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Conjugated estrogens (topical)", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77515/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77415, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Danazol", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77516/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77416, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Darbepoetin alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77517/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77417, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Prasterone enantate", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77518/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77418, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Dienestrol (topical)", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77519/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77419, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Diethylstilbestrol", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77520/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77420, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Drospirenone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77521/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Norethisterone, More", "alternatives_b": "Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77421, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Erythropoietin", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77522/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77422, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Esterified estrogens", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77523/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77423, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Estradiol (topical)", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77524/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Norethisterone, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Progesterone, Norgestrel, Ulipristal, Norethisterone, Norelgestromin, More", "alternatives_b": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77424, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Estrone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77525/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77425, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Estrone sulfate", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77526/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77426, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Estrone sulfate (topical)", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77527/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77427, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Fluoxymesterone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77528/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77428, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Lenalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been observed at significantly increased rates when lenalidomide was coadministered with dexamethasone for the treatment of multiple myeloma.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events. The decision to take prophylactic measures should be done carefully after a thorough assessment of underlying risk factors. If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77529/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] \"Product Information. Revlimid (lenalidomide).\" Celgene Corporation, Summit, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[6] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77429, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Methyltestosterone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77530/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77430, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Ospemifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77531/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77431, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Oxandrolone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77532/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77432, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Oxymetholone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77533/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77433, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Peginesatide", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77534/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Luspatercept, Daprodustat", "updated_at": 1767369485}, {"id": 77434, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Pomalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide. Deep venous thrombosis (DVT) and pulmonary embolism (PE) occur in patients with multiple myeloma treated with pomalidomide.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide. Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77535/", "reference_text": "[1] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.[2] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[3] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[4] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 77435, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77536/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Voxelotor, Betibeglogene autotemcel, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77436, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Raloxifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77537/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77437, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Reteplase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77538/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77438, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Stanozolol", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77539/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77439, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Streptokinase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77540/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77440, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77541/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77441, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Tenecteplase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77542/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77442, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Testolactone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77543/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77443, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Testosterone (topical)", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77544/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77444, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Thalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, oestrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of thalidomide. When used in multiple myeloma, there is an increased risk of venous thromboembolism such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when thalidomide is combined with standard chemotherapeutic agents and/or steroids.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of thalidomide treatment.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77545/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77445, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77546/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77446, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Urokinase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77547/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77447, "ingredient1": "Anistreplase", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77548/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77448, "ingredient1": "Conjugated estrogens (topical)", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77549/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77449, "ingredient1": "Danazol", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77550/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77450, "ingredient1": "Darbepoetin alfa", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77551/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77451, "ingredient1": "Conestat alfa", "ingredient2": "Prasterone enantate", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77552/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77452, "ingredient1": "Dienestrol (topical)", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77553/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77453, "ingredient1": "Diethylstilbestrol", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77554/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77454, "ingredient1": "Drospirenone", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77555/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Norethisterone, More", "alternatives_b": "Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77455, "ingredient1": "Erythropoietin", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77556/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77456, "ingredient1": "Esterified estrogens", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77557/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77457, "ingredient1": "Estradiol (topical)", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77558/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Norethisterone, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Progesterone, Norgestrel, Ulipristal, Norethisterone, Norelgestromin, More", "alternatives_b": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77458, "ingredient1": "Estrone", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77559/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77459, "ingredient1": "Estrone sulfate", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77560/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77460, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77561/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77461, "ingredient1": "Fluoxymesterone", "ingredient2": "Conestat alfa", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77562/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77462, "ingredient1": "Conestat alfa", "ingredient2": "Lenalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide. Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been observed at significantly increased rates when lenalidomide was coadministered with dexamethasone for the treatment of multiple myeloma.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events. The decision to take prophylactic measures should be done carefully after a thorough assessment of underlying risk factors. If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77563/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] \"Product Information. Revlimid (lenalidomide).\" Celgene Corporation, Summit, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[6] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77463, "ingredient1": "Conestat alfa", "ingredient2": "Methyltestosterone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77564/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77464, "ingredient1": "Conestat alfa", "ingredient2": "Ospemifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77565/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77465, "ingredient1": "Conestat alfa", "ingredient2": "Oxandrolone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77566/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77466, "ingredient1": "Conestat alfa", "ingredient2": "Oxymetholone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77567/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77467, "ingredient1": "Conestat alfa", "ingredient2": "Peginesatide", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77568/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Luspatercept, Daprodustat", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77468, "ingredient1": "Conestat alfa", "ingredient2": "Pomalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide. Deep venous thrombosis (DVT) and pulmonary embolism (PE) occur in patients with multiple myeloma treated with pomalidomide.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide. Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77569/", "reference_text": "[1] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.[2] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[3] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[4] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77469, "ingredient1": "Conestat alfa", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77570/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Voxelotor, Betibeglogene autotemcel, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77470, "ingredient1": "Conestat alfa", "ingredient2": "Raloxifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77571/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77471, "ingredient1": "Conestat alfa", "ingredient2": "Reteplase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77572/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77472, "ingredient1": "Conestat alfa", "ingredient2": "Stanozolol", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77573/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77473, "ingredient1": "Conestat alfa", "ingredient2": "Streptokinase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77574/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77474, "ingredient1": "Conestat alfa", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77575/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77475, "ingredient1": "Conestat alfa", "ingredient2": "Tenecteplase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77576/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77476, "ingredient1": "Conestat alfa", "ingredient2": "Testolactone", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77577/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77477, "ingredient1": "Conestat alfa", "ingredient2": "Testosterone (topical)", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77578/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77478, "ingredient1": "Conestat alfa", "ingredient2": "Thalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, oestrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of thalidomide. When used in multiple myeloma, there is an increased risk of venous thromboembolism such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when thalidomide is combined with standard chemotherapeutic agents and/or steroids.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy initiated. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks. Anticoagulation therapy should be continued during the remaining course of thalidomide treatment.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77579/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77479, "ingredient1": "Conestat alfa", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77580/", "reference_text": "[1] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012): 902-9[2] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals, Costa Mesa, CA.[3] \"Product Information. Berinert (complement C1 esterase inhibitor).\" CSL Behring, King of Prussia, PA.[4] \"Product Information. Cinryze (complement C1 esterase inhibitor).\" ViroPharma Incorporated, Exton, PA.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[32] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[33] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[34] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[38] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Hemin, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77480, "ingredient1": "Conestat alfa", "ingredient2": "Urokinase", "severity": "Moderate", "effect": "C1 esterase inhibitors inhibit proteases in the coagulation/fibrinolytic system and may inhibit tissue plasminogen activators (tPAs).", "source": "DDInter", "management_text": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "mechanism_text": "Synergism", "recommendation": "Simultaneous administration of a C1 esterase inhibitor and a tPA should preferably be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77581/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Cangrelor, Dipyridamole, More", "alternatives_b": "Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77481, "ingredient1": "Dabrafenib", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77582/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77482, "ingredient1": "Aluminum hydroxide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77583/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77483, "ingredient1": "Aminolevulinic acid", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.", "source": "DDInter", "management_text": "Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.", "mechanism_text": "Synergism", "recommendation": "Photosensitizing agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77584/", "reference_text": "[1] \"Product Information. Gleolan (aminolevulinic acid).\" NX Development Corp, Lexington, KY.[2] \"Product Information. Nulibry (fosdenopterin).\" Origin Biosciences Inc, Boston, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77484, "ingredient1": "Amprenavir", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77585/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77485, "ingredient1": "Dabrafenib", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77586/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77486, "ingredient1": "Dabrafenib", "ingredient2": "Bedaquiline", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline.", "source": "DDInter", "management_text": "The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77587/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[4] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Ripretinib, Alpelisib, Ruxolitinib, More", "updated_at": 1767369485}, {"id": 77487, "ingredient1": "Dabrafenib", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77588/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Duvelisib, Tivozanib, Zanubrutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77488, "ingredient1": "Dabrafenib", "ingredient2": "Boceprevir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77589/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77489, "ingredient1": "Dabrafenib", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77590/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77490, "ingredient1": "Dabrafenib", "ingredient2": "Caspofungin", "severity": "Moderate", "effect": "Coadministration with inducers or mixed inducer/inhibitors of certain metabolic pathways may produce clinically meaningful reductions in the plasma concentrations of caspofungin.", "source": "DDInter", "management_text": "Caspofungin product labeling recommends that during coadministration with efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone or carbamazepine, an increase in the daily dosage to 70 mg (following the usual 70 mg loading dose) should be considered in patients who are not clinically responding.", "mechanism_text": "Metabolism", "recommendation": "Caspofungin product labeling recommends that during coadministration with efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone or carbamazepine, an increase in the daily dosage to 70 mg (following the usual 70 mg loading dose) should be considered in patients who are not clinically responding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77591/", "reference_text": "[1] \"Product Information. Cancidas (caspofungin)\" Merck & Co, Inc, West Point, PA.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 77491, "ingredient1": "Dabrafenib", "ingredient2": "Cerivastatin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77592/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77492, "ingredient1": "Dabrafenib", "ingredient2": "Cisapride", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77593/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Metoclopramide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77493, "ingredient1": "Dabrafenib", "ingredient2": "Copanlisib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77594/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77494, "ingredient1": "Daclatasvir", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77595/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77495, "ingredient1": "Dapsone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77596/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Clofazimine", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77496, "ingredient1": "Dapsone (topical)", "ingredient2": "Dabrafenib", "severity": "Minor", "effect": "Theoretically, coadministration of dapsone with inducers of CYP450 3A4 such as rifamycins, anticonvulsants, barbiturates, and St. John's wort may increase the formation of dapsone hydroxylamine, a metabolite associated with hemolysis. Dose-related hemolysis is the most common adverse event associated with oral dapsone in both patients with or without glucose-6-phosphate dehydrogenase (G6PD) deficiency.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77597/", "reference_text": "[1] \"Product Information. Aczone (dapsone topical).\" QLT USA, Inc, Fort Collins, CO.[2] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Clofazimine", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 77497, "ingredient1": "Darifenacin", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77598/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77498, "ingredient1": "Darolutamide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77599/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide", "updated_at": 1767369485}, {"id": 77499, "ingredient1": "Darunavir", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77600/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Sunitinib, Futibatinib, Regorafenib, Imatinib, Alpelisib, Lenvatinib, Erdafitinib, Trametinib, Nintedanib, Vandetanib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77500, "ingredient1": "Dasatinib", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77601/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Futibatinib, Alpelisib, Trametinib, Erdafitinib, Neratinib, Nintedanib, Dasatinib, Capmatinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77501, "ingredient1": "Deflazacort", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.", "source": "DDInter", "management_text": "Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77602/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77502, "ingredient1": "Dabrafenib", "ingredient2": "Prasterone enantate", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77603/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77503, "ingredient1": "Delavirdine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77604/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77504, "ingredient1": "Deoxycholic acid", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with agents that alter hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytics, or agents that commonly cause thrombocytopenia may increase the risk of submental hematoma or bruising in association with deoxycholic acid administration.", "source": "DDInter", "management_text": "Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.", "mechanism_text": "Synergism", "recommendation": "Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77605/", "reference_text": "[1] \"Product Information. Kybella (deoxycholic acid).\" Kythera Biopharmaceuticals, Inc., Westlake Village, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Minoxidil, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, Dupilumab, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77505, "ingredient1": "Diazepam", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77606/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Meprobamate, Lorazepam, Chlordiazepoxide, Halazepam, Hydroxyzine, Oxazepam", "alternatives_b": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77506, "ingredient1": "Diethylstilbestrol", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77607/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Histrelin, Leuprolide, Bicalutamide, Triptorelin, Goserelin, Bazedoxifene", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77507, "ingredient1": "Dihydroergotamine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77608/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77508, "ingredient1": "Disopyramide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77609/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77509, "ingredient1": "Docetaxel", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of docetaxel, which is a substrate of the isoenzyme. Rifampin and hyperforin, a component of St. John's wort, have been shown to significantly induce the in vitro metabolism of docetaxel in human hepatocyte cultures.", "source": "DDInter", "management_text": "Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of docetaxel underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with docetaxel is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77610/", "reference_text": "[1] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[2] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[3] Baker SD \"Drug interactions with the taxanes.\" Pharmacotherapy 17(5 Pt 2) (1997): s126-32[4] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[5] Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R \"Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.\" Clin Cancer Res 11(19 Pt 1) (2005): 6972-9[6] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9[10] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[11] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[12] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[13] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[14] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77510, "ingredient1": "Donepezil", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77611/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Rivastigmine, Galantamine, Tacrine, Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 77511, "ingredient1": "Doravirine", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, some authorities recommend that the doravirine dose be increased to 100 mg twice daily (approximately 12 hours apart).", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77612/", "reference_text": "[1] \"Product Information. Pifeltro (doravirine).\" Merck & Company Inc, Whitehouse Station, NJ.[2] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Encorafenib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77512, "ingredient1": "Doxorubicin", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77613/", "reference_text": "[1] \"Product Information. Adriamycin PFS (doxorubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR \"Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects.\" Clin Pharmacol Ther 31 (1982): 263[3] \"Product Information. Doxil (doxorubicin liposomal).\" Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Acalabrutinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77513, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77614/", "reference_text": "[1] \"Product Information. Adriamycin PFS (doxorubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR \"Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects.\" Clin Pharmacol Ther 31 (1982): 263[3] \"Product Information. Doxil (doxorubicin liposomal).\" Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Pralsetinib, Asciminib, Acalabrutinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77514, "ingredient1": "Dronedarone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77615/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Regorafenib, Alpelisib, Trametinib, Erlotinib, Erdafitinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77515, "ingredient1": "Drospirenone", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77616/", "reference_text": "[1] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[2] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[4] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[5] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[6] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[7] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[8] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[9] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[10] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[11] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[12] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[13] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[14] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[15] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[16] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[17] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[19] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[20] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[21] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[22] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[23] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[24] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[25] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[26] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[27] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[28] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[30] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[31] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[32] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[33] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[34] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[35] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[36] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[37] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[38] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[39] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[40] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[41] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[42] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[43] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[44] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[45] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[46] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[47] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[48] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[49] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[50] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[51] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[52] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[53] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[54] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[55] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[56] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[57] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[58] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[59] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[60] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[61] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[62] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[63] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[64] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[65] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[66] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[67] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[68] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[69] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[70] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[71] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[72] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[73] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[74] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[75] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[76] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[77] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[78] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[79] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[80] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[81] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[82] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[83] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[84] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77516, "ingredient1": "Duvelisib", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77617/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Copanlisib, Alpelisib, Dacomitinib, Lenvatinib, Erdafitinib, Trametinib, Afatinib, Alectinib, Duvelisib, Tivozanib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77517, "ingredient1": "Echinacea", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77618/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77518, "ingredient1": "Efavirenz", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77619/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Tivozanib, Futibatinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77519, "ingredient1": "Elagolix", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77620/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Pralsetinib, Asciminib, Vandetanib, Neratinib, Nintedanib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 77520, "ingredient1": "Eliglustat", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77621/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 77521, "ingredient1": "Elvitegravir", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77622/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77522, "ingredient1": "Encorafenib", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may decrease the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. The extent to which CYP450 3A4 inducers may affect encorafenib exposure has not been studied.", "source": "DDInter", "management_text": "Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77623/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[3] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Axitinib, Futibatinib, Ruxolitinib, Erdafitinib, Neratinib, Selumetinib, Gefitinib, Infigratinib, Capmatinib, Pemigatinib, Dacomitinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77523, "ingredient1": "Entrectinib", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77624/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Futibatinib, Entrectinib, Regorafenib, Copanlisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77524, "ingredient1": "Enzalutamide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77625/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide", "alternatives_b": "Alectinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77525, "ingredient1": "Eplerenone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77626/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Amiloride, Triamterene, Spironolactone", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77526, "ingredient1": "Erdafitinib", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.", "source": "DDInter", "management_text": "According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77627/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77527, "ingredient1": "Ergometrine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77628/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77528, "ingredient1": "Ergotamine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77629/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77529, "ingredient1": "Erlotinib", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib. If alternative treatment is unavailable and a potent inducer (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, St. John's wort) is to be used for more than a few days, an increase in the dosage of erlotinib should be considered as tolerated at 2-week intervals. Close clinical and laboratory monitoring for altered efficacy and safety, including renal and liver functions and serum electrolytes, is recommended.", "mechanism_text": "Metabolism", "recommendation": "Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77630/", "reference_text": "[1] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.[2] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[14] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Acalabrutinib, Dacomitinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77530, "ingredient1": "Erythromycin", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77631/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77531, "ingredient1": "Escitalopram", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77632/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Dacomitinib, Pexidartinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77532, "ingredient1": "Estazolam", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77633/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77533, "ingredient1": "Esterified estrogens", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77634/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Entrectinib, Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77534, "ingredient1": "Estradiol (topical)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77635/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene, Methyltestosterone, Estetrol, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77535, "ingredient1": "Estrone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77636/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77536, "ingredient1": "Estrone sulfate", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77637/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77537, "ingredient1": "Eszopiclone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77638/", "reference_text": "[1] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77538, "ingredient1": "Ethosuximide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77639/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77539, "ingredient1": "Etonogestrel", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77640/", "reference_text": "[1] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[2] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[4] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[5] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[6] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[7] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[8] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[9] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[10] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[11] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[12] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[13] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[14] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[15] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[16] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[17] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[19] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[20] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[21] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[22] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[23] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[24] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[25] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[26] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[27] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[28] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[30] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[31] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[32] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[33] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[34] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[35] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[36] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[37] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[38] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[39] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[40] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[41] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[42] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[43] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[44] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[45] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[46] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[47] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[48] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[49] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[50] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[51] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[52] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[53] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[54] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[55] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[56] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[57] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[58] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[59] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[60] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[61] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[62] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[63] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[64] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[65] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[66] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[67] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[68] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[69] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[70] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[71] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[72] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[73] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[74] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[75] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[76] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[77] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[78] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[79] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[80] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[81] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[82] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[83] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[84] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77540, "ingredient1": "Etoposide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77641/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77541, "ingredient1": "Etravirine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations of etravirine, which is a substrate of CYP450 2C19, 2C9, and 3A4.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if etravirine is used with CYP450 inducers. Close clinical and laboratory monitoring of antiretroviral response is recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if etravirine is used with CYP450 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77642/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77542, "ingredient1": "Everolimus", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the blood concentrations and pharmacologic effects of everolimus.", "source": "DDInter", "management_text": "Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine. If concomitant use is required, a dose adjustment of everolimus should be considered to achieve the recommended therapeutic range for the condition being treated. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase and 2 weeks after discontinuation of the inducer.", "mechanism_text": "Metabolism", "recommendation": "Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77643/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Brigatinib, More", "updated_at": 1767369485}, {"id": 77543, "ingredient1": "Exemestane", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. However, it has also been suggested that suppression of estrogen levels is not affected by the interaction, thus dosage adjustment of exemestane is not required. The extent to which other, less potent CYP450 3A4 inducers may interact with exemestane is unknown. Caution is advised if they are used with exemestane.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77644/", "reference_text": "[1] \"Product Information. Aromasin (exemestane)\" Pharmacia & Upjohn, Kalamazoo, MI.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, More", "updated_at": 1767369485}, {"id": 77544, "ingredient1": "Exenatide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77645/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77545, "ingredient1": "Fedratinib", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77646/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Futibatinib, Fedratinib, Copanlisib, Alpelisib, Vemurafenib, Erlotinib, Lenvatinib, Erdafitinib, Vandetanib, Trametinib, Afatinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77546, "ingredient1": "Felodipine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77647/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol, Clevidipine, Enalapril, Moexipril, Ramipril, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77547, "ingredient1": "Fesoterodine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when fesoterodine is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fesoterodine is used with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77648/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77548, "ingredient1": "Flibanserin", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77649/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ritodrine, Bremelanotide, Black cohosh, Cabergoline", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 77549, "ingredient1": "Fludrocortisone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77650/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77550, "ingredient1": "Flurbiprofen", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77651/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Rabeprazole, Phenylbutazone, Tolazoline, Ketoprofen, Tolmetin, Meclofenamic acid, Dimethyl sulfoxide, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, More", "alternatives_b": "Entrectinib, Imatinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77551, "ingredient1": "Fluvastatin", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77652/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77552, "ingredient1": "Glasdegib", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided. If concomitant use cannot be avoided, the glasdegib dose should be increased as tolerated from 100 mg once a day to 200 mg once a day or from 50 mg once a day to 100 mg once a day. Once the moderate CYP450 3A4 inducer has been discontinued for 7 days, the glasdegib dose should return to the dose taken prior to initiating the moderate CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77653/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31[8] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77553, "ingredient1": "Glimepiride", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77654/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77554, "ingredient1": "Glipizide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77655/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77555, "ingredient1": "Glyburide", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77656/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77556, "ingredient1": "Granisetron", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77657/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Palonosetron", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77557, "ingredient1": "Guanfacine", "ingredient2": "Dabrafenib", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers. For extended-release guanfacine, some manufacturers recommend increasing the dosage up to double the recommended level when initiating therapy in patients who are already receiving a CYP450 3A4 inducer. Further dosage adjustments may be required based on patient tolerance and response. If a CYP450 3A4 inducer is added to existing guanfacine therapy, the guanfacine dosage may be increased up to double the recommended level over 1 to 2 weeks. The dosage should be decreased to the recommended level over 1 to 2 weeks following discontinuation of the CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77658/", "reference_text": "[1] Kiechel JR, Lavene D, Guerret M, Comoy E, Godin M, Fillastre JP \"Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure.\" Eur J Clin Pharmacol 25 (1983): 463-6[2] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77558, "ingredient1": "Halofantrine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77659/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77559, "ingredient1": "Haloperidol", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77660/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77560, "ingredient1": "Halothane", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77661/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77561, "ingredient1": "Idelalisib", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77662/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Idelalisib, Tivozanib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77562, "ingredient1": "Iloperidone", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77663/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Imatinib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77563, "ingredient1": "Imatinib", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77664/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Bolton AE, Peng B, Hubert M, et al. \"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.\" Cancer Chemother Pharmacol 53 (2004): 102-6[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Sunitinib, Regorafenib, Imatinib, Lenvatinib, Erlotinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, More", "updated_at": 1767369485}, {"id": 77564, "ingredient1": "Imipramine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77665/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77565, "ingredient1": "Indinavir", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77666/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77566, "ingredient1": "Indomethacin", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77667/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77567, "ingredient1": "Insulin human", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77668/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77568, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77669/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77569, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77670/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77570, "ingredient1": "Insulin degludec", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77671/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Lixisenatide", "updated_at": 1767369485}, {"id": 77571, "ingredient1": "Insulin detemir", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77672/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77572, "ingredient1": "Insulin glargine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77673/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77573, "ingredient1": "Insulin glulisine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77674/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77574, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77675/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77575, "ingredient1": "Insulin human (isophane)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77676/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77576, "ingredient1": "Insulin lispro", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77677/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77577, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77678/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77578, "ingredient1": "Insulin human (regular)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77679/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77579, "ingredient1": "Insulin human (zinc)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77680/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77580, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77681/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77581, "ingredient1": "Irbesartan", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77682/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Eprosartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Telmisartan, Candesartan, Hydrochlorothiazide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77582, "ingredient1": "Irinotecan", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77683/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77583, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77684/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77584, "ingredient1": "Isavuconazonium", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77685/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Vandetanib, Ibrutinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77585, "ingredient1": "Isradipine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77686/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Clevidipine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77586, "ingredient1": "Istradefylline", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77687/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77587, "ingredient1": "Itraconazole", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77688/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77588, "ingredient1": "Ivabradine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivabradine and its active N-desmethylated metabolite, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers. The potential for decreased efficacy of ivabradine should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77689/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[3] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[8] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[9] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Adenosine, Regadenoson, Alprostadil, Ubidecarenone, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol", "updated_at": 1767369485}, {"id": 77589, "ingredient1": "Ivacaftor", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77690/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 77590, "ingredient1": "Dabrafenib", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77691/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tivozanib, Futibatinib, Fedratinib, Regorafenib, Trametinib, Neratinib, Nintedanib, Afatinib, Dacomitinib, Pexidartinib, Alectinib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77591, "ingredient1": "Dabrafenib", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme. Subtherapeutic levels of ixabepilone may result.", "source": "DDInter", "management_text": "The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ixabepilone is unknown. Whenever possible, therapeutic agents with low enzyme induction potential should be considered in patients treated with ixabepilone.", "mechanism_text": "Metabolism", "recommendation": "The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77692/", "reference_text": "[1] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77592, "ingredient1": "Dabrafenib", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77693/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77593, "ingredient1": "Dabrafenib", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77694/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77594, "ingredient1": "Dabrafenib", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77695/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Regorafenib, Bosutinib, Lapatinib, Trametinib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 77595, "ingredient1": "Dabrafenib", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77696/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Larotrectinib, Lenvatinib, Erdafitinib, Neratinib, Trametinib, Afatinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77596, "ingredient1": "Dabrafenib", "ingredient2": "Lefamulin", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77697/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Futibatinib, Copanlisib, Dacomitinib, Erdafitinib, Abemaciclib, Trametinib, Afatinib, Duvelisib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 77597, "ingredient1": "Dabrafenib", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77698/", "reference_text": "[1] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.[2] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Regorafenib, Lenvatinib, Abemaciclib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "updated_at": 1767369485}, {"id": 77598, "ingredient1": "Dabrafenib", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77699/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dacomitinib, Pexidartinib, Fedratinib, Bosutinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Regorafenib, Ruxolitinib, More", "alternatives_b": "Pegloticase, Febuxostat, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol", "updated_at": 1767369485}, {"id": 77599, "ingredient1": "Dabrafenib", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77700/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Tucatinib, Vemurafenib, Lenvatinib, Erdafitinib, Trametinib, Vandetanib, Nintedanib, Ibrutinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77600, "ingredient1": "Dabrafenib", "ingredient2": "Letrozole", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77701/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77601, "ingredient1": "Dabrafenib", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77702/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pralsetinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Clevidipine", "updated_at": 1767369485}, {"id": 77602, "ingredient1": "Dabrafenib", "ingredient2": "Levobupivacaine", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77703/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Ropivacaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77603, "ingredient1": "Dabrafenib", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may increase the peak activity and/or decrease the duration of action of levomethadyl acetate, which is primarily metabolized by the isoenzyme. Induction of CYP450 3A4 also results in increased formation of the active metabolites, nor-LAAM and dinor-LAAM. High plasma levels of these metabolites may increase the risk of QT interval prolongation and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. The dose or dosing interval may require adjustment if an interaction is suspected. A 12-lead ECG should be performed before initiating levomethadyl acetate therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77704/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77604, "ingredient1": "Dabrafenib", "ingredient2": "Levonorgestrel", "severity": "Major", "effect": "RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77705/", "reference_text": "[1] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[2] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[4] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[5] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[6] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[7] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[8] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[9] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[10] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[11] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[12] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[13] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[14] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[15] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[16] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[17] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[19] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[20] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[21] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[22] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[23] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[24] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[25] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[26] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[27] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[28] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[30] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[31] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[32] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[33] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[34] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[35] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[36] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[37] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[38] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[39] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[40] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[41] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[42] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[43] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[44] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[45] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[46] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[47] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[48] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[49] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[50] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[51] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[52] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[53] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[54] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[55] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[56] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[57] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[58] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[59] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[60] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[61] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[62] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[63] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[64] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[65] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[66] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[67] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[68] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[69] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[70] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[71] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[72] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[73] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[74] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[75] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[76] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[77] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[78] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[79] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[80] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[81] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[82] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[83] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[84] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77605, "ingredient1": "Dabrafenib", "ingredient2": "Linagliptin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77706/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77606, "ingredient1": "Dabrafenib", "ingredient2": "Liraglutide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77707/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77607, "ingredient1": "Dabrafenib", "ingredient2": "Lomitapide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77708/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Cabozantinib, Copanlisib, Alpelisib, Trametinib, Erdafitinib, Neratinib, Vandetanib, Dacomitinib, Tivozanib, Encorafenib", "updated_at": 1767369485}, {"id": 77608, "ingredient1": "Dabrafenib", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77709/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Alpelisib, Lenvatinib, Erdafitinib, Trametinib, Vandetanib, Afatinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib, Binimetinib", "updated_at": 1767369485}, {"id": 77609, "ingredient1": "Dabrafenib", "ingredient2": "Lorlatinib", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. In addition to the potential for diminished efficacy of lorlatinib, the risk of serious hepatotoxicity may be increased due to activation of the pregnane X receptor (PXR) by both lorlatinib and CYP450 3A4 inducers. The effect of concomitant use of moderate CYP450 3A4 inducers on lorlatinib pharmacokinetics or the risk of hepatotoxicity is unknown.", "source": "DDInter", "management_text": "Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is required, monitoring of AST, ALT and bilirubin is recommended 48 hours after initiating lorlatinib and at least 3 times during the first week of treatment. Depending upon the relative importance of each drug, lorlatinib or the CYP450 3A4 inducer should be discontinued for persistent Grade 2 or higher hepatotoxicity.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77710/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Lenvatinib, Trametinib, Asciminib, Dacomitinib, Tivozanib, Alectinib, Binimetinib, Lorlatinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77610, "ingredient1": "Dabrafenib", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77711/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Eprosartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Telmisartan, Candesartan, Hydrochlorothiazide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 77611, "ingredient1": "Dabrafenib", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77712/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77612, "ingredient1": "Dabrafenib", "ingredient2": "Lumateperone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77713/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77613, "ingredient1": "Dabrafenib", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77714/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77614, "ingredient1": "Dabrafenib", "ingredient2": "Lurbinectedin", "severity": "Major", "effect": "Coadministration with a strong or moderate CYP450 3A4 inducer is predicted to decrease lurbinectedin systemic exposure, which may reduce its efficacy.", "source": "DDInter", "management_text": "Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77715/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77615, "ingredient1": "Dabrafenib", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macimorelin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The prescribing information for macimorelin recommends discontinuing potent CYP450 3A4 inducers (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, St. John's wort) as well as some moderate ones (e.g., bosentan, efavirenz, etravirine, modafinil) prior to macimorelin administration. A sufficient washout period following discontinuation of the inducers is also advised before using macimorelin. No recommendations are available for other, less potent CYP450 3A4 inducers; however, it may be appropriate to follow the same precaution.", "mechanism_text": "Metabolism", "recommendation": "The prescribing information for macimorelin recommends discontinuing potent CYP450 3A4 inducers (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77716/", "reference_text": "[1] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris, Charleston, SC.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris, Charleston, SC.", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, Folic acid, More", "updated_at": 1767369485}, {"id": 77616, "ingredient1": "Dabrafenib", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77717/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77617, "ingredient1": "Dabrafenib", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77718/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 77618, "ingredient1": "Dabrafenib", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77719/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Imatinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "updated_at": 1767369485}, {"id": 77619, "ingredient1": "Dabrafenib", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may decrease the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers. A dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77720/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 77620, "ingredient1": "Dabrafenib", "ingredient2": "Medroxyprogesterone acetate", "severity": "Major", "effect": "RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77721/", "reference_text": "[1] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[2] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[4] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[5] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[6] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[7] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[8] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[9] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[10] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[11] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[12] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[13] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[14] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[15] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[16] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[17] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[19] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[20] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[21] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[22] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[23] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[24] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[25] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[26] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[27] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[28] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[30] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[31] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[32] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[33] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[34] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[35] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[36] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[37] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[38] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[39] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[40] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[41] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[42] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[43] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[44] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[45] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[46] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[47] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[48] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[49] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[50] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[51] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[52] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[53] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[54] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[55] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[56] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[57] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[58] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[59] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[60] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[61] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[62] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[63] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[64] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[65] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[66] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[67] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[68] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[69] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[70] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[71] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[72] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[73] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[74] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[75] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[76] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[77] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[78] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[79] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[80] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[81] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[82] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[83] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[84] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol, Histrelin, Leuprolide, Bicalutamide, Triptorelin, Goserelin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77621, "ingredient1": "Dabrafenib", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77722/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77622, "ingredient1": "Dabrafenib", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of mefloquine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from mefloquine therapy, and the dosage adjusted if necessary. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with mefloquine is unknown.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77723/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[3] Schmidt LE, Dalhoff K \"Food-drug interactions.\" Drugs 62 (2002): 1481-502[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77623, "ingredient1": "Dabrafenib", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77724/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol, Histrelin, Leuprolide, Bicalutamide, Triptorelin, Goserelin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77624, "ingredient1": "Dabrafenib", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77725/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ropivacaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Fenoprofen, Rabeprazole, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77625, "ingredient1": "Dabrafenib", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77726/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77626, "ingredient1": "Dabrafenib", "ingredient2": "Methadone", "severity": "Major", "effect": "Coadministration with inducers of various CYP450 isoenzymes may decrease the plasma concentrations of methadone, which is metabolized by CYP450 3A4, 2B6, 2C19, 2C9, and 2D6. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on methadone following the addition of an inducer. Conversely, discontinuation of the inducer may increase methadone plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers. Pharmacologic response to methadone should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77727/", "reference_text": "[1] Tong TG, Pond SM, Kreek MJ, et al \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981): 349-51[2] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976): 1104-6[3] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996): 925-6[4] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988): 623-9[5] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999): 1004-5[6] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991): 443-4[7] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999): 957-62[8] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc, Birmingham, AL.[9] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977): 1211[10] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976): 227[11] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984): 1287-8[12] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000): 405-7[13] Foster DJ, Somogyi AA, Bochner F \"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.\" Br J Clin Pharmacol 47 (1999): 403-12[14] Benmebarek M, Devaud C, Gex-Fabry M, et al. \"Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone.\" Clin Pharmacol Ther 76 (2004): 55-63[15] Oda Y, Kharasch ED \"Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.\" J Pharmacol Exp Ther 298 (2001): 1021-32[16] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF \"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.\" Chem Res Toxicol 9 (1996): 365-73[17] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[18] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[19] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[20] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Morphine, Naltrexone, Oxymorphone, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77627, "ingredient1": "Dabrafenib", "ingredient2": "Methoxsalen", "severity": "Moderate", "effect": "Concomitant use of methoxsalen with other known photosensitizing agents may increase the risk of photosensitivity reactions. These agents include anthralin, coal tar or coal tar derivatives, griseofulvin, hypericin extracts (e.g., St John's Wort), fluoroquinolones, phenothiazines, retinoids, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, sulfonylureas, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange.", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid sun exposure, even through window glass or cloud cover, for at least 8 hours after methoxsalen ingestion and during the 24 hours following photochemotherapy or photopheresis treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77728/", "reference_text": "[1] \"Product Information. Uvadex (methoxsalen).\" Therakos Inc, Exton, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Oxsoralen (methoxsalen).\" ICN Pharmaceuticals Inc, Costa Mesa, CA.[5] Royal Australian College of General Practicioners (RACGP), the Pharmaceutical Society of Australia (PSA), the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) \"Australian Medicines Handbook. Available from: URL: https://www.amh.net.au/\"[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Acitretin, Etretinate, Trioxsalen, Tazarotene, Calcipotriol, Trioxsalen, Calcitriol", "alternatives_b": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77628, "ingredient1": "Dabrafenib", "ingredient2": "Methyl aminolevulinate (topical)", "severity": "Moderate", "effect": "Concomitant use of aminolevulinate topical preparations with other known photosensitizing agents may enhance the phototoxic reaction to photodynamic therapy. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of treated areas to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) during the period between application of aminolevulinic acid or methyl aminolevulinate and photoactivation, and for 48 hours post-illumination. Concomitant use with other topical medicinal products should be avoided.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77729/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Metvixia (methyl aminolevulinate topical).\" Galderma Laboratories Inc, Cranbury, NJ.[4] \"Product Information. Levulan Kerastick (aminolevulinic acid)\" Berlex, Richmond, CA.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77629, "ingredient1": "Dabrafenib", "ingredient2": "Methylergometrine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77730/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77630, "ingredient1": "Dabrafenib", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77731/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, Fluorometholone, Clobetasol, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77631, "ingredient1": "Dabrafenib", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77732/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77632, "ingredient1": "Dabrafenib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77733/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77633, "ingredient1": "Dabrafenib", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77734/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Axitinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 77634, "ingredient1": "Dabrafenib", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of mifepristone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use with potent CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and rifamycins should generally be avoided. Other, less potent inducers such as aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants may also interact. Caution is advised if they are used with mifepristone.", "mechanism_text": "Metabolism", "recommendation": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use with potent CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and rifamycins should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77735/", "reference_text": "[1] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[2] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[3] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[4] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Ospemifene, Raloxifene, Danazol, Bazedoxifene", "alternatives_b": "Regorafenib, Alpelisib, Trametinib, Erlotinib, Erdafitinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77635, "ingredient1": "Dabrafenib", "ingredient2": "Miglitol", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77736/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77636, "ingredient1": "Dabrafenib", "ingredient2": "Mirabegron", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme and efflux transporter. No dosage adjustment is recommended when mirabegron is administered in combination with rifampin and probably other CYP450 3A4/P-gp inducers.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77737/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77637, "ingredient1": "Dabrafenib", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77738/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77638, "ingredient1": "Dabrafenib", "ingredient2": "Mitotane", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77739/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Ribociclib, Afatinib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77639, "ingredient1": "Dabrafenib", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77740/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Futibatinib, Regorafenib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77640, "ingredient1": "Dabrafenib", "ingredient2": "Montelukast", "severity": "Moderate", "effect": "Coadministration with inducers of hepatic CYP450 isoenzymes may decrease the plasma concentrations of montelukast, which is metabolized by CYP450 2C8, 2C9, and 3A4 .", "source": "DDInter", "management_text": "No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers. However, clinical monitoring for potentially reduced therapeutic effects may be appropriate, especially for potent inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77741/", "reference_text": "[1] \"Product Information. Singulair (montelukast).\" Merck & Co, Inc, West Point, PA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77641, "ingredient1": "Dabrafenib", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77742/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 77642, "ingredient1": "Dabrafenib", "ingredient2": "Naloxegol", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of naloxegol should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77743/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 77643, "ingredient1": "Dabrafenib", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77744/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ritodrine, Bremelanotide, Black cohosh, Cabergoline, Rabeprazole, Phenylbutazone, Tolazoline, Ketoprofen, Tolmetin, Meclofenamic acid, Dimethyl sulfoxide, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77644, "ingredient1": "Dabrafenib", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77745/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 77645, "ingredient1": "Dabrafenib", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77746/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77646, "ingredient1": "Dabrafenib", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77747/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Alpelisib, Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77647, "ingredient1": "Dabrafenib", "ingredient2": "Neratinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided. According to some authorities, if the CYP450 3A4 inducer cannot be avoided, the dose of neratinib should be increased to 320 mg once daily. The daily dose of neratinib should not exceed 320 mg. The previous dose of neratinib may be resumed following discontinuation of the CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77748/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[5] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[6] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Entrectinib, Pralsetinib, Acalabrutinib, Dacomitinib, Pacritinib, Avapritinib, Larotrectinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77648, "ingredient1": "Dabrafenib", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77749/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Trametinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77649, "ingredient1": "Dabrafenib", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77750/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Clevidipine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77650, "ingredient1": "Dabrafenib", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77751/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Regorafenib, Nilotinib, Trametinib, Neratinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77651, "ingredient1": "Dabrafenib", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77752/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Clevidipine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77652, "ingredient1": "Dabrafenib", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77753/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Clevidipine", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77653, "ingredient1": "Dabrafenib", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77754/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77654, "ingredient1": "Dabrafenib", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77755/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Esomeprazole, Amoxicillin, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77655, "ingredient1": "Dabrafenib", "ingredient2": "Norgestrel", "severity": "Major", "effect": "RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77756/", "reference_text": "[1] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[2] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[4] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[5] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[6] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[7] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[8] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[9] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[10] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[11] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[12] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[13] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[14] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[15] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[16] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[17] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[19] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[20] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[21] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[22] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[23] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[24] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[25] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[26] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[27] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[28] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[30] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[31] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[32] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[33] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[34] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[35] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[36] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[37] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[38] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[39] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[40] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[41] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[42] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[43] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[44] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[45] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[46] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[47] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[48] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[49] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[50] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[51] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[52] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[53] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[54] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[55] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[56] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[57] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[58] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[59] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[60] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[61] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[62] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[63] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[64] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[65] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[66] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[67] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[68] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[69] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[70] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[71] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[72] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[73] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[74] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[75] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[76] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[77] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[78] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[79] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[80] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[81] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[82] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[83] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[84] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 77656, "ingredient1": "Dabrafenib", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inducers. The potential for decreased efficacy of olaparib should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77757/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dacomitinib, Tepotinib, Selumetinib, Vandetanib, Afatinib, Tivozanib, Brigatinib, Encorafenib, Axitinib, Sunitinib, Regorafenib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77657, "ingredient1": "Dabrafenib", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77758/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[11] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[12] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, More", "updated_at": 1767369485}, {"id": 77658, "ingredient1": "Dabrafenib", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77759/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Palonosetron", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77659, "ingredient1": "Dabrafenib", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or 2B6 may decrease the plasma concentrations of osilodrostat, which is partially metabolized by these isoenzymes. According to the product labeling, multiple CYP450 isoenzymes (CYP450 3A4, 2B6, and 2D6) and UDP-glucuronosyltransferases contribute to osilodrostat metabolism, and no single pathway contributes greater than 25% to the total clearance. Some of the known CYP450 3A4 and 2B6 inducers also induce UDP-glucuronosyltransferases.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer. An increase in the dosage of osilodrostat may be required. Dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations of their signs and symptoms. A reduction in dosage of osilodrostat may be required if the CYP450 3A4 and/or 2B6 inducer is discontinued during treatment with osilodrostat.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77760/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Futibatinib, Regorafenib, Copanlisib, Alpelisib, Trametinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Nintedanib, Capmatinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77660, "ingredient1": "Dabrafenib", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77761/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77661, "ingredient1": "Dabrafenib", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77762/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77662, "ingredient1": "Dabrafenib", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77763/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[11] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[12] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77663, "ingredient1": "Dabrafenib", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.", "mechanism_text": "Metabolism", "recommendation": "Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77764/", "reference_text": "[1] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM \"Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract).\" Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[2] \"Product Information. Abraxane (paclitaxel protein-bound).\" American Pharmaceutical Partners, Schaumberg, IL.[3] \"Product Information. Taxol (paclitaxel).\" Bristol-Myers Squibb, Princeton, NJ.[4] Spencer CM, Faulds D \"Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.\" Drugs 48 (1994): 794-847[5] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[6] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[11] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[12] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[13] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77664, "ingredient1": "Dabrafenib", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77765/", "reference_text": "[1] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Lenvatinib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Capmatinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77665, "ingredient1": "Dabrafenib", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme. The interaction has not been evaluated clinically, but simulations using physiologically-based pharmacokinetic (PBPK) models suggest an approximately 70% decrease in panobinostat systemic exposure in the presence of potent CYP450 3A4 inducers.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers. The potential for decreased efficacy of panobinostat should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77766/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 77666, "ingredient1": "Dabrafenib", "ingredient2": "Paricalcitol", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77767/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Etelcalcetide, Cinacalcet, Doxercalciferol, Salmon calcitonin, Calcifediol", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77667, "ingredient1": "Dabrafenib", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of pazopanib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Alternative treatment lacking CYP450 3A4-inducing activity should be considered in patients receiving pazopanib; otherwise, pazopanib should not be used. Other known CYP450 3A4 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they may interact with pazopanib is unknown.", "mechanism_text": "Metabolism", "recommendation": "The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77768/", "reference_text": "[1] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Regorafenib, Copanlisib, Abemaciclib, Erlotinib, Ponatinib, Neratinib, Erdafitinib, Trametinib, Nintedanib, Afatinib, Dacomitinib, More", "updated_at": 1767369485}, {"id": 77668, "ingredient1": "Dabrafenib", "ingredient2": "Pemigatinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77769/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77669, "ingredient1": "Dabrafenib", "ingredient2": "Pexidartinib", "severity": "Moderate", "effect": "Coadministration of pexidartinib with moderate CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of pexidartinib. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of pexidartinib.", "source": "DDInter", "management_text": "Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inducer. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77770/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Tivozanib, Futibatinib, Trametinib, Asciminib, Pexidartinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77670, "ingredient1": "Dabrafenib", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77771/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 77671, "ingredient1": "Dabrafenib", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77772/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Alectinib, Lenvatinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77672, "ingredient1": "Dabrafenib", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77773/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77673, "ingredient1": "Dabrafenib", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77774/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77674, "ingredient1": "Dabrafenib", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77775/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, More", "alternatives_b": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77675, "ingredient1": "Dabrafenib", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77776/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77676, "ingredient1": "Dabrafenib", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77777/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 77677, "ingredient1": "Dabrafenib", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77778/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77678, "ingredient1": "Dabrafenib", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of ponatinib underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ponatinib is unknown.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77779/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[4] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Entrectinib, Asciminib, Dacomitinib, Tepotinib, Selumetinib, Vandetanib, Capmatinib, Tivozanib, Axitinib, Sunitinib, Lenvatinib, More", "updated_at": 1767369485}, {"id": 77679, "ingredient1": "Dabrafenib", "ingredient2": "Posaconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77780/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Trametinib, Afatinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77680, "ingredient1": "Dabrafenib", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A may decrease the plasma concentrations of pralsetinib which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77781/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77681, "ingredient1": "Dabrafenib", "ingredient2": "Pramlintide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77782/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77682, "ingredient1": "Dabrafenib", "ingredient2": "Pravastatin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77783/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77683, "ingredient1": "Dabrafenib", "ingredient2": "Praziquantel", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved. Alternative agents for schistosomiasis should be considered whenever possible in patients receiving treatment with a CYP450 3A4 inducer. Otherwise, clinical response to praziquantel should be closely monitored.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77784/", "reference_text": "[1] Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M \"Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers.\" Clin Pharmacol Ther 72 (2002): 505-13[2] Bittencourt PR, Gracia CM, Martins R, et al \"Phenytoin and carbamazepine decrease oral bioavailability of praziquantel.\" Neurology 42 (1992): 492-6[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Biltricide (praziquantel).\" Bayer, West Haven, CT.[5] Castro N, Medina R, Sotelo J, Jung H \"Bioavailability of praziquantel increases with concomitant administration of food.\" Antimicrob Agents Chemother 44 (2000): 2903-4[6] Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J \"Interaction between grapefruit juice and praziquantel in humans.\" Antimicrob Agents Chemother 46 (2002): 1614-6", "alternatives_a": "Triclabendazole, Oxamniquine", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77684, "ingredient1": "Dabrafenib", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77785/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77685, "ingredient1": "Dabrafenib", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77786/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77686, "ingredient1": "Dabrafenib", "ingredient2": "Pretomanid", "severity": "Major", "effect": "Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77787/", "reference_text": "[1] \"Product Information. Pretomanid (pretomanid).\" The Global Alliance for TB Drug Development, New York, NY.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] \"Product Information. Pretomanid (pretomanid).\" The Global Alliance for TB Drug Development, New York, NY.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77687, "ingredient1": "Dabrafenib", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77788/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 77688, "ingredient1": "Dabrafenib", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77789/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77689, "ingredient1": "Dabrafenib", "ingredient2": "Progesterone (topical)", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77790/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Entrectinib, Pralsetinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77690, "ingredient1": "Dabrafenib", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77791/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, Metoprolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77691, "ingredient1": "Dabrafenib", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77792/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77692, "ingredient1": "Dabrafenib", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77793/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77693, "ingredient1": "Dabrafenib", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77794/", "reference_text": "[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[11] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990): 124-5[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974): 1113[15] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999): 71-8[16] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998): 1042-50[19] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[21] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985): 26-35[29] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975): 467-8[30] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984): 1125-6[31] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980): 495-503[44] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Entrectinib, Pralsetinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77694, "ingredient1": "Dabrafenib", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77795/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Selumetinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, Erlotinib, More", "updated_at": 1767369485}, {"id": 77695, "ingredient1": "Dabrafenib", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St. John's wort. The possibility of diminished therapeutic efficacy should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77796/", "reference_text": "[1] Fabre C, Criddle J, Nolder D, Klein JL \"Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin.\" Trans R Soc Trop Med Hyg 99 (2005): 871-3[2] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[3] Twum-Barima Y, Carruthers SG \"Quinidine-rifampin interaction.\" N Engl J Med 304 (1981): 1466-9[4] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[5] Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, Looareesuwan S, White NJ \"Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria.\" Antimicrob Agents Chemother 47 (2003): 1509-1513[6] Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S \"Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man.\" Br J Clin Pharmacol 40 (1995): 87-91[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[18] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[19] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[20] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2[21] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 77696, "ingredient1": "Dabrafenib", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.", "source": "DDInter", "management_text": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John's wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.", "mechanism_text": "Metabolism", "recommendation": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77797/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77697, "ingredient1": "Dabrafenib", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77798/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77698, "ingredient1": "Dabrafenib", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. The extent to which other, less potent CYP450 3A4 inducers may interact with ranolazine is unknown. Caution is advised if they are used with ranolazine.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77799/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Adenosine, Regadenoson, Alprostadil, Ubidecarenone", "alternatives_b": "Regorafenib, Temsirolimus, Trametinib, Erlotinib, Neratinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77699, "ingredient1": "Dabrafenib", "ingredient2": "Regorafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77800/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Dacomitinib, Tepotinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77700, "ingredient1": "Dabrafenib", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77801/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Avapritinib, Fedratinib, Larotrectinib, Selumetinib, Cobimetinib, Afatinib, Duvelisib, Tivozanib, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, Abarelix, Flutamide, More", "updated_at": 1767369485}, {"id": 77701, "ingredient1": "Dabrafenib", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77802/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77702, "ingredient1": "Dabrafenib", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters.", "source": "DDInter", "management_text": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77803/", "reference_text": "[1] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[2] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[3] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[4] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[5] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Fluticasone, Ipratropium, Cromoglicic acid, Nedocromil, Tiotropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 77703, "ingredient1": "Dabrafenib", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ribociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine. Pharmacologic effects of ribociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy. Alternative treatment may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77804/", "reference_text": "[1] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[5] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Futibatinib, Regorafenib, Trametinib, Erdafitinib, Nintedanib, Ribociclib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77704, "ingredient1": "Dabrafenib", "ingredient2": "Rifabutin", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77805/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid, More", "alternatives_b": "Futibatinib, Lenvatinib, Trametinib, Nintedanib, Dacomitinib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77705, "ingredient1": "Dabrafenib", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77806/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid", "alternatives_b": "Alectinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77706, "ingredient1": "Dabrafenib", "ingredient2": "Rifapentine", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77807/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid", "alternatives_b": "Alectinib, Lenvatinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77707, "ingredient1": "Dabrafenib", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.", "mechanism_text": "Metabolism", "recommendation": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77808/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77708, "ingredient1": "Dabrafenib", "ingredient2": "Rimegepant", "severity": "Major", "effect": "Coadministration with strong or moderate inducers of CYP450 3A4 may significantly reduce the plasma concentrations and therapeutic effects of rimegepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77809/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Zanubrutinib, Brigatinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More", "updated_at": 1767369485}, {"id": 77709, "ingredient1": "Dabrafenib", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77810/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77710, "ingredient1": "Dabrafenib", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77811/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Lenvatinib, Trametinib, Vandetanib, Alectinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77711, "ingredient1": "Dabrafenib", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme as well as the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein. Pharmacologic effects of rivaroxaban should be monitored more closely whenever the inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77812/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.", "alternatives_a": "Betrixaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Dacomitinib, Bosutinib, Vandetanib, Cobimetinib, Afatinib, Axitinib, Ripretinib, Lenvatinib, Erlotinib, Osimertinib, Infigratinib, More", "updated_at": 1767369485}, {"id": 77712, "ingredient1": "Dabrafenib", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77813/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Entrectinib, Dacomitinib, Tepotinib, Larotrectinib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Tivozanib, Encorafenib, Selpercatinib, More", "updated_at": 1767369485}, {"id": 77713, "ingredient1": "Dabrafenib", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77814/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77714, "ingredient1": "Dabrafenib", "ingredient2": "Rosiglitazone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77815/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77715, "ingredient1": "Dabrafenib", "ingredient2": "Rosuvastatin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77816/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ramipril, Lisinopril, Perindopril, Niacin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate, Fenofibric acid, Mipomersen, More", "alternatives_b": "Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77716, "ingredient1": "Dabrafenib", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer. However, patients should be closely monitored and the dose titrated based on safety and efficacy.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77817/", "reference_text": "[1] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 77717, "ingredient1": "Dabrafenib", "ingredient2": "Saquinavir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77818/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Tivozanib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77718, "ingredient1": "Dabrafenib", "ingredient2": "Saxagliptin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77819/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77719, "ingredient1": "Dabrafenib", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77820/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Tolcapone, Rotigotine, Pergolide, Pramipexole, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77720, "ingredient1": "Dabrafenib", "ingredient2": "Selpercatinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77821/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Futibatinib, Copanlisib, Alpelisib, Trametinib, Erdafitinib, Neratinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib, Selpercatinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77721, "ingredient1": "Dabrafenib", "ingredient2": "Selumetinib", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.", "source": "DDInter", "management_text": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77822/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77722, "ingredient1": "Dabrafenib", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77823/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Dacomitinib, Pexidartinib, Tepotinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, More", "updated_at": 1767369485}, {"id": 77723, "ingredient1": "Dabrafenib", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77824/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Dacomitinib, Tepotinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, More", "updated_at": 1767369485}, {"id": 77724, "ingredient1": "Dabrafenib", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of a diminished therapeutic response to sildenafil should be considered.", "source": "DDInter", "management_text": "Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77825/", "reference_text": "[1] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001): 239-48[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000): 392-7[4] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77725, "ingredient1": "Dabrafenib", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77826/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Finasteride, Dutasteride, Terazosin", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 77726, "ingredient1": "Dabrafenib", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77827/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[5] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[6] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[7] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[10] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[11] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[12] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin, Fenofibric acid, Mipomersen, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77727, "ingredient1": "Dabrafenib", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration with drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 may decrease the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/strong CYP450 3A4 dual inducer or a moderate CYP450 2C9 inducer in combination with a separate strong CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.g., carbamazepine, enzalutamide, rifampin) is not recommended for all patients. Concomitant use of siponimod and moderate or strong CYP450 3A4 inducers (e.g., apalutamide, bosentan, dabrafenib, dexamethasone, efavirenz, eslicarbazepine, etravirine, fosphenytoin, lorlatinib, lumacaftor, mitotane, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, St. John's wort) is not recommended for patients with CYP450 2C9*1/*3 and *2/*3 genotypes.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77828/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Dacomitinib, Tepotinib, Selumetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, Ripretinib, Regorafenib, Erlotinib, Neratinib, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 77728, "ingredient1": "Dabrafenib", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77829/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[6] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 77729, "ingredient1": "Dabrafenib", "ingredient2": "Sitagliptin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77830/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77730, "ingredient1": "Dabrafenib", "ingredient2": "Sodium bicarbonate", "severity": "Moderate", "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77831/", "reference_text": "[1] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.[2] \"Product Information. Zantac (ranitidine).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Dexilant (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Aciphex (rabeprazole)\" Janssen Pharmaceuticals, Titusville, NJ.[8] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Mannitol, Chlorhexidine, Neomycin, Calcium chloride, Potassium chloride, Magnesium sulfate, Sodium acetate, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 77731, "ingredient1": "Dabrafenib", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of solifenacin, which has been shown to be a substrate of the isoenzyme in vitro.", "source": "DDInter", "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77832/", "reference_text": "[1] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77732, "ingredient1": "Dabrafenib", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77833/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Futibatinib, Lenvatinib, Erdafitinib, Neratinib, Asciminib, Trametinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 77733, "ingredient1": "Dabrafenib", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77834/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Futibatinib, Lenvatinib, Erdafitinib, Neratinib, Asciminib, Trametinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 77734, "ingredient1": "Dabrafenib", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77835/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Futibatinib, Lenvatinib, Erdafitinib, Neratinib, Asciminib, Trametinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77735, "ingredient1": "Dabrafenib", "ingredient2": "Sonidegib", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77836/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77736, "ingredient1": "Dabrafenib", "ingredient2": "Sorafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77837/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Duvelisib, More", "updated_at": 1767369485}, {"id": 77737, "ingredient1": "Dabrafenib", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77838/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Alectinib, Lenvatinib, Trametinib, Dacomitinib", "updated_at": 1767369485}, {"id": 77738, "ingredient1": "Dabrafenib", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77839/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Asciminib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Afatinib, Tivozanib, Selpercatinib, Regorafenib, Alpelisib, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "updated_at": 1767369485}, {"id": 77739, "ingredient1": "Dabrafenib", "ingredient2": "Sulfamethoxazole", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77840/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Aminosalicylic acid, More", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77740, "ingredient1": "Dabrafenib", "ingredient2": "Sunitinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or dose increase for sunitinib may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77841/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Imatinib, Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, Sunitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77741, "ingredient1": "Dabrafenib", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of suvorexant should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the suvorexant dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77842/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Dacomitinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, Erlotinib, Ponatinib, More", "alternatives_b": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "updated_at": 1767369485}, {"id": 77742, "ingredient1": "Dabrafenib", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77843/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[6] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Minoxidil, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, Dupilumab, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, Erlotinib, Ponatinib, More", "updated_at": 1767369485}, {"id": 77743, "ingredient1": "Dabrafenib", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.", "mechanism_text": "Metabolism", "recommendation": "For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77844/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.[4] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[5] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77744, "ingredient1": "Dabrafenib", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.", "source": "DDInter", "management_text": "In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77845/", "reference_text": "[1] Biochem Pharmacol \"Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.\" Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al \"Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.\" Cancer Res 50 (1990): 5851-7[3] \"Product Information. Targretin (bexarotene)\" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ \"Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.\" Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[8] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[9] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More", "updated_at": 1767369485}, {"id": 77745, "ingredient1": "Dabrafenib", "ingredient2": "Tamsulosin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77846/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Finasteride, Dutasteride, Terazosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77746, "ingredient1": "Dabrafenib", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77847/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "updated_at": 1767369485}, {"id": 77747, "ingredient1": "Dabrafenib", "ingredient2": "Tazemetostat", "severity": "Major", "effect": "Coadministration with moderate or potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77848/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Futibatinib, Copanlisib, Alpelisib, Lenvatinib, Erdafitinib, Neratinib, Abemaciclib, Vandetanib, Trametinib, Afatinib, Alectinib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77748, "ingredient1": "Dabrafenib", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77849/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Tucatinib, Alpelisib, Lenvatinib, Trametinib, Vandetanib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77749, "ingredient1": "Dabrafenib", "ingredient2": "Telithromycin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77850/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77750, "ingredient1": "Dabrafenib", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of temsirolimus with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided. When used for the treatment of renal cell carcinoma, some authorities advise a dose increase from the recommended 25 mg IV once weekly to 50 mg IV once weekly depending on patient tolerability. The dosage should be reduced to the normally recommended dose following discontinuation of the potent CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77851/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77751, "ingredient1": "Dabrafenib", "ingredient2": "Teniposide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77852/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77752, "ingredient1": "Dabrafenib", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77853/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77753, "ingredient1": "Dabrafenib", "ingredient2": "Testosterone (topical)", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77854/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Methyltestosterone, Fluoxymesterone, Methyltestosterone", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77754, "ingredient1": "Dabrafenib", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77855/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77755, "ingredient1": "Dabrafenib", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77856/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Betrixaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Sunitinib, Alpelisib, Bosutinib, Temsirolimus, Lapatinib, Erlotinib, Lenvatinib, Trametinib, Vandetanib, Gefitinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77756, "ingredient1": "Dabrafenib", "ingredient2": "Tinidazole", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77857/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tetracycline, Fluconazole, Cefepime, Norfloxacin, Ciprofloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, More", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77757, "ingredient1": "Dabrafenib", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77858/", "reference_text": "[1] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999): s29-40[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000): 1333-9[3] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999): 708-12[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[7] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004): 482-9[8] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997): 87,90[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997): 194-209[13] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000): 465-70[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[17] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[20] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[21] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[22] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[23] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[24] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[25] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[26] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[27] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[28] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[29] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Entrectinib, Imatinib, Dacomitinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Duvelisib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77758, "ingredient1": "Dabrafenib", "ingredient2": "Tofacitinib", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of tofacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response; however, the extent to which these medications interact with tofacitinib has not been established.", "source": "DDInter", "management_text": "Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended when possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77859/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Entrectinib, Dacomitinib, Tepotinib, Lapatinib, Selumetinib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, Axitinib, More", "updated_at": 1767369485}, {"id": 77759, "ingredient1": "Dabrafenib", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77860/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77760, "ingredient1": "Dabrafenib", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77861/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, Folic acid, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77761, "ingredient1": "Dabrafenib", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77862/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77762, "ingredient1": "Dabrafenib", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77863/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, Regorafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77763, "ingredient1": "Dabrafenib", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77864/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Anastrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77764, "ingredient1": "Dabrafenib", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77865/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Furosemide, Bumetanide, Etacrynic acid, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, More", "updated_at": 1767369485}, {"id": 77765, "ingredient1": "Dabrafenib", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77866/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, Brigatinib, Encorafenib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77766, "ingredient1": "Dabrafenib", "ingredient2": "Trametinib", "severity": "Moderate", "effect": "Although this combination is used therapeutically and recommended for certain indications (e.g., melanoma, anaplastic thyroid cancer, non-small cell lung cancer), concomitant use of dabrafenib and trametinib may be associated with increased risk of severe and possibly life-threatening adverse events. These include skin toxicities (e.g., Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms), intracranial and gastrointestinal hemorrhage, venous thromboembolism, and serious febrile events.", "source": "DDInter", "management_text": "The manufacturer's product labeling should be consulted for recommendations on dosage adjustments or discontinuation in the event of severe toxicities. Patients should be instructed to contact their doctor if they experience unusual bleeding or bruising or severe weakness; fever; red, purple or intolerable rash; shortness of breath, chest pain, or arm or leg swelling.", "mechanism_text": "Synergism", "recommendation": "The manufacturer's product labeling should be consulted for recommendations on dosage adjustments or discontinuation in the event of severe toxicities.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77867/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Flaherty; Infante; Daud; Gonzalez; Kefford; Sosman; Hamid; Schuchter; Cebon; Ibrahim; Kudchadkar; BurrisNag \"Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations.\" NEJM 367:1694-1703 (2012): 5[3] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[5] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77767, "ingredient1": "Dabrafenib", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77868/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77768, "ingredient1": "Dabrafenib", "ingredient2": "Treprostinil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 2C8 may decrease the plasma concentrations of treprostinil, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to treprostinil should be monitored more closely whenever a CYP450 2C8 inducer is added to or withdrawn from therapy, and the treprostinil dosage adjusted as necessary. Patients should be advised to notify their physician if they experience worsening of their condition.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to treprostinil should be monitored more closely whenever a CYP450 2C8 inducer is added to or withdrawn from therapy, and the treprostinil dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77869/", "reference_text": "[1] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[2] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[3] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Betrixaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77769, "ingredient1": "Dabrafenib", "ingredient2": "Tretinoin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77870/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77770, "ingredient1": "Dabrafenib", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77871/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77771, "ingredient1": "Dabrafenib", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77872/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[9] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Ertugliflozin, Semaglutide, Empagliflozin, Dulaglutide, Canagliflozin, Dapagliflozin", "alternatives_b": "Futibatinib, Regorafenib, Lenvatinib, Erdafitinib, Pralsetinib, Asciminib, Vandetanib, Neratinib, Trametinib, Afatinib, Nintedanib, More", "updated_at": 1767369485}, {"id": 77772, "ingredient1": "Dabrafenib", "ingredient2": "Troleandomycin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77873/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Tucatinib, Alpelisib, Lenvatinib, Trametinib, Nintedanib, Vandetanib, Afatinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 77773, "ingredient1": "Dabrafenib", "ingredient2": "Tucatinib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77874/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tucatinib, Alpelisib, Lenvatinib, Erdafitinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77774, "ingredient1": "Dabrafenib", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with moderate or weak inducers of CYP450 3A4 may decrease the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme. Dedicated drug interaction studies have not been conducted to assess concomitant use of ubrogepant with moderate or weak CYP450 3A4 inducers.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers. If needed, a second 100 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77875/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, More", "updated_at": 1767369485}, {"id": 77775, "ingredient1": "Dabrafenib", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response.", "source": "DDInter", "management_text": "Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inducers. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77876/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Entrectinib, Dacomitinib, Tepotinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Encorafenib, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "updated_at": 1767369485}, {"id": 77776, "ingredient1": "Dabrafenib", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77877/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77777, "ingredient1": "Dabrafenib", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Coadministration with inhibitors of the hepatic uptake transporter OATP 1B1 (e.g., rifampin, cyclosporine, paritaprevir) or the hepatic efflux transporter MRP2 (e.g., ritonavir) may increase the systemic exposure to valsartan, which is a substrate of both transporters.", "source": "DDInter", "management_text": "Caution is advised if valsartan is used in combination with inhibitors of OATP 1B1 or MRP2. Pharmacologic response and blood pressure should be monitored more closely following the addition, discontinuation, or change of dosage of the transporter inhibitor, and the valsartan dosage adjusted as necessary.", "mechanism_text": "Others", "recommendation": "Caution is advised if valsartan is used in combination with inhibitors of OATP 1B1 or MRP2.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77878/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir).\" AbbVie US LLC, North Chicago, IL.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[5] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Exforge (amlodipine-valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[11] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Olmesartan, Azilsartan medoxomil, Nebivolol, Telmisartan, Candesartan, Hydrochlorothiazide, Aliskiren, Eprosartan, Ramipril, Lisinopril, Perindopril, More", "alternatives_b": "Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, More", "updated_at": 1767369485}, {"id": 77778, "ingredient1": "Dabrafenib", "ingredient2": "Vandetanib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77879/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "alternatives_b": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77779, "ingredient1": "Dabrafenib", "ingredient2": "Vardenafil", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77880/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77780, "ingredient1": "Dabrafenib", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77881/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Futibatinib, Fedratinib, Regorafenib, Vemurafenib, Trametinib, Nintedanib, Cobimetinib, Dacomitinib, Alectinib", "updated_at": 1767369485}, {"id": 77781, "ingredient1": "Dabrafenib", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of venetoclax, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77882/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[4] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[5] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[6] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[7] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[8] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Acalabrutinib, Dacomitinib, Avapritinib, Selumetinib, Cobimetinib, Zanubrutinib, Axitinib, Sunitinib, Ruxolitinib, Lenvatinib, Erlotinib, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 77782, "ingredient1": "Dabrafenib", "ingredient2": "Verteporfin", "severity": "Moderate", "effect": "Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77883/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Visudyne (verteporfin)\" Valeant Pharmaceuticals, Costa Mesa, CA.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Aflibercept, Bevacizumab", "alternatives_b": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77783, "ingredient1": "Dabrafenib", "ingredient2": "Vilazodone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to vilazodone should be considered during coadministration with CYP450 3A4 inducers. Pharmacologic effects of vilazodone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of a diminished therapeutic response to vilazodone should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77884/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, More", "alternatives_b": "Entrectinib, Asciminib, Dacomitinib, Tepotinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77784, "ingredient1": "Dabrafenib", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77885/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77785, "ingredient1": "Dabrafenib", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77886/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77786, "ingredient1": "Dabrafenib", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77887/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77787, "ingredient1": "Dabrafenib", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77888/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Topotecan", "alternatives_b": "Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77788, "ingredient1": "Dabrafenib", "ingredient2": "Voriconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77889/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Fluconazole, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Futibatinib, Trametinib, Nintedanib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77789, "ingredient1": "Dabrafenib", "ingredient2": "Voxelotor", "severity": "Major", "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations and pharmacologic effects of voxelotor. The proposed mechanism is accelerated clearance of voxelotor due to induction of the CYP450 3A4 isoenzyme, which is the primary route of elimination of voxelotor.", "source": "DDInter", "management_text": "The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible. If coadministration is required, the manufacturer recommends increasing the voxelotor dose to 2500 mg once daily. Pharmacologic response to voxelotor should also be monitored more closely.", "mechanism_text": "Metabolism", "recommendation": "The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77890/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc., South San Francisco, CA.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Sunitinib, Futibatinib, Regorafenib, Copanlisib, Alpelisib, Vemurafenib, Erlotinib, Lenvatinib, Erdafitinib, Vandetanib, Trametinib, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 77790, "ingredient1": "Dabrafenib", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77891/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Betrixaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Entrectinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Bosutinib, Lapatinib, Ribociclib, Cobimetinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77791, "ingredient1": "Dabrafenib", "ingredient2": "Zafirlukast", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77892/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Dacomitinib, Pacritinib, Vemurafenib, Vandetanib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, More", "updated_at": 1767369485}, {"id": 77792, "ingredient1": "Dabrafenib", "ingredient2": "Zanubrutinib", "severity": "Major", "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77893/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[3] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Futibatinib, Alpelisib, Lenvatinib, Dabrafenib, Asciminib, Nintedanib, Ibrutinib, Afatinib, Dacomitinib, Tivozanib, Alectinib, Binimetinib", "updated_at": 1767369485}, {"id": 77793, "ingredient1": "Dabrafenib", "ingredient2": "Zileuton", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77894/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Ibrutinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77794, "ingredient1": "Dabrafenib", "ingredient2": "Ziprasidone", "severity": "Minor", "effect": "Coadministration with drugs that are inducers of the CYP450 3A4 isoenzyme may only modestly decrease the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77895/", "reference_text": "[1] Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A \"The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.\" Br J Clin Pharmacol 49(suppl 1) (2000): s65-70[2] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[14] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77795, "ingredient1": "Dabrafenib", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77896/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77796, "ingredient1": "Dabrafenib", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of zonisamide, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77897/", "reference_text": "[1] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[2] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M \"Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.\" Eur J Clin Pharmacol 54 (1998): 177-83[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[14] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77797, "ingredient1": "Amprenavir", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77898/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 77798, "ingredient1": "Anisindione", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists. The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.", "source": "DDInter", "management_text": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77899/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[6] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[7] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[8] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[9] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[10] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[11] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[12] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[13] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[14] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[15] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[16] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[17] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[18] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[21] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[22] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[23] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[24] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[27] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[28] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[29] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[30] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[31] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[32] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[33] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[34] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[35] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[36] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[37] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[39] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[40] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[41] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[42] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[43] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[44] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77799, "ingredient1": "Daclatasvir", "ingredient2": "Artesunate", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77900/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 77800, "ingredient1": "Daclatasvir", "ingredient2": "Berotralstat", "severity": "Major", "effect": "Coadministration of berotralstat with drugs that are both inhibitors of the efflux transporters P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) as well as substrates of the isoenzyme CYP450 3A4 may lead to an increase in the plasma concentrations and effects of both drugs. Berotralstat is a substrate of both P-gp and BCRP. Increased plasma concentrations of berotralstat may increase the risk of adverse effects, including the potential for QT prolongation. Berotralstat may cause concentration-dependent prolongation of the Fridericia-corrected QT interval (QTcF). In addition, berotralstat is considered a moderate CYP450 3A4 inhibitor and has been reported in drug interaction studies to increase the peak plasma concentration (Cmax) and systemic exposure (AUC) of sensitive CYP450 3A4 substrate midazolam by approximately 1.5-fold and 2.25-fold, respectively.", "source": "DDInter", "management_text": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with drugs that are both inhibitors of P-gp or BCRP as well as substrates of CYP450 3A4, such as cyclosporine. Patients should be advised to contact their physician if they experience any undue adverse effects from their medications. Patients should seek prompt medical attention if they experience symptoms that could indicated the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with drugs that are both inhibitors of P-gp or BCRP as well as substrates of CYP450 3A4, such as cyclosporine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77901/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77801, "ingredient1": "Daclatasvir", "ingredient2": "Boceprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77902/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 77802, "ingredient1": "Daclatasvir", "ingredient2": "Cerivastatin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77903/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77803, "ingredient1": "Daclatasvir", "ingredient2": "Clotrimazole", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77904/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 77804, "ingredient1": "Darunavir", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77905/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Lamivudine, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Stavudine, Famciclovir, More", "updated_at": 1767369485}, {"id": 77805, "ingredient1": "Daunorubicin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77906/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Etravirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77806, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77907/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Etravirine, More", "updated_at": 1767369485}, {"id": 77807, "ingredient1": "Delavirdine", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77908/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77808, "ingredient1": "Dicoumarol", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists. The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.", "source": "DDInter", "management_text": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77909/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[6] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[7] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[8] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[9] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[10] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[11] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[12] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[13] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[14] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[15] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[16] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[17] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[18] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[21] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[22] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[23] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[24] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[27] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[28] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[29] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[30] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[31] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[32] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[33] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[34] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[35] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[36] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[37] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[39] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[40] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[41] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[42] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[43] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[44] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6", "alternatives_a": "Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 77809, "ingredient1": "Digoxin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the serum concentrations of digoxin. The proposed mechanism is daclatasvir inhibition of the P-glycoprotein-mediated renal tubular secretion of digoxin.", "source": "DDInter", "management_text": "Serum digoxin levels and pharmacologic effects should be closely monitored following the addition or withdrawal of daclatasvir, and the digoxin dosage adjusted as needed. Patients already receiving daclatasvir who are initiating digoxin should start at the lowest appropriate digoxin dosage, with further adjustments based on serum digoxin levels and clinical response. Patients already receiving digoxin prior to initiating daclatasvir should have serum digoxin levels taken before starting daclatasvir, then have digoxin levels lowered by reducing dosage approximately 30% to 50% or by modifying the dosing frequency with continued monitoring. Patients should be advised to seek medical attention if they experience signs of digoxin toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeat.", "mechanism_text": "Excretion", "recommendation": "Serum digoxin levels and pharmacologic effects should be closely monitored following the addition or withdrawal of daclatasvir, and the digoxin dosage adjusted as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77910/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[3] Becquemont L, Verstuyft C, Kerb R, et al. \"Effect of grapefruit juice on digoxin pharmacokinetics in humans.\" Clin Pharmacol Ther 70 (2001): 311-6", "alternatives_a": "Digitoxin", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 77810, "ingredient1": "Docetaxel", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77911/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 77811, "ingredient1": "Doxorubicin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77912/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Dolutegravir, Cobicistat, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 77812, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77913/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 77813, "ingredient1": "Dronedarone", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77914/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Amiodarone, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77814, "ingredient1": "Duvelisib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77915/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77815, "ingredient1": "Echinacea", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77916/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77816, "ingredient1": "Edoxaban", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of edoxaban, which is a substrate of the efflux transporter.", "source": "DDInter", "management_text": "When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil. This dosage recommendation is based on data from a clinical study, the Hokusai VTE study, and is limited to use with the specific P-gp inhibitors mentioned.", "mechanism_text": "Absorption", "recommendation": "When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77917/", "reference_text": "[1] Mendell J, Zahir H, Matsushima N, et al. \"Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor.\" Am J Cardiovasc Drugs (2013):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Savaysa (edoxaban).\" Daiichi Sankyo, Inc., Parsippany, NJ.[4] Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K \"Edoxaban drugdrug interactions with ketoconazole, erythromycin, and cyclosporine.\" Br J Clin Pharmacol 0 (2016): epub[5] Mendell J, Zahir H, Matsushima N, et al. \"Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor.\" Am J Cardiovasc Drugs (2013):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Savaysa (edoxaban).\" Daiichi Sankyo, Inc., Parsippany, NJ.[8] Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K \"Edoxaban drugdrug interactions with ketoconazole, erythromycin, and cyclosporine.\" Br J Clin Pharmacol 0 (2016): epub[9] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Etravirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77817, "ingredient1": "Efavirenz", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77918/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Paritaprevir, Cabotegravir, Zanamivir, Oseltamivir, Brincidofovir, Elbasvir, Voxilaprevir, Pibrentasvir, Rimantadine, Telbivudine, Efavirenz, More", "updated_at": 1767369485}, {"id": 77818, "ingredient1": "Eluxadoline", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77919/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 77819, "ingredient1": "Encorafenib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.", "source": "DDInter", "management_text": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77920/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[4] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77820, "ingredient1": "Enzalutamide", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77921/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, Voxilaprevir, More", "updated_at": 1767369485}, {"id": 77821, "ingredient1": "Epirubicin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77922/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Etravirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77822, "ingredient1": "Erdafitinib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp.", "source": "DDInter", "management_text": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77923/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77823, "ingredient1": "Erlotinib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77924/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 77824, "ingredient1": "Erythromycin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77925/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Dapsone, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Elbasvir, Famciclovir, Tipranavir, Voxilaprevir, Ribavirin, More", "updated_at": 1767369485}, {"id": 77825, "ingredient1": "Etoposide", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77926/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77826, "ingredient1": "Etravirine", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77927/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, Remdesivir, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 77827, "ingredient1": "Everolimus", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77928/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Cabotegravir, Maraviroc, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 77828, "ingredient1": "Fedratinib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77929/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77829, "ingredient1": "Fexofenadine", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77930/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 77830, "ingredient1": "Fidaxomicin", "ingredient2": "Daclatasvir", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77931/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin", "alternatives_b": "Lamivudine, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Valaciclovir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 77831, "ingredient1": "Flibanserin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with flibanserin may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever flibanserin is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77932/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77832, "ingredient1": "Fluconazole", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77933/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Brincidofovir, Elbasvir, Darunavir, More", "updated_at": 1767369485}, {"id": 77833, "ingredient1": "Fluvastatin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77934/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 77834, "ingredient1": "Glasdegib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77935/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 77835, "ingredient1": "Guanfacine", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the systemic exposure and risk of adverse effects of drugs that are substrates of the hepatic uptake transporter, organic cation transporter 1 (OCT1). The proposed mechanism is decreased clearance due to daclatasvir-mediated inhibition of OCT1. The clinical significance is unknown.", "source": "DDInter", "management_text": "Caution is advised if daclatasvir is used concomitantly with drugs that are substrates of OCT1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever daclatasvir is added to or withdrawn from therapy with these drugs. Patients should also be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if daclatasvir is used concomitantly with drugs that are substrates of OCT1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77936/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77836, "ingredient1": "Idarubicin", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77937/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Etravirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77837, "ingredient1": "Idelalisib", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77938/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Famciclovir, Ribavirin, Tecovirimat, Maribavir, More", "updated_at": 1767369485}, {"id": 77838, "ingredient1": "Imatinib", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77939/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, More", "updated_at": 1767369485}, {"id": 77839, "ingredient1": "Indacaterol", "ingredient2": "Daclatasvir", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77940/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Etravirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77840, "ingredient1": "Indinavir", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77941/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Remdesivir, Famciclovir, More", "updated_at": 1767369485}, {"id": 77841, "ingredient1": "Isavuconazonium", "ingredient2": "Daclatasvir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77942/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77842, "ingredient1": "Itraconazole", "ingredient2": "Daclatasvir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77943/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More", "updated_at": 1767369485}, {"id": 77843, "ingredient1": "Daclatasvir", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77944/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, More", "updated_at": 1767369485}, {"id": 77844, "ingredient1": "Daclatasvir", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77945/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77845, "ingredient1": "Daclatasvir", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77946/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77846, "ingredient1": "Daclatasvir", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77947/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, Zolmitriptan, More", "updated_at": 1767369485}, {"id": 77847, "ingredient1": "Daclatasvir", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77948/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 77848, "ingredient1": "Daclatasvir", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77949/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "updated_at": 1767369485}, {"id": 77849, "ingredient1": "Daclatasvir", "ingredient2": "Lenalidomide", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77950/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 77850, "ingredient1": "Daclatasvir", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77951/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Dolutegravir, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77851, "ingredient1": "Daclatasvir", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77952/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 77852, "ingredient1": "Daclatasvir", "ingredient2": "Lorlatinib", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77953/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77853, "ingredient1": "Daclatasvir", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77954/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 77854, "ingredient1": "Daclatasvir", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77955/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 77855, "ingredient1": "Daclatasvir", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77956/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77856, "ingredient1": "Daclatasvir", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77957/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77857, "ingredient1": "Daclatasvir", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77958/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 77858, "ingredient1": "Daclatasvir", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.", "source": "DDInter", "management_text": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Others", "recommendation": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77959/", "reference_text": "[1] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[4] \"Multum Information Services, Inc. Expert Review Panel\"[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77859, "ingredient1": "Daclatasvir", "ingredient2": "Modafinil", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77960/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Simeprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 77860, "ingredient1": "Daclatasvir", "ingredient2": "Nafcillin", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77961/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 77861, "ingredient1": "Daclatasvir", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp). Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77962/", "reference_text": "[1] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 77862, "ingredient1": "Daclatasvir", "ingredient2": "Naloxegol", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism, Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77963/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77863, "ingredient1": "Daclatasvir", "ingredient2": "Nefazodone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77964/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Brincidofovir, More", "updated_at": 1767369485}, {"id": 77864, "ingredient1": "Daclatasvir", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77965/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 77865, "ingredient1": "Daclatasvir", "ingredient2": "Nevirapine", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77966/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Zanamivir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Telbivudine, More", "updated_at": 1767369485}, {"id": 77866, "ingredient1": "Daclatasvir", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the plasma concentrations of nilotinib, which is a substrate of both the isoenzyme and the efflux transporter. Data are not available for nilotinib in combination with other CYP450 3A4 or P-glycoprotein inhibitors. Theoretically, a reverse interaction may also occur, since many CYP450 3A4 and P-glycoprotein inhibitors are also substrates, and nilotinib is an inhibitor of both.", "source": "DDInter", "management_text": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors. Pharmacologic response to nilotinib should be monitored more closely whenever a CYP450 3A4 or P-glycoprotein inhibitor is added to or withdrawn from therapy, and the nilotinib dosage adjusted as necessary. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 480 msec will require suspension of nilotinib therapy and immediate action to correct any concomitant risk factors before resuming treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Patients should also be monitored for altered efficacy and safety of the concomitant administered drug.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77967/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77867, "ingredient1": "Daclatasvir", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77968/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77868, "ingredient1": "Daclatasvir", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77969/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77869, "ingredient1": "Daclatasvir", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77970/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Elbasvir, Famciclovir, Ribavirin, Tecovirimat, Pibrentasvir, Rimantadine, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77870, "ingredient1": "Daclatasvir", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77971/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, More", "updated_at": 1767369485}, {"id": 77871, "ingredient1": "Daclatasvir", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77972/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 77872, "ingredient1": "Daclatasvir", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77973/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Famciclovir, Tipranavir, Darunavir, More", "updated_at": 1767369485}, {"id": 77873, "ingredient1": "Daclatasvir", "ingredient2": "Pravastatin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77974/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Maraviroc, Amprenavir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77874, "ingredient1": "Daclatasvir", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77975/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 77875, "ingredient1": "Daclatasvir", "ingredient2": "Prucalopride", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77976/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Rilpivirine, Etravirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77876, "ingredient1": "Daclatasvir", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77977/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Amiodarone, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 77877, "ingredient1": "Daclatasvir", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the oral bioavailability of ranolazine, which has been shown in vitro to be a substrate of P-gp. Ranolazine can prolong the QT interval in a dose-dependent manner, thus increased plasma levels may potentiate the risk of ventricular arrhythmias including ventricular fibrillation and torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors. Pharmacologic response to ranolazine should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the ranolazine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77978/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77878, "ingredient1": "Daclatasvir", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally. Relugolix is a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours. Patients should be monitored more frequently for adverse effects. Alternatively, treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77979/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, More", "updated_at": 1767369485}, {"id": 77879, "ingredient1": "Daclatasvir", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters.", "source": "DDInter", "management_text": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77980/", "reference_text": "[1] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[2] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[3] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[4] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[5] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Fluticasone, Ipratropium, Cromoglicic acid, Betamethasone, More", "updated_at": 1767369485}, {"id": 77880, "ingredient1": "Daclatasvir", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77981/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77881, "ingredient1": "Daclatasvir", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77982/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 77882, "ingredient1": "Daclatasvir", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77983/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Elbasvir, Famciclovir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, Telbivudine, Entecavir, More", "updated_at": 1767369485}, {"id": 77883, "ingredient1": "Daclatasvir", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77984/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 77884, "ingredient1": "Daclatasvir", "ingredient2": "Rifaximin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77985/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Tetracycline, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 77885, "ingredient1": "Daclatasvir", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of ripretinib and its active metabolite, DP-5439. In vitro studies indicate that ripretinib and DP-5439 are substrates of the P-gp efflux transporter.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp. Clinical and laboratory monitoring should be considered whenever a P-gp inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects such as nausea, vomiting, constipation, diarrhea, alopecia, arthralgia, myalgia, hypertension, cardiac dysfunction, and palmar-plantar erythrodysesthesia.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77986/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[6] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[7] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[11] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[12] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[13] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[14] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[15] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[16] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[19] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[20] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[21] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[22] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[23] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[30] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[31] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[32] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[33] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[34] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[36] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77886, "ingredient1": "Daclatasvir", "ingredient2": "Ritonavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77987/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Paritaprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, Darunavir, Maribavir, Rimantadine, Elvitegravir, Telbivudine, More", "updated_at": 1767369485}, {"id": 77887, "ingredient1": "Daclatasvir", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77988/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 77888, "ingredient1": "Daclatasvir", "ingredient2": "Rolapitant", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when rolapitant is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when rolapitant is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77989/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Nabilone, Granisetron, Scopolamine, Dronabinol, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 77889, "ingredient1": "Daclatasvir", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of romidepsin, which is a substrate of the efflux transporter. Although there are no formal drug interaction studies, the interaction may increase the risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.", "source": "DDInter", "management_text": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors. Pharmacologic response to romidepsin should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the romidepsin dosage adjusted as necessary. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77990/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Etravirine, More", "updated_at": 1767369485}, {"id": 77890, "ingredient1": "Daclatasvir", "ingredient2": "Rosuvastatin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77991/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Amlodipine, Ramipril, Valsartan, Lisinopril, Perindopril, Niacin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate, More", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, More", "updated_at": 1767369485}, {"id": 77891, "ingredient1": "Daclatasvir", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of Multidrug and Toxin Extrusion (MATE) 1, MATE 2-K, organic cation transporter (OCT) 1, and/or OCT 2. The proposed mechanism, based on in vitro data, is decreased clearance due to rucaparib-mediated inhibition of these transport proteins. Rucaparib appears to be a potent inhibitor of MATE 1 and MATE2-K, a moderate inhibitor of OCT1, and a weak inhibitor of OCT2.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of MATE 1, MATE 2-K, OCT 1 and/or OCT 2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of MATE 1, MATE 2-K, OCT 1 and/or OCT 2, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77992/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 77892, "ingredient1": "Daclatasvir", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77993/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Remdesivir, Famciclovir, Maribavir, Pibrentasvir, More", "updated_at": 1767369485}, {"id": 77893, "ingredient1": "Daclatasvir", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77994/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77894, "ingredient1": "Daclatasvir", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77995/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Terazosin, Alfuzosin, Tadalafil, Finasteride, Dutasteride, Solifenacin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 77895, "ingredient1": "Daclatasvir", "ingredient2": "Simeprevir", "severity": "Moderate", "effect": "Coadministration with simeprevir may increase the plasma concentrations of daclatasvir. The proposed mechanism of interaction is simeprevir inhibition of the intestinal and/or renal efflux of daclatasvir via P-glycoprotein.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with simeprevir. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used with simeprevir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77996/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 77896, "ingredient1": "Daclatasvir", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide 1B1 (OATP 1B1) or breast cancer resistance protein (BCRP) transporters, such as HMG-CoA reductase inhibitors. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by daclatasvir. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Caution and monitoring for adverse effects are advised during concomitant use of daclatasvir with drugs that are substrates of the OATP1B1 or BCRP transporters, particularly HMG-CoA reductase inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77997/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Guar gum, Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, More", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Doravirine, Bictegravir, More", "updated_at": 1767369485}, {"id": 77897, "ingredient1": "Daclatasvir", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77998/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Cabotegravir, Maraviroc, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Bictegravir, More", "updated_at": 1767369485}, {"id": 77898, "ingredient1": "Daclatasvir", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/77999/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 77899, "ingredient1": "Daclatasvir", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78000/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 77900, "ingredient1": "Daclatasvir", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78001/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 77901, "ingredient1": "Daclatasvir", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78002/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "updated_at": 1767369485}, {"id": 77902, "ingredient1": "Daclatasvir", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78003/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More", "updated_at": 1767369485}, {"id": 77903, "ingredient1": "Daclatasvir", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.", "source": "DDInter", "management_text": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Distribution", "recommendation": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78004/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 77904, "ingredient1": "Daclatasvir", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78005/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 77905, "ingredient1": "Daclatasvir", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78006/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Stavudine, Famciclovir, Tipranavir, More", "updated_at": 1767369485}, {"id": 77906, "ingredient1": "Daclatasvir", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78007/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Cobicistat, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77907, "ingredient1": "Daclatasvir", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78008/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 77908, "ingredient1": "Daclatasvir", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78009/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 77909, "ingredient1": "Daclatasvir", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78010/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Famciclovir, Tipranavir, Doravirine, Bictegravir, Ribavirin, Maribavir, More", "updated_at": 1767369485}, {"id": 77910, "ingredient1": "Daclatasvir", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the oral bioavailability of tolvaptan, which has been shown in vitro to be a substrate of the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine. Serum sodium concentration and neurologic status should be closely monitored, and the tolvaptan dosage adjusted accordingly. Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Discontinuation or interruption of tolvaptan therapy should be considered in patients who develop too rapid a rise in serum sodium.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78011/", "reference_text": "[1] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77911, "ingredient1": "Daclatasvir", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78012/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "updated_at": 1767369485}, {"id": 77912, "ingredient1": "Daclatasvir", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78013/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 77913, "ingredient1": "Daclatasvir", "ingredient2": "Tucatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78014/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, Oseltamivir, More", "alternatives_b": "Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Ibrutinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77914, "ingredient1": "Daclatasvir", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors. If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Distribution", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78015/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, Zolmitriptan, More", "updated_at": 1767369485}, {"id": 77915, "ingredient1": "Daclatasvir", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of venetoclax with P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78016/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 77916, "ingredient1": "Daclatasvir", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78017/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77917, "ingredient1": "Daclatasvir", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78018/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 77918, "ingredient1": "Daclatasvir", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78019/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 77919, "ingredient1": "Daclatasvir", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78020/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 77920, "ingredient1": "Daclatasvir", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78021/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Famciclovir, Darunavir, More", "updated_at": 1767369485}, {"id": 77921, "ingredient1": "Daclatasvir", "ingredient2": "Voxelotor", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78022/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 77922, "ingredient1": "Daclatasvir", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists. The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.", "source": "DDInter", "management_text": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78023/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[6] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[7] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[8] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[9] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[10] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[11] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[12] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[13] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[14] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[15] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[16] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[17] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[18] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[21] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[22] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[23] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[24] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[27] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[28] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[29] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[30] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[31] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[32] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[33] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[34] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[35] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[36] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[37] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[39] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[40] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[41] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[42] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[43] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[44] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6", "alternatives_a": "Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Remdesivir, Doravirine, Bictegravir, More", "updated_at": 1767369485}, {"id": 77923, "ingredient1": "Amoxapine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78024/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77924, "ingredient1": "Dacomitinib", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78025/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77925, "ingredient1": "Darifenacin", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78026/", "reference_text": "[1] \"Product Information. Enablex (darifenacin).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77926, "ingredient1": "Desipramine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78027/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77927, "ingredient1": "Deutetrabenazine", "ingredient2": "Dacomitinib", "severity": "Major", "effect": "Deutetrabenazine has been associated with modest QT prolongation. Coadministration with a strong CYP450 2D6 inhibitor may increase the plasma concentrations of the pharmacologically active dihydro-metabolites of deutetrabenazine, alfa- and beta-HTBZ (dihydrotetrabenazine), which may increase the risk of adverse effects, including somnolence, clinically relevant QT interval prolongation, parkinsonism, akathisia, neuroleptic malignant syndrome, depression, and suicidality.", "source": "DDInter", "management_text": "Pharmacologic response to deutetrabenazine should be monitored more closely whenever a strong CYP450 2D6 inhibitor (e.g.,fluoxetine, paroxetine, or quinidine) is added to or withdrawn from therapy. Deutetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. Assessment of baseline QT interval and periodic monitoring during therapy may be considered. The maximum recommended dosage of deutetrabenazine is 18 mg per dose and 36 mg per day during coadministration with a potent CYP450 2D6 inhibitor or in patients who are poor metabolizers of CYP450 2D6. Patients and their caregivers should be advised to notify their physician if they experience new or worsening depression, suicidal thoughts, parkinsonism, restlessness, agitation, dysphagia, and/or excessive sedation while taking deutetrabenazine. Patients should also be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to deutetrabenazine should be monitored more closely whenever a strong CYP450 2D6 inhibitor (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78028/", "reference_text": "[1] \"Product Information. Austedo (deutetrabenazine).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 77928, "ingredient1": "Dexfenfluramine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78029/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77929, "ingredient1": "Dexlansoprazole", "ingredient2": "Dacomitinib", "severity": "Major", "effect": "Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs.", "source": "DDInter", "management_text": "Concomitant use of dacomitinib with PPIs should generally be avoided. If acid suppression therapy is required, locally-acting antacids or H2-receptor antagonists may be considered. The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of dacomitinib with PPIs should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78030/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77930, "ingredient1": "Diphenhydramine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78031/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Mepyramine, Tripelennamine, Pheniramine, Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 77931, "ingredient1": "Donepezil", "ingredient2": "Dacomitinib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78032/", "reference_text": "[1] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses.\" Br J Clin Pharmacol 46 (1998): 30-4[2] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[3] Rojas-Fernandez C, Fisher C \"Drug interactions and donepezil.\" J Am Geriat Soc 40 (2000): 597-8", "alternatives_a": "Rivastigmine, Aducanumab, Memantine, Ginkgo biloba, Tacrine", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "updated_at": 1767369485}, {"id": 77932, "ingredient1": "Doxepin", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78033/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77933, "ingredient1": "Doxepin (topical)", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78034/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Lapatinib, Selumetinib, Ribociclib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 77934, "ingredient1": "Doxorubicin", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78035/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Acalabrutinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77935, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78036/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Pralsetinib, Asciminib, Acalabrutinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77936, "ingredient1": "Duloxetine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of duloxetine, which is partially metabolized by the isoenzyme. Theoretically, high plasma levels of duloxetine may increase the risk of serious adverse effects such as hypertension, hypertensive crisis, increased heart rate, orthostatic hypotension, syncope, and serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "Caution is advised if duloxetine is used in combination with CYP450 2D6 inhibitors, particularly potent ones like paroxetine, fluoxetine, or quinidine. Pharmacologic response to duloxetine should be monitored more closely whenever a CYP450 2D6 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duloxetine is used in combination with CYP450 2D6 inhibitors, particularly potent ones like paroxetine, fluoxetine, or quinidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78037/", "reference_text": "[1] Skinner MH, Kuan HY, Pan A, et al. \"Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.\" Clin Pharmacol Ther 73 (2003): 170-7[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Tepotinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77937, "ingredient1": "Eliglustat", "ingredient2": "Dacomitinib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78038/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 77938, "ingredient1": "Esomeprazole", "ingredient2": "Dacomitinib", "severity": "Major", "effect": "Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs.", "source": "DDInter", "management_text": "Concomitant use of dacomitinib with PPIs should generally be avoided. If acid suppression therapy is required, locally-acting antacids or H2-receptor antagonists may be considered. The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of dacomitinib with PPIs should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78039/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77939, "ingredient1": "Fenfluramine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78040/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Brivaracetam, Topiramate, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Pexidartinib, Tepotinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, More", "updated_at": 1767369485}, {"id": 77940, "ingredient1": "Flecainide", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78041/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77941, "ingredient1": "Fluoxetine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78042/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Pexidartinib, Tepotinib, Larotrectinib, Bosutinib, Cobimetinib, Capmatinib, Afatinib, Duvelisib, Tivozanib, Brigatinib, More", "updated_at": 1767369485}, {"id": 77942, "ingredient1": "Fluphenazine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78043/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77943, "ingredient1": "Haloperidol", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78044/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77944, "ingredient1": "Idelalisib", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.", "source": "DDInter", "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78045/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Idelalisib, Tivozanib", "updated_at": 1767369485}, {"id": 77945, "ingredient1": "Iloperidone", "ingredient2": "Dacomitinib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of iloperidone, which is a substrate of the isoenzymes.", "source": "DDInter", "management_text": "The dosage of iloperidone should be reduced by one-half when administered concomitantly with potent CYP450 3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, clarithromycin, telithromycin) and/or potent CYP450 2D6 inhibitors (e.g., dacomitinib, fluoxetine, paroxetine, quinidine). Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Following discontinuation of the potent CYP450 3A4 or 2D6 inhibitor, the iloperidone dosage should be returned to the previous level.", "mechanism_text": "Metabolism", "recommendation": "The dosage of iloperidone should be reduced by one-half when administered concomitantly with potent CYP450 3A4 inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78046/", "reference_text": "[1] \"Product Information. Fanapt (iloperidone).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Imatinib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77946, "ingredient1": "Imipramine", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78047/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77947, "ingredient1": "Dacomitinib", "ingredient2": "Lansoprazole", "severity": "Major", "effect": "Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs.", "source": "DDInter", "management_text": "Concomitant use of dacomitinib with PPIs should generally be avoided. If acid suppression therapy is required, locally-acting antacids or H2-receptor antagonists may be considered. The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of dacomitinib with PPIs should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78048/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Vemurafenib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77948, "ingredient1": "Dacomitinib", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Coadministration of lumateperone with uridine diphosphate glucuronosyltransferase (UGT) inhibitors may increase the plasma concentrations of lumateperone, which is metabolized by the enzyme in vitro.", "source": "DDInter", "management_text": "The use of lumateperone with UGT inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "The use of lumateperone with UGT inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78049/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77949, "ingredient1": "Dacomitinib", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78050/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77950, "ingredient1": "Dacomitinib", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78051/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 77951, "ingredient1": "Dacomitinib", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78052/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77952, "ingredient1": "Dacomitinib", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78053/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Pemoline, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77953, "ingredient1": "Dacomitinib", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78054/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77954, "ingredient1": "Dacomitinib", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78055/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Cisapride", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77955, "ingredient1": "Dacomitinib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78056/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77956, "ingredient1": "Dacomitinib", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78057/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77957, "ingredient1": "Dacomitinib", "ingredient2": "Midodrine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78058/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 77958, "ingredient1": "Dacomitinib", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Coadministration of mirtazapine with drugs that inhibit one or more of its metabolic pathways may result in increased plasma concentrations of mirtazapine. In vitro data from human liver microsomes indicate that CYP450 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite, while CYP450 3A4 is primarily responsible for the formation of the N-desmethyl and N-oxide metabolites.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4. Therapeutic response to mirtazapine should be monitored more closely following initiation, discontinuation, or dosing change of CYP450 inhibitors, and the mirtazapine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78059/", "reference_text": "[1] Sitsen JM, Maris FA, Timmer CJ \"Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.\" Eur J Clin Pharmacol 56 (2000): 389-94[2] \"Product Information. Remeron (mirtazapine).\" Organon, West Orange, NJ.[3] Stormer E, von Moltke LL, Shader RI, Greenblatt DJ \"Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4\" Drug Metab Dispos 28 (2000): 1168-75[4] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H \"Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.\" Biochem Pharmacol 93 (2015): 104-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, Ripretinib, More", "updated_at": 1767369485}, {"id": 77959, "ingredient1": "Dacomitinib", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78060/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Amlodipine, Valsartan, Irbesartan, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77960, "ingredient1": "Dacomitinib", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "INTERVAL: Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs.", "source": "DDInter", "management_text": "The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists. As an alternative, locally-acting antacids may be considered. Concomitant use of dacomitinib with PPIs should generally be avoided.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78061/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77961, "ingredient1": "Dacomitinib", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78062/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77962, "ingredient1": "Dacomitinib", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations and adverse opioid effects of oliceridine, which is primarily metabolized by both isoenzymes in vitro. In addition, oliceridine concentrations may decrease following discontinuation of a concomitant moderate or potent CYP450 2D6 or 3A4 inhibitor, possibly resulting in decreased opioid efficacy or withdrawal syndrome. The effect of a CYP450 2D6 inhibitor on the pharmacokinetics of oliceridine has not been studied. However, it may be similar to that reported in CYP450 2D6 poor metabolizers, whose plasma clearance of oliceridine is reduced by approximately 50% compared to those who are nonpoor CYP450 2D6 metabolizers.", "source": "DDInter", "management_text": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4. If concomitant use is considered necessary, patients may require less frequent dosing of oliceridine and should be closely monitored for respiratory depression, sedation, and QT prolongation. If a moderate or potent CYP450 2D6 or 3A4 inhibitor is discontinued, an increase of the oliceridine dosage may be considered while monitoring for signs of opioid withdrawal until stable drug effects are achieved.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78063/", "reference_text": "[1] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[2] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, Axitinib, More", "alternatives_b": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Nalbuphine, More", "updated_at": 1767369485}, {"id": 77963, "ingredient1": "Dacomitinib", "ingredient2": "Pantoprazole", "severity": "Major", "effect": "Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs.", "source": "DDInter", "management_text": "Concomitant use of dacomitinib with PPIs should generally be avoided. If acid suppression therapy is required, locally-acting antacids or H2-receptor antagonists may be considered. The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of dacomitinib with PPIs should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78064/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Clarithromycin, Vonoprazan, Amoxicillin", "alternatives_b": "Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Vemurafenib, Selumetinib, Ribociclib, Cobimetinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77964, "ingredient1": "Dacomitinib", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78065/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77965, "ingredient1": "Dacomitinib", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78066/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77966, "ingredient1": "Dacomitinib", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Coadministration of pexidartinib with strong CYP450 3A4 inhibitors and/or uridine diphosphate glucuronosyltransferase (UGT) inhibitors may significantly increase the plasma concentrations and the incidence and severity of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4 and/or UGT, the primary isoenzymes responsible for the metabolic clearance of pexidartinib.", "source": "DDInter", "management_text": "The use of pexidartinib with strong CYP450 3A4 inhibitors and/or UGT inhibitors should generally be avoided. If concomitant use is required, the dose of pexidartinib should be reduced according to the manufacturer's recommendations. If concomitant use of a strong CYP450 3A4 inhibitor or UGT inhibitor is discontinued, the dose of pexidartinib may be increased, after 3 plasma half-lives of the strong CYP450 3A4 inhibitor or UGT inhibitor, to the dose that was used prior to starting the strong CYP450 3A4 inhibitor or UGT inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of pexidartinib with strong CYP450 3A4 inhibitors and/or UGT inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78067/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tivozanib, Futibatinib, Trametinib, Asciminib, Pexidartinib", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 77967, "ingredient1": "Dacomitinib", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Due to the narrow therapeutic index of pimozide, the manufacturers consider its use with potent CYP450 2D6 inhibitors to be contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Due to the narrow therapeutic index of pimozide, the manufacturers consider its use with potent CYP450 2D6 inhibitors to be contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78068/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[7] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[8] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77968, "ingredient1": "Dacomitinib", "ingredient2": "Pirfenidone", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor. Pirfenidone is primarily (70% to 80%) metabolized by CYP450 1A2, with minor contribution from CYP450 2C9, 2C19, 2D6, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided. No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78069/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Entrectinib, Dabrafenib, Acalabrutinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "updated_at": 1767369485}, {"id": 77969, "ingredient1": "Dacomitinib", "ingredient2": "Pitolisant", "severity": "Major", "effect": "Coadministration with strong inhibitors of CYP450 2D6 may increase plasma concentrations of pitolisant. The proposed mechanism is decreased clearance of pitolisant due to inhibition of its metabolism via this isoenzyme.", "source": "DDInter", "management_text": "A dosage reduction is recommended for pitolisant during coadministration with strong inhibitors of CYP450 2D6. For patients receiving a strong CYP450 2D6 inhibitor, the dose of pitolisant should be initiated at 8.9 mg once daily and increased after 7 days to a maximum dosage of 17.8 mg once daily. For patients already receiving a stable dose of pitolisant, the dose of pitolisant should be reduced by half when initiating treatment with a strong CYP450 2D6 inhibitor. Patients should be monitored for clinical response and increased adverse effects such as headache, insomnia, nausea, anxiety, increased heart rate, QT prolongation, hallucinations, abdominal pain, upper respiratory tract infections, and musculoskeletal pain.", "mechanism_text": "Metabolism", "recommendation": "A dosage reduction is recommended for pitolisant during coadministration with strong inhibitors of CYP450 2D6.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78070/", "reference_text": "[1] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Pralsetinib, Dabrafenib, Pacritinib, Bosutinib, Cobimetinib, Ibrutinib, Tivozanib, Brigatinib, Axitinib, Regorafenib, Alpelisib, More", "updated_at": 1767369485}, {"id": 77970, "ingredient1": "Dacomitinib", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78071/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77971, "ingredient1": "Dacomitinib", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78072/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77972, "ingredient1": "Dextropropoxyphene", "ingredient2": "Dacomitinib", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78073/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Nalbuphine, More", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77973, "ingredient1": "Dacomitinib", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78074/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Asciminib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77974, "ingredient1": "Dacomitinib", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78075/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77975, "ingredient1": "Dacomitinib", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Moderate", "effect": "INTERVAL: Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs.", "source": "DDInter", "management_text": "The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists. As an alternative, locally-acting antacids may be considered. Concomitant use of dacomitinib with PPIs should generally be avoided.", "mechanism_text": "Absorption", "recommendation": "The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78076/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77976, "ingredient1": "Dacomitinib", "ingredient2": "Ranolazine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 2D6 may modestly increase the plasma concentrations of ranolazine, which is partially metabolized by the isoenzyme. When ranolazine 1000 mg twice a day was given to healthy volunteers with the potent CYP450 2D6 inhibitor paroxetine at 20 mg once a day, mean steady-state ranolazine plasma concentrations increased by 1.2-fold. This is not considered clinically significant, and no dosage adjustment of ranolazine is required when used with CYP450 2D6 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78077/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Regorafenib, Temsirolimus, Trametinib, Erlotinib, Neratinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 77977, "ingredient1": "Dacomitinib", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78078/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77978, "ingredient1": "Dacomitinib", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78079/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Lenvatinib, Trametinib, Vandetanib, Alectinib, Tivozanib, Sorafenib", "updated_at": 1767369485}, {"id": 77979, "ingredient1": "Dacomitinib", "ingredient2": "Sacituzumab govitecan", "severity": "Major", "effect": "Coadministration of sacituzumab govitecan with inhibitors of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) may increase the risk of adverse effects, such as nausea, vomiting, diarrhea, and neutropenia. The proposed mechanism involves increased exposure to the pharmacologically active metabolite SN-38, a topoisomerase I inhibitor linked to sacituzumab govitecan, which is metabolized via UGT1A1. Genetic variants of the UGT1A1 gene such as the UGT1A1*28 allele lead to reduced UGT1A1 enzyme activity and patients who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia from SN-38.", "source": "DDInter", "management_text": "Concomitant use of sacituzumab govitecan with UGT1A1 inhibitors should be avoided. If coadministration is unavoidable, patients should be closely monitored for the development of severe nausea, vomiting, diarrhea, and neutropenia. Patients should be advised to promptly report symptoms such as chills, fever, malaise, sore throat, mouth sores, unusual fatigue, bruising, or bleeding.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sacituzumab govitecan with UGT1A1 inhibitors should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78080/", "reference_text": "[1] \"Product Information. Trodelvy (sacituzumab govitecan).\" Immunomedics, Morris Plains, NJ.[2] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 77980, "ingredient1": "Dacomitinib", "ingredient2": "Tamoxifen", "severity": "Major", "effect": "Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen's antiestrogenic activity.", "source": "DDInter", "management_text": "Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.", "mechanism_text": "Metabolism", "recommendation": "Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78081/", "reference_text": "[1] Goetz MP, Rae JM, Suman VJ, et al. \"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.\" J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. \"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.\" J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. \"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.\" J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA \"Germline pharmacogenetics of tamoxifen response: have we learned enough?\" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G \"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.\" J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M \"Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.\" Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. \"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.\" J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al \"Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.\" Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S \"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.\" Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P \"Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.\" J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. \"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.\" Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P \"Genetics and drug interactions affect tamoxifen metabolism.\" Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. \"The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.\" Br J Clin Pharmacol 54 (2002): 157-167[14] Young D \"Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.\" Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A \"Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition.\" J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D \"CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.\" Cancer Res 57 (1997): 3402-6[17] Rochat B \"Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism.\" Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. \"Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.\" J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H \"Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues.\" J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA \"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.\" J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M \"Pharmacogenomics of tamoxifen therapy.\" Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM \"Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.\" Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM \"Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response.\" Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al \"Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.\" Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL \"Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.\" J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J \"Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.\" J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H \"Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.\" Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL \"A hot flash on tamoxifen metabolism.\" J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J \"Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer.\" Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. \"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment.\" Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC \"Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.\" Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al \"Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen.\" ([2009 May 30]):[35] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Regorafenib, Ruxolitinib, More", "updated_at": 1767369485}, {"id": 77981, "ingredient1": "Dacomitinib", "ingredient2": "Tamsulosin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of tamsulosin, which is primarily metabolized in the liver by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tamsulosin is used concomitantly with moderate CYP450 3A4 inhibitors (e.g., amiodarone, aprepitant, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, fusidic acid, imatinib, isavuconazonium, verapamil) and/or moderate to potent CYP450 2D6 inhibitors (e.g., abiraterone, bupropion, celecoxib, cinacalcet, darifenacin, dronedarone, duloxetine, fluoxetine, lorcaserin, paroxetine, propafenone, quinidine, ranolazine, rolapitant, terbinafine), particularly at a dosage higher than 0.4 mg/day. The potential for increased risk of adverse effects such as postural hypotension, syncope, and priapism should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tamsulosin is used concomitantly with moderate CYP450 3A4 inhibitors (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78082/", "reference_text": "[1] Kamimura H, Oishi S, Matsushima H, et al. \"Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes.\" Xenobiotica 28 (1998): 909-22[2] Franco-Salinas G, de la Rosette JJ, Michel MC \"Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.\" Clin Pharmacokinet 49 (2010): 177-88[3] \"Product Information. Flomax (tamsulosin).\" Boehringer-Ingelheim, Ridgefield, CT.[4] \"Product Information. Flomax (tamsulosin).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Terazosin, Alfuzosin, Tadalafil, Finasteride, Silodosin, Dutasteride, Solifenacin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "Entrectinib, Acalabrutinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 77982, "ingredient1": "Dacomitinib", "ingredient2": "Tetrabenazine", "severity": "Major", "effect": "Tetrabenazine may cause modest prolongation of the QT interval. Coadministration with a potent CYP450 2D6 inhibitor may increase the plasma concentrations of the pharmacologically active metabolites of tetrabenazine. However, effects at higher exposures to either tetrabenazine or its metabolites have not been evaluated. Coadministration with potent CYP450 2D6 inhibitors may significantly increase the plasma concentrations of the pharmacologically active metabolites of tetrabenazine.", "source": "DDInter", "management_text": "Pharmacologic response to tetrabenazine should be monitored more closely whenever a potent CYP450 2D6 inhibitor (e.g., fluoxetine, paroxetine, or quinidine) is added to or withdrawn from therapy. Tetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. Assessment of baseline QT interval and periodic monitoring during therapy may be considered. In patients already stabilized on tetrabenazine, the daily dosage of tetrabenazine should be halved. The maximum dosage recommended is 25 mg per dose and 50 mg per day during coadministration with a potent CYP450 2D6 inhibitor or in patients who are poor metabolizers of CYP450 2D6. Patients and their caregivers should be advised to notify their physician if they experience new or worsening depression, suicidal thoughts, parkinsonism, restlessness, agitation, dysphagia, and/or excessive sedation while taking tetrabenazine. Patients should also be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to tetrabenazine should be monitored more closely whenever a potent CYP450 2D6 inhibitor (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78083/", "reference_text": "[1] \"Product Information. Xenazine (tetrabenazine).\" Prestwick Pharmaceuticals Inc, Washington DC, VA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77983, "ingredient1": "Dacomitinib", "ingredient2": "Thioridazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, all of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated. Depending on the elimination half-life of these drugs, a considerable waiting period may be appropriate following their discontinuation before thioridazine is initiated. For example, the manufacturer of fluoxetine recommends that thioridazine not be administered within 5 weeks after discontinuing fluoxetine because of the drug's long half-life.", "mechanism_text": "Metabolism", "recommendation": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78084/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[2] Greendyke RM, Gulya A \"Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.\" J Clin Psychiatry 49 (1988): 105-7[3] Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J \"Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.\" J Clin Psychopharmacol 19 (1999): 494-9[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982): 223-4[5] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969): 135-8[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[9] Silver JM, Yudofsky SC, Kogan M, Katz BL \"Elevation of thioridazine plasma levels by propranolol.\" Am J Psychiatry 143 (1986): 1290-2[10] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996): 543-53[11] Greendyke RM, Kanter DR \"Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.\" J Clin Psychopharmacol 7 (1987): 178-82[12] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Quetiapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77984, "ingredient1": "Dacomitinib", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78085/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, Pindolol, Atenolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77985, "ingredient1": "Dacomitinib", "ingredient2": "Timolol (ophthalmic)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the systemic effects of topically administered timolol, which is metabolized by the isoenzyme. Following ocular administration, timolol is systemically absorbed and can reach plasma levels associated with adverse beta-adrenergic blocking effects such as bronchospasm, depression, bradycardia, and hypotension. The risk may be increased if clearance of the drug is significantly diminished by concomitant CYP450 2D6 inhibitors.", "source": "DDInter", "management_text": "Patients should be monitored for systemic beta-adrenergic blocking effects of topical timolol during coadministration with CYP450 2D6 inhibitors such as cimetidine, quinidine, and certain selective serotonin reuptake inhibitors. Particular caution is warranted in elderly patients, since they are generally more susceptible to adverse effects of topically administered beta blockers.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for systemic beta-adrenergic blocking effects of topical timolol during coadministration with CYP450 2D6 inhibitors such as cimetidine, quinidine, and certain selective serotonin reuptake inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78086/", "reference_text": "[1] Fraunfelder FT, Fraunfelder FW; Randall JA \"Drug-Induced Ocular Side Effects 5th\" Boston, MA: Butterworth-Heinemann (2001):[2] Edeki TI, He HB, Wood AJJ \"Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction.\" JAMA 274 (1995): 1611-3[3] Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF \"Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.\" Br J Clin Pharmacol 19 (1985): 329-33[4] Dinai Y, Sharir M, Floman NN, Halkin H \"Bradycardia induced by interaction between quinidine and ophthalmic timolol.\" Ann Intern Med 103 (1985): 890-1[5] Higginbotham E \"Topical beta-adrenergic antagonists and quinidine: a risky interaction.\" Arch Ophthalmol 114 (1996): 745-6[6] Ishii Y, Nakamura K, Tsutsumi K, Kotegawa T, Nakano S, Nakatsuka K \"Drug interaction between cimetidine and timolol ophthalmic solution: Effect on heart rate and intraocular pressure in healthy Japanese volunteers.\" J Clin Pharmacol 40 (2000): 193-9[7] Alvan G, Calissendorff B, Seideman P, Widmark K, Widmark G \"Absorption of ocular timolol.\" Clin Pharmacokinet 5 (1980): 95-100", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, Pindolol, Atenolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 77986, "ingredient1": "Dacomitinib", "ingredient2": "Tolterodine", "severity": "Minor", "effect": "Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of tolterodine, which is primarily metabolized by this isoenzyme in patients that are extensive metabolizers, or EMs (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent). Moreover, since the active 5-hydroxymethyl metabolite (5-HM) generated by CYP450 2D6 is equipotent compared with tolterodine, and the sum of unbound serum concentrations of tolterodine and 5-HM are only 25% higher during the interaction, little alteration in the overall pharmacologic activity would be expected. Thus, dosage reductions should not be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78087/", "reference_text": "[1] Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L \"Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance.\" Br J Clin Pharmacol 48 (1999): 553-63[2] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 77987, "ingredient1": "Dacomitinib", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78088/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Zanubrutinib, More", "updated_at": 1767369485}, {"id": 77988, "ingredient1": "Dacomitinib", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 2D6 by dacomitinib.", "source": "DDInter", "management_text": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever dacomitinib is added to or withdrawn from therapy. Avoid concomitant use with dacomitinib where minimal increases in concentration of the CYP450 2D6 substrate may lead to serious or life-threatening toxicities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dacomitinib is used in combination with CYP450 2D6 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78089/", "reference_text": "[1] \"Product Information. Vizimpro (dacomitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Pexidartinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 77989, "ingredient1": "Dacomitinib", "ingredient2": "Valbenazine", "severity": "Major", "effect": "Coadministration with a strong CYP450 2D6 inhibitor may increase the exposure of (+)-alfa-dihydrotetrabenazine, the active metabolite of valbenazine, which may increase the risk of adverse effects, including somnolence and QT interval prolongation. The proposed mechanism is decreased clearance due to inhibition of CYP450 2D6 activity. Increased concentrations of valbenazine and (+)-alfa-dihydrotetrabenazine may lead to clinically significant prolongation of the QT interval. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). The extent of drug-induced QT prolongation is dependent on the particular drugs involved and dosages of the drugs. In addition, central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Pharmacologic response to valbenazine should be monitored more closely whenever a strong inhibitor of CYP450 2D6 (e.g., paroxetine, fluoxetine, quinidine) is added to or withdrawn from therapy. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. Assessment of baseline QT interval and periodic monitoring during therapy may be considered. The manufacturer recommends a dosage reduction for valbenazine during concomitant administration with strong CYP450 2D6 inhibitors or in patients who are poor metabolizers of CYP450 2D6. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When valbenazine is used in combination with other drugs that cause CNS depression, patients should be monitored for potentially excessive or prolonged CNS depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to valbenazine should be monitored more closely whenever a strong inhibitor of CYP450 2D6 (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78090/", "reference_text": "[1] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.[2] \"Product Information. Ingrezza (valbenazine).\" Neurocrine Biosciences, Inc., San Diego, CA.", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "updated_at": 1767369485}, {"id": 77990, "ingredient1": "Dacomitinib", "ingredient2": "Vortioxetine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of vortioxetine, which is primarily metabolized by the isoenzyme. High plasma levels of vortioxetine may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "The dosage of vortioxetine should be reduced by one-half when used in combination with potent CYP450 2D6 inhibitors such as bupropion, cinacalcet, fluoxetine, paroxetine, quinidine, ritonavir, and terbinafine. Following discontinuation of the potent CYP450 2D6 inhibitor, vortioxetine dosage should be returned to the original level. Since fluoxetine and paroxetine are also selective serotonin reuptake inhibitors, additive serotonergic effects with vortioxetine should be considered, and concomitant use avoided if possible.", "mechanism_text": "Metabolism", "recommendation": "The dosage of vortioxetine should be reduced by one-half when used in combination with potent CYP450 2D6 inhibitors such as bupropion, cinacalcet, fluoxetine, paroxetine, quinidine, ritonavir, and terbinafine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78091/", "reference_text": "[1] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[3] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Vilazodone, Sertraline, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 77991, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Dactinomycin", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78092/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77992, "ingredient1": "Dactinomycin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78093/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77993, "ingredient1": "Dactinomycin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78094/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77994, "ingredient1": "Dactinomycin", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78095/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77995, "ingredient1": "Dactinomycin", "ingredient2": "Chloramphenicol (ophthalmic)", "severity": "Moderate", "effect": "Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) have been reported after the administration of chloramphenicol.", "source": "DDInter", "management_text": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78096/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Sim SM, Back DJ, Breckenridge AM \"The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.\" Br J Clin Pharmacol 32 (1991): 17-21[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Burger DM, Meenhorst PL, Koks CH, Beijnen JH \"Drug interactions with zidovudine.\" AIDS 7 (1993): 445-60[5] \"Product Information. Chloromycetin (chloramphenicol).\" Parke-Davis, Morris Plains, NJ.[6] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 77996, "ingredient1": "Dactinomycin", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78097/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77997, "ingredient1": "Dactinomycin", "ingredient2": "Cinoxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78098/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77998, "ingredient1": "Dactinomycin", "ingredient2": "Coccidioides immitis spherule", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78099/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 77999, "ingredient1": "Dactinomycin", "ingredient2": "Cytarabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78100/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pemetrexed, Clofarabine, Trifluridine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine, Capecitabine, Pertuzumab, More", "updated_at": 1767369485}, {"id": 78000, "ingredient1": "Dactinomycin", "ingredient2": "Cytarabine (liposomal)", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/78101/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pemetrexed, Clofarabine, Trifluridine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine, Capecitabine, Pertuzumab, More", "updated_at": 1767369485}]